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 General introduction⏐11 
The large intestine, the inner tube of life 
The last part of the digestive tract, the large intestine, is a tube of approximately 
135 cm long that separates the external from the internal milieu. The main 
functions of the human large intestine are the extraction of water, electrolytes and 
nutrients from the luminal contents and the microbial metabolisation of undigested 
food components, such as dietary fibres. At the same time, the colonic mucosa 
forms a tight barrier that prevents the entrance of potentially toxic luminal 
components, such as bacteria and their metabolites, viruses and dietary antigens 
into the portal and systemic circulation.1  
Barrier function 
The mucosal barrier is essential for the maintenance of colonic and host health.2 It 
consists of a monolayer of epithelial cells (colonocytes), which are firmly connected 
to each other by dynamic structures called tight junctions (TJ) that restrict the 
passage of even very small (2 kDa) molecules (Figure 1.1).3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic picture of the colonic epithelial barrier. 
 
 
The epithelial monolayer is covered by a thick viscous mucus layer that protects 
the epithelial lining against luminal toxic substances and is a medium for lubrication 
and transport, which prevents mechanical damage.4,5 The mucus layer mainly 
consists of mucin glycoproteins and trefoil factors, but also contains other proteins 
C
ha
pt
er
 1
 
 
 
12 
secreted by the intestinal epithelium such as secretory IgA (sIgA), which prevents 
the epithelial adherence and penetration of bacteria.6 Underneath the single layer 
of epithelial cells lies the lamina propria, which contains numerous immune cells 
that provide a permanent protection against invading microorganisms. The 
mucosal immune system can be divided into two interactive systems: the innate 
and the adaptive immune system.7 The innate immune response, which is rapid but 
non-specific, depends largely on the recognition of conserved microbial structures 
by so-called pattern recognition receptors. Therefore, due to the discrimination 
between different bacteria, the mucosal immune system contributes to tolerance to 
commensal bacteria, but is concomitantly able to induce an immune response 
towards pathogens. Dendritic cells and macrophages play a pivotal role in this 
innate defence by sampling pathogens and bacteria. The adaptive immune 
response by T-cells and B-cells reacts slower (3-5 days), but highly specific. This 
response is directed against specific antigens present on pathogens. The different 
cells of the immune system secrete a wide variety of cytokines used for inter-cell 
communication.8 
Oxidative stress 
Oxidative stress is characterised by an imbalance between the generation of free 
radicals, mainly reactive oxygen and nitrogen species and the antioxidant defence 
mechanisms, leading to a cascade of reactions in which lipids, proteins and/or DNA 
may get damaged, which subsequently could result in a disruption of the mucosal 
barrier function.10 Therefore, antioxidant defence mechanisms, including 
antioxidant enzymes, such as glutathione-S-transferase (GST), and non-enzymatic 
antioxidant molecules, such as glutathione (GSH), are essential for the 
maintenance of gut barrier function. During inflammation excessive production of 
reactive oxygen species and reactive nitrogen species generated by inflammatory 
cells contribute to oxidative stress. This can lead to a depletion of the antioxidant 
defence mechanisms and increased epithelial permeability.9  
Colonic microbiota 
The colonic lumen harbours a complex diversity of micro-organisms, called the 
colonic microbiota. This complex ecosystem consists of ~1014 bacterial cells and 
more than 1000 different bacterial species. The number of bacterial cells, which are 
mainly living within the gastrointestinal tract, is estimated to outnumber human cells 
by 10 to 1.11 The colonic microbiota plays a pivotal role for the maintenance of 
human health as it contributes to colonization resistance, the metabolisation of 
non-digested nutrients, synthesis of vitamins B and K, metabolism of bile acids, 
and immune function of the host.11 Nowadays, several studies indicate that the 
intestinal microbiota has an important role in the development of various conditions 
including inflammatory bowel diseases12, cancer13 and even obesity.14 The 
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composition of the colonic microbiota and the availability of nutrients for 
fermentation determines for a great deal its effects on colonic (patho)physiology 
and host health.  
Prebiotics and probiotics 
There is growing interest in functional foods that affect the composition and activity 
of the gut microbiota. One approach is the ingestion of live microorganisms  that 
enter the gut and persist long enough to have beneficial effects on the host 
(probiotics).15 Another approach is to consume non-digestible carbohydrates 
(prebiotics) that are selectively fermented by indigenous beneficial bacteria, 
thereby resulting in increased saccharolytic fermentation.16 One of the proposed 
health-promoting effects of prebiotics is the increase in the production of short 
chain fatty acids (SCFA) in the intestinal lumen (Figure 1.2).17  
 
 
Figure 1.2 In the small intestine digestion and absorption of different nutrients occurs, whereas in 
the large intestine, microbial fermentation of food residues takes place. Saccharolytic 
fermentation of dietary fibres and resistant starches by the colonic microbiota leads to 
the formation of SCFA, mainly acetate, propionate and butyrate, but also valerate and 
caproate. SCFA are rapidly absorbed and eventually approximately only 5% of the 
produced SCFA ends up in the faeces. 
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Short chain fatty acids (SCFA) 
SCFA are end-products of luminal microbial fermentation of predominantly non-
digestible dietary carbohydrates. SCFA with different carbon chain lengths (acetate 
(C2), propionate (C3), butyrate (C4), valerate (C5) and caproate (C6)) are 
produced in varying amounts depending on the diet and the composition of the 
intestinal microbiota.18 Most microorganisms in the colon prefer to ferment 
carbohydrates and switch to protein fermentation when fermentable carbohydrates 
are depleted.19 While carbohydrate fermentation generally leads to health-
promoting SCFA production, protein fermentation yields branched-chain fatty acids 
and potentially toxic metabolites (e.g. ammonia, amines, N-nitroso compounds, 
phenols, indoles and thiols).20 Therefore, highest concentrations of SCFA are 
found in the proximal part of the colon. In autopsy samples from sudden death 
victims, total SCFA concentrations varied from 137 to 197 mmol/kg chyme in the 
caecum to 86 to 97 mmol/kg chyme in the descending colon.21,22 In these samples, 
C2:C3:C4:C5:C6 was found to be present in a molar ratio of approximately 
54:20:21:4:1.21 SCFA are rapidly absorbed and have shown to have distinct 
bioactivity depending on their chain length. With regard to maintenance of colonic 
health and barrier function, butyrate has drawn most attention as this fatty acid is 
the major energy source for the colonocytes.23,24 Furthermore, butyrate has been 
shown to have anti-inflammatory properties mainly through inhibition of nuclear 
factor kappa B (NF-κB) that controls inflammation by acting as a transcription 
factor.25 In addition, butyrate has been shown to modulate oxidative stress26, affect 
the composition of the mucus layer27 and to have anti-carcinogenic effects mainly 
by affecting proliferation, differentiation and apoptosis of colonocytes.28 The exact 
mechanism by which butyrate is able to induce these effects is complex and 
thought to involve multiple distinct mechanisms.29 The most frequently described 
mechanism by which butyrate is able to induce changes in gene expression is 
through the inhibition of histone deacetylase. Hyperacetylation of histones disrupts 
their association with DNA, resulting in a more “open” chromatin structure that 
facilitates access of transcription factors to specific genes.30 Although to a lesser 
extent than butyrate, propionate and valerate have also been demonstrated to 
possess the ability to induce histone hyperacetylation, while acetate and caproate 
show no effects on histone acetylation.31-33 However, studies on the effects of the 
acetate, propionate, valerate and caproate on colonic health are limited.  
 General introduction⏐15 
Aims and outline of the thesis 
Increased SCFA production in the large intestine is a possible mechanism by which 
prebiotics beneficially affect host health. Functional foods containing these 
prebiotics aim to improve the health of the consumer, focussing mainly on healthy 
people or patients with mild disease. The main goal of the project was to evaluate 
the effects of SCFA, especially butyrate on colonic health in vitro and in vivo in 
healthy volunteers and in patients with ulcerative colitis in clinical remission. These 
patients are characterised by low-grade levels of inflammation and oxidative stress 
of the colonic mucosa, and are therefore used as a model for patients with a mildly 
compromised colon. As important determinants of the colonic health status, colonic 
inflammation, oxidative stress and the mucus layer are object of study in the 
present thesis. 
 
First, in chapter 2 the recent knowledge regarding the role of butyrate on colonic 
function has been reviewed. In chapter 3 an in vitro study is presented comparing 
the effects of different SCFA with varying chain lengths (C2-C6) on inflammation, 
the antioxidant status and epithelial integrity using a co-culture model that 
combines a human epithelial cell line with whole blood. As butyrate is regarded to 
be the most potent SCFA with regard to colonic health, the effects of this SCFA 
were studied in healthy volunteers. The effects of butyrate on the distal colon were 
investigated, because this way it was possible to control for the local concentration 
of butyrate and to collect tissue samples without prior bowel cleansing. For local 
distal administration of butyrate once daily rectal enemas were used for 14 days 
and the effects on colonic oxidative stress and inflammation were evaluated. The 
results of this human intervention study with a randomised double blind placebo 
controlled cross-over design in healthy volunteers are described in chapter 4. Next, 
this intervention with rectal butyrate administration was repeated in subjects 
characterised by a chronic low-grade colonic inflammation and mildly elevated 
levels of oxidative stress, such as patients with ulcerative colitis (UC) in clinical 
remission. This study with a randomised double blind placebo controlled parallel 
design is described in chapter 5. Besides inflammation and oxidative stress, the 
colonic mucus layer is another important part of the colonic barrier that could be 
affected by SCFA. Chapter 6 describes a sampling technique to study the 
composition of the colonic mucus layer. In chapter 7 the effect of butyrate on 
colonic mucus in healthy individuals and patients with low-grade inflammation is 
reported. In chapter 8, the major findings of all studies are reviewed and 
implications for future research are discussed. 
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Abstract 
Background 
Butyrate, a short chain fatty acid, is a main end-product of intestinal microbial fermentation of mainly 
dietary fibre. Butyrate is an important energy source for intestinal epithelial cells and plays a role in the 
maintenance of colonic homeostasis. The aim of this review is to provide an overview on the present 
knowledge of the bioactivity of butyrate, emphasizing effects and possible mechanisms of action in 
relation to human colonic function. 
 
Methods 
A PubMed search was performed to select relevant publications using the search terms: ‘butyrate, short 
chain fatty acid, fibre, colon, inflammation, carcinogenesis, barrier, oxidative stress, permeability and 
satiety’.  
 
Results 
Butyrate exerts potent effects on a variety of colonic mucosal functions such as inhibition of 
inflammation and carcinogenesis, reinforcing various components of the colonic defence barrier and 
decreasing oxidative stress. In addition, butyrate may also promote satiety. Two important mechanisms 
include the inhibition of NF-κb activation and histone deacetylation. However, the observed effects of 
butyrate largely depend on concentrations and models used and human data are still limited.  
 
Conclusion 
Although most studies point towards beneficial effects of butyrate, more human in vivo studies are 
needed to contribute to our current understanding of butyrate-mediated effects on colonic function in 
health and disease. 
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Introduction 
Short-chain fatty acids (SCFA), primarily acetate, propionate and butyrate, are 
organic acids produced within the intestinal lumen by bacterial fermentation of 
mainly undigested dietary carbohydrates, but also in a minor part by dietary and 
endogenous proteins, such as mucus, and sloughed epithelial cells.1 Most micro-
organisms prefer to ferment carbohydrate over protein and therefore saccharolytic 
bacterial fermentation occurs predominantly in the proximal colon, while proteolytic 
fermentation mainly takes place in the distal colon where fermentable 
carbohydrates are depleted. The latter is considered less favourable for the host 
because potentially toxic metabolites are formed such as ammonia, sulphur-
containing compounds, indoles and phenols. Since this distal part of the colon is 
the predominant location of several gastrointestinal disorders, such as ulcerative 
colitis and colon cancer, it could be hypothesised that the production of these toxic 
metabolites and a lower availability of SCFA are involved in the pathogeneses of 
these diseases.2, 3  
The production of SCFA allows the salvage of energy mainly from carbon sources 
as dietary fibre that is not digested in the small intestine. It has been estimated that 
SCFA can contribute to about 5-15% of the total caloric requirements of humans.4 
An important SCFA produced is butyrate that, besides being an energy source for 
the epithelial cells, also influences a wide array of cellular functions affecting 
colonic health. As such, butyrate may have an anti-carcinogenic and anti-
inflammatory potential, affect the intestinal barrier and play a role in satiety and 
oxidative stress. 
Due to this important role of butyrate and the rather low consumption of 
fermentable dietary fibre in today’s Western diet, food manufacturers are interested 
in adding fibre sources to foods and beverages that rely on slow bacterial 
fermentation to increase distal colonic butyrate concentrations. In medical 
application, butyrate has also been proposed as a potential therapeutic agent for 
colonic inflammation.5 In a book by Cummings et al. published in 19956, the effects 
of butyrate have been clearly reviewed, but the reported effects have often been 
based on in vitro and animal data. During the last decade additional human 
(intervention) studies have been published as well as knowledge on possible 
mechanisms of action is improving. This review summarises the present 
knowledge on the bioactivity of butyrate, emphasizing effects and possible 
mechanisms of action in relation to human colonic function (Figure 2.1). 
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Figure 2.1 Different domains that may be affected by butyrate produced in the colonic lumen. 
 
Production and absorption of SCFA 
Total and relative molar concentrations of the main SCFA, acetate, propionate and 
butyrate produced in the human intestine, depend on the site of fermentation, diet 
and composition of the intestinal microbiota.7 Absolute concentrations of butyrate in 
human faeces were found to range from 11 to 25 mmol/L8,9, and molar ratios of 
acetate to propionate to butyrate varied between 48:29:23 and 70:15:15, 
respectively, with mean values of approximately 60:20:20.1,9 However, the in situ 
production of total colonic SCFA is difficult to determine because more than 95% of 
the SCFA are rapidly absorbed and metabolised by the host.1 Subsequently, faecal 
concentrations of SCFA are not necessarily representative for those in the more 
proximal colon and can also be affected by intestinal transit time.10 Probably for 
these reasons various studies were not able to show effects of different 
fermentable substrates on faecal SCFA concentrations.11,12 
Because of the difficult accessibility of the human colon, estimates of luminal SCFA 
concentrations are based on analyses in human gut contents of sudden-death 
victims13,14 and stomal effluent of patients with transverse or sigmoid colostomy.15 
In autopsy samples, total SCFA concentrations varied from 137 to 197 mmol/kg 
chyme in the caecum to 86 to 97 mmol/kg chyme in the descending colon.13,14 In 
transverse colostomy samples SCFA concentrations were high (1400 mol/kg dry 
matter) compared to those in sigmoid colostomy samples (550 mol/kg dry matter), 
which were similar to the concentrations in faeces from controls.15 In line with the 
SCFA concentrations, the pH value is the lowest in the proximal colon (pH≈5.6) 
and increases towards the distal colon (pH≈6.3).14  
As SCFA are weak acids (pKa≈4.8), more than 90% exist in the anionic, 
dissociated form in the colonic lumen.16 Several different mechanisms of uptake of 
SCFA across the apical membrane of the colonocytes have been proposed, 
including diffusion of the undissociated (lipid soluble) form16, SCFA/HCO3- 
exchange17,18 and active transport of the dissociated form by SCFA-transporters. 
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Two SCFA-transporters have been reported: the monocarboxylate transporter 
isoform 1 (MCT1), which is coupled to a transmembrane H+-gradient19 and 
SLC5A8, which is a Na+-coupled co-transporter and is also denoted sodium-
coupled monocarboxylate transporter (SMCT1).20 SCFA, with butyrate being the 
most potent one, hereby stimulate the absorption of sodium and water21 and can 
be considered as anti-diarrhoeal agents.22 The transport mechanisms involved in 
basolateral transport of SCFA are still unclear.  
The majority of the absorbed butyrate is metabolised by the colonic epithelium, 
resulting in low concentrations of butyrate in portal blood. Human portal butyrate 
concentrations ranged from 1.3 to 14.4 μmol/L in patients during gall-bladder 
surgery23 and from 14 to 64 μmol/L in sudden death victims.14 Most likely the liver 
subsequently extracts the majority of the remaining butyrate, resulting in even 
lower venous systemic serum butyrate concentrations ranging from 0.5 to 3.3 
μmol/L.24-27 Serum concentrations of propionate and acetate in peripheral blood 
have been shown to range from 3.8 to 5.4 and from 98 to 143 μmol/L, 
respectively.24-27  
Delivery of butyrate 
An important source of butyrate is colonic fermentation of dietary fibre. The rate 
and amount of butyrate being produced along the colonic lumen during dietary fibre 
supplementation depends on its chemical structure, such as solubility and degree 
of polymerisation. Insoluble fibres (e.g. cellulose and lignin) have a rather low 
fermentability, but are associated with increased faecal mass and decreased 
colonic transit time. Soluble fibres are highly fermentable and hence generate 
greater quantities of SCFA in the colon.28 Fibres with a higher degree of 
polymerization are more resistant to saccharolytic fermentation resulting in 
prolonged fermentation, expanding towards the distal colon.29 Examples of 
fermentable dietary and chemically modified fibres that are associated with a 
higher production of SCFA either in vitro or in vivo are: oligofructose30, inulin31, 
psyllium32, germinated barley foodstuff33, hydrolysed guar gum34, oat bran9,35, corn 
starch12, isomalt11, gluconic acid36 and butyrylated starch.37 Although the beneficial 
effects of these fibres are often attributed to the increased butyrate production, 
these soluble fibres can also affect other intestinal characteristics influencing 
intestinal health, such as increased faecal bulk, shortened colonic transit time, 
changes in the composition of the gut microbiota, lowered intraluminal pH and 
changed bile acid profiles.38 
Apart from dietary fibres, also other ingested substrates can contribute to an 
increase in the colonic butyrate concentrations by different mechanisms. An 
example is the oligosaccharide acarbose that increases the amount of starch 
entering the colon by acting as an α-glucosidase inhibitor.8,25 In addition, tributyrin, 
a triglyceride containing three butyrate molecules esterified to glycerol, augments 
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butyrate concentrations after hydrolysation by pancreatic and gastric lipases.39 Also 
butyrate tablets coated with a slow release pH dependent coating releasing 
butyrate in the distal ileum and proximal colon can be used.40,41 However, these 
tablets may not always disintegrate and release their content at the intended 
location due to inter-individual differences in intra-colonic pH and transit time.42 
Finally, consumption of several types of butyrate producing probiotic bacterial 
strains, such as Butyrivibrio fibrisolvens43 and Clostridium butyricum33,44, have 
been studied in animal models. 
Besides using oral substrates to increase colonic butyrate concentrations, a 
number of clinical intervention studies in patients with distal colonic inflammation 
have applied rectal enemas to deliver butyrate to the distal colon.45 However, use 
of enemas is often hampered by a low compliance rate and a short and 
discontinuous exposure of the colon mucosa to butyrate.46 These studies will be 
discussed in a later section. 
Butyrate and colon carcinogenesis 
One of the proposed beneficial effects of butyrate on human intestinal health is the 
prevention and inhibition of colon carcinogenesis. Although epidemiological studies 
are still inconclusive, the majority of these studies showed an inverse relationship 
between dietary fibre intake and the incidence of colorectal cancer.40,41,47-53 Several 
studies hypothesised that increased colonic concentrations of butyrate are an 
important mediator in the observed protective effect of fermentable dietary 
fibre.32,47,54,55 In many of these studies, however, the physiological properties of the 
ingested dietary fibres have not been considered.56 A role for butyrate in the 
development of colon cancer has recently been supported by the down-regulation 
of butyrate transporters (MCT1 and SMCT1) in human colon cancer tissue57,58, 
which results in a reduced uptake and metabolism of butyrate in the colonocytes. In 
addition, the SMTC1 activity was positively correlated with the disease-free 
survival.59 Moreover, a lower butyrate to acetate ratio has been found in luminal 
samples of patients with adenomatous polyps or colon cancer versus healthy 
controls.60 Although several well-designed animal models have demonstrated a 
protective effect of butyrate on colorectal carcinogenesis55,61-67, direct evidence for 
a protective effect of butyrate on carcinogenesis in humans is still lacking. 
Knowledge and hypotheses concerning the mechanisms behind the effects of 
butyrate on carcinogenesis are mainly based on in vitro cell systems. In vitro 
exposure of many tumour cell lines to butyrate leads to anti-carcinogenic effects by 
induction of apoptosis68,69, inhibition of proliferation70,71 and promotion of a more 
differentiated phenotype.70,71  
In contrast to these relatively consistent findings in tumour cell lines, the observed 
effects of butyrate on non-carcinogenic cells are more diverse and do not always 
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point into the same direction as in tumour cells.70,72 Also some data from human 
(intervention) studies are available, which focus predominantly on the effect of 
SCFA on colonocytic proliferation. Treatment with SCFA enemas for two weeks 
increased rectal proliferative activity in patients with a closed atrophic rectum that 
was deprived of its natural SCFA source.73 In a study by Scheppach et al.74, human 
colonic biopsies were exposed to butyrate ex vivo for four hours, which revealed 
that butyrate increased the proliferation rate at the basal 60% area of the crypt. It 
has been proposed that butyrate stimulates the physiological pattern of 
proliferation that is normally confined to the basal crypt.75 Expansion of the 
proliferative zone towards the crypt surface has been considered a biomarker of 
increased susceptibility to cancer formation.76 In colonic biopsies from patients with 
ulcerative colitis expansion of the proliferative zone has been shown and was 
found to be independent of the degree of inflammation.77 Treatment with butyrate 
enemas for two weeks decreased the proliferation rate in the upper part of the crypt 
in colonic biopsies of active UC patients, resulting in values comparable to those of 
healthy control subjects.45  
These apparent contradicting effects of butyrate found in normal colonocytes and 
in neoplastic cells are often referred to as the  “butyrate paradox”.70 There are 
several explanations for these contrasting effects. First, they may reflect inherent 
differences of the cells, the cell’s state of activation and their energy status. 
Furthermore, it may be the result of different concentrations of butyrate and the 
different exposure times to butyrate used in these experiments. Finally, the ability 
of the cells to β-oxidise butyrate may influence their response to butyrate as it can 
influence the rate of removal of butyrate from the cytoplasm and hence the 
availability of butyrate to exert its effects.78,79 
Mechanisms of butyrate’s anti-carcinogenic effect 
Although the exact underlying mechanisms of action have not yet been elucidated, 
the ability of butyrate to influence cell function is considered to be due to its 
regulation of gene expression, which is often attributed to its inhibition of histone 
deacetylase (HDAC).78,80 This results in hyperacetylation of histones and 
enhancement of the accessibility of transcription factors to nucleosomal DNA.69,81,82 
However, it is likely that butyrate has other intracellular targets, including 
hyperacetylation of non-histone proteins, alteration of DNA methylation, selective 
inhibition of histone phosphorylation and modulation of intracellular kinase 
signalling.80 This multiplicity of effects may underlie the ability of butyrate to 
modulate gene expression and have impact on key regulators of apoptosis and cell 
cycle as was demonstrated for cell cycle inhibitor p21Waf1/Cip1 and proapoptotic 
protein BAK.68,69,81,83 Interestingly, cancer cells appear to be more sensitive to the 
actions of HDAC inhibitors than non-transformed cells, but the mechanistic basis 
for this apparent selectivity is poorly understood.83 
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One of the effects also demonstrated in humans is the effect of butyrate on the 
plasminogen/plasmin system (PPS). Increases in tumour and serum levels of 
several components of the PPS are found to correlate with a more invasive tumour 
cell phenotype and a worse prognosis in patients with colon cancer.84 In vitro85 and 
in vivo studies86,87 have shown that butyrate is able to alter the balance of 
components of the PPS in a manner that favours net decreased plasminogen 
activator activity. 
Other effects of butyrate studied in multiple colonic cancer cell lines include the 
enhancement of the activity of the detoxifying enzyme glutathion-S-transferase.88 
Furthermore, butyrate may have an inhibitory effect on tumour cell migration by 
inhibiting decay-accelerating factor (DAF) expression89 and pro-metastatic 
metalloproteinase activation.90,91 Finally, it has also been suggested that butyrate 
inhibits tumour-induced angiogenesis through modulation of two angiogenesis 
related proteins, vascular endothelial growth factor (VEGF) and hypoxia-inducible 
factor 1α (HIF-1α).92  
 
In conclusion, butyrate may have a protective role in the prevention and 
progression of colorectal carcinogenesis. However, the effects on apoptosis and 
proliferation appear to differ between normal and neoplastic tissue. The different 
models and concentrations being used may partly explain this paradox. Therefore, 
effects and mechanisms identified by in vitro models have to be confirmed in 
humans under physiologic conditions. 
Butyrate and inflammation 
The intestinal epithelium, particularly in the colon, is permanently in close 
association with a myriad of microbes and their products. Therefore, the 
enterocytes must sense and respond appropriately to this potential immunological 
challenge of the luminal content. This leads to a normal physiological state of 
controlled low-grade inflammation.93 However, mechanisms that allow individuals 
to tolerate commensal microbes, and thus limit the inflammatory response, are not 
yet completely understood. In some conditions, such as inflammatory bowel 
disease, this immunologic control is thought to be disturbed.94  
Several studies, both in vitro and in vivo, indicate that bacterial metabolites such as 
butyrate may affect the host immune response. As butyrate is known to be an 
important energy source for the colonic epithelium, it has been hypothesised that a 
lack of luminal SCFA or the inability to oxidise butyrate leads to a nutritional 
deficiency of the colonic epithelium, causing mucosal atrophy in short term and 
“nutritional colitis” in long term.95 Possible changes in intestinal butyrate 
concentrations and/or oxidation of butyrate have been reported in diversion colitis 
and ulcerative colitis (UC). Diversion colitis may occur as complication after a 
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surgically diverted intestine (e.g. Hartmann’s procedure), and is characterised by 
severely decreased luminal concentrations of SCFA of 0, 4 and 0.8 mmol/L for 
acetate, propionate and butyrate, respectively, measured in the bypassed part of 
the rectosigmoid.96 UC is an inflammatory bowel disease, characterised by 
alternating periods of flare ups and quiescent disease.97 Increased95,98 as well as 
decreased99,100 faecal concentrations of butyrate have been reported in patients 
with active UC, but these were never as low as in diversion colitis.96 In addition, a 
diminished capacity of the intestinal mucosa to oxidise butyrate has been reported 
in patients with active UC.101,102 In patients with inactive UC, however, a normal 
butyrate oxidation has been found in vivo101,103, which suggests that abnormal 
butyrate oxidation is not a primary defect in colon mucosa of UC patients. A 
possible explanation for the decreased oxidation in UC patients was proposed by 
Nancey et al. who showed that butyrate oxidation could be reduced by TNFα at 
concentrations found in inflamed human mucosa.104 It has also been reported that 
butyrate oxidation in colonocytes can be inhibited by hydrogen sulphide in vitro.105 
Increased luminal concentrations of sulphide as well as high numbers of sulphate 
reducing bacteria have been reported in UC patients.105,106 However, evidence for 
hydrogen sulphide as a metabolic toxin in UC in vivo remains limited.105-108  
Intervention studies 
Several animal studies have been performed to evaluate the effects of butyrate on 
inflammation and preventive as well as therapeutic effects have been reported.109-
112  
Human studies analysing the effects of SCFA were performed in patients with 
colonic inflammation using rectal enemas containing SCFA mixtures or butyrate 
alone (Table 2.1).45,46,73,96,113-126 The majority of these studies focused on UC 
patients with moderately to active disease. Although some controlled studies with 
enemas containing butyrate or SCFA mixtures in UC patients did not find beneficial 
effects113 or only trends towards clinical improvement46,114,115, various other studies 
revealed a significant improvement of clinical and inflammatory parameters.45,116-119 
Studies in patients with diversion colitis reported inconsistent results with regard to 
improvement of clinical symptoms and inflammatory parameters in response to 
administration of mixtures of SCFA versus placebo.96,120 Two other human 
intervention studies determined mucosal cell proliferation in patients after 
Hartmann’s procedure and found trophic effects of SCFA mixtures in the mucosa of 
the closed rectal and sigmoid segment.73,121  
The effects of butyrate containing enemas on radiation proctitis122-125 and 
pouchitis126 have been studied in small groups. Besides one report125 that showed 
that butyrate was an effective treatment of radiation proctitis, other studies did not 
report clear-cut beneficial effects of SCFA irrigation in these two patient groups.122-
124,126  
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The equivocal results in human intervention studies using enemas may partly be 
explained by differences in treatment duration, butyrate enemas versus SCFA 
enemas, differences in concentrations and volumes of these SCFA and the small 
number of patients included. Moreover, some studies suffered from methodological 
limitations such as a cross-over design with insufficient wash-out time that may 
have resulted in differences in pre-treatment levels between groups (Table 2.1). 
As there are limitations to prolonged use of rectal enemas, especially with regard to 
compliance, oral ingestion of fermentable dietary fibre and the use of enteric-
coated tablets containing butyrate have been explored. Administration of such 
tablets (4 g of butyrate daily) in combination with mesalazine versus mesalazine 
alone, significantly improved the disease activity score in patients with mild to 
moderate UC.41 Similar butyrate tablets also resulted in a significant clinical 
improvement in Crohn’s disease patients, but this study lacked a control group.127 
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Table 2.1 Studies performed using butyrate and/or SCFA enemas in different patient groups.  
Patients   N Enema treatment Results  Ref 
 10 100 mM butyrate and placebo 
100 ml, pH=7, b.i.d. for 2 wks.  
Wash  out: 2 wks 
Butyrate → stool frequency↓, blood 
discharge↓and endoscopic and 
histologic scores↓ 
  45 
 45 Corticosteroid (CS), 5-ASA or 130 mM 
SCFA (46:23:31*)  
60 ml, pH=7, b.i.d. for 6 wks  
SCFA equally efficacious to CS or 5-
ASA  
  
117 
 40 150 mM SCFA (53:20:27) vs. placebo 
100 ml b.i.d. for 6 wks  
SCFA → intestinal bleeding↓, urgency↓ 
and patient self-evaluation score↑ 
  
119 
 47 130 mM SCFA (46:23:31) vs.100 mM 
butyrate vs. placebo 
60 ml, pH=5.5, b.i.d. for 4-8 wks  
No differences between groups. 
Butyrate for 8 wks → fewer colonic 
segments affected endoscopically  
  
114 
 38 80 mM butyrate vs. placebo 
60 ml, pH=7 for 6 wks 
No differences between butyrate and 
placebo treatment 
  
113 
 91 150 mM SCFA (53:20:27) vs. placebo 
100 ml, pH=7 b.i.d. for 6 wks  
SCFA enemas were not of therapeutic 
value 
  46 
 35 130 mM SCFA (46:23:31) vs. 100 mM 
butyrate vs. placebo 
60 ml, pH=5.5, b.i.d. for 4-8 wks  
Butyrate → trend for reduced density of 
neutrophils in lamina propria.  
SCFA and butyrate → cell proliferation 
in upper crypt↓  
  
115 
 11 100 mM butyrate vs placebo 
60 ml, pH=5.5 b.i.d. for 4-8 wks 
Butyrate → nr of nuclear translocated 
NF-κB positive macrophages↓, nr of 
neutrophils↓ and Disease Activity 
Index↓ 
  
116 
Active 
distal UC 
 51 5-ASA & saline vs. 5-ASA & 80 mM 
butyrate 
80 ml b.i.d. for 6 wks  
5-ASA in combination with butyrate → 
more patients into remission, bowel 
movements↓, urgency↓ and patient’s 
self-evaluation↑ 
  
118 
 4 130 mM SCFA (46:23:31) vs. placebo 
60 ml, pH=7 b.i.d. for 2-60 wks 
SCFA → clinical symptoms↓and 
histological score↓ 
  96 Diversion 
colitis 
 13 130 mM SCFA (46:23:31) vs. placebo 
60 ml, pH=7 b.i.d. for 2 wks 
No endoscopic or histologic changes   
120 
 6 150 mM SCFA (58:27:15) 
100 ml b.i.d. for 10-14 days  
SCFA had a trophic and vasodilatory 
effect 
  
121 
After 
Hartmann’s 
procedure   8 150 mM SCFA (50:29:21) and placebo
100 ml, pH=7.0 b.i.d. for 2 wks.  
No wash-out 
SCFA → proliferation↑, mainly in the 
middle and upper thirds of the crypts 
  73 
 7 SCFA for 4 wks SCFA → clinical symptoms↓   
122 
 15 40 mM Butyrate. vs placebo 
b.i.d for 2 wks. Wash-out: 1 week 
No differences between groups   
124 
 19 130 mM SCFA (46:23:31) vs. placebo 
60 ml pH=7 b.i.d. for 5 wks  
SCFA → rectal bleeding↓, endoscopic 
score↓ and hemoglobin↑ 
 
123 
Radiation 
proctitis 
 20 80 mM butyrate and placebo 
80 ml for 3 wks. No wash-out 
Butyrate → clinical symptoms↓, 
endoscopic and histological scores↓ 
  
125 
Pouch after 
UC 
 25 130 mM SCFA (46:23:31) 
30 ml b.i.d. pH= 7 for 1-2 wks  
SCFA → no effects on defaecation 
frequency and endoscopic and 
histologic scores of pouches 
  
126 
*Ratio=Acetate:Propionate:Butyrate; N=number of patients included; SCFA=short chain fatty acids; 
CS=corticosteroid; 5-ASA=5-aminosalicylic acid; b.i.d.=twice daily 
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The effects of fermentable fibre supplementations, such as germinated barley 
foodstuff128-130, inulin131,132, psyllium133,134 and oat bran9, that increase faecal 
butyrate concentrations, have also been studied in several clinical trials. 
Germinated barley foodstuff prolonged remission in inactive UC patients128 and 
attenuated clinical activity in active UC patients.129,130 Inulin supplementation 
resulted in a decreased mucosal inflammation of the ileal reservoir in patients with 
an ileal-anal pouch anastomosis132 and lowered faecal calprotectin concentrations 
in patients with active UC.131 Two other studies in UC patients in remission, 
evaluating the supplementation of psyllium and oat bran, showed that the 
supplementation was safe, increased faecal butyrate concentrations and were 
found to be effective in the maintenance of remission.9,133,134 However, this 
effectiveness should be confirmed in larger clinical trials.  
Although not all studies in patients with colonic inflammation confirmed the 
reduction of inflammation and clinical symptoms due to luminal administration of 
butyrate or stimulation of luminal butyrate production by the ingestion of dietary 
fibre, an amelioration of the inflammation and symptoms in active UC patients is 
strongly suggested. In addition, butyrate might also play a role in the prevention of 
inflammation as supported by the results with UC patients in remission.  
Mechanisms of butyrate’s anti-inflammatory effect 
Apart from being an important energy source for the colonocytes, butyrate can 
exert direct immuno-modulatory effects.111,116,135 Suppression of nuclear factor 
kappa B (NF-κB) activation, which may result from the inhibition of HDAC, is the 
most frequently studied anti-inflammatory effect of butyrate.136,137  
NF-κB is a transcription factor that controls the expression of genes encoding pro-
inflammatory cytokines, chemokines, inducible inflammatory enzymes such as 
inducible NO synthase and cyclooxygenase-2, adhesion molecules, growth factors, 
some acute phase proteins, and immune receptors.138 In a study with UC patients, 
the increased mucosal levels of activated NF-κB were reduced by butyrate and this 
correlated with a decrease in the disease activity index and the numbers of 
infiltrated neutrophils and lymphocytes.116 This anti-inflammatory effect of butyrate 
via NF-κB inhibition, contributing for example to decreased concentrations of 
myloperoxidase, cyclooxygenase-2, adhesion molecules and different cytokine 
levels, has been confirmed in several in vitro and in vivo studies.109,111,112 
Apart from inhibition of NF-κB activation, butyrate may also exert an anti-
inflammatory activity through inhibition of the interferon-γ -production and/or -
signalling139,140 and the upregulation of peroxisome proliferator-activated receptor-γ 
(PPARγ).141-145 PPARγ is a ligand-activated transcription factor that is highly 
expressed in colonic epithelial cells and its activation is thought to exert anti-
inflammatory effects.146 PPARγ protein expression is 60% lower in the non-
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inflamed colonic mucosa of UC patients compared to controls.147 Modulation of 
PPARγ protein expression in UC may prove to be an interesting treatment for UC. 
Finally, butyrate as well as other SCFA can act as signalling molecules through 
specific G-protein-coupled receptors, GPR41 and GPR43, identified for SCFA.148-
150 These two SCFA receptors are expressed on immune cells, particularly 
polymorphonuclear leukocytes, and are also highly present in the colonic 
mucosa.151 It has been hypothesised that these receptors play a role in the immune 
surveillance of the colonic mucosa towards microbial activity.149-151  
In conclusion, several mechanisms for the anti-inflammatory activity of butyrate 
have been described, which can contribute to the observed clinical effectiveness of 
colonic butyrate supplementation on colonic inflammation.  
Butyrate and oxidative stress 
As described above, butyrate may influence the inflammatory process and the 
initiation and progression of carcinogenesis. In both these processes, oxidative 
stress is involved.152,153 Oxidative stress is the result of an imbalance between the 
generation of reactive oxygen and reactive nitrogen species and the antioxidant 
defence mechanisms, resulting in a cascade of reactions in which lipids, proteins 
and DNA may be damaged. Neutrophilic granulocytes are an important source of 
potent oxidising species in the inflamed colon.152  
There is some evidence that butyrate is able to modulate oxidative stress. In two 
studies, pre-incubation of isolated rat154 or human155 colonocytes with butyrate 
showed a significant reduction of H2O2-induced DNA damage. In rats, resistant 
starch intake decreased the levels of colonocyte DNA damage induced by a high 
protein diet. This DNA damage correlated negatively with caecal butyrate 
concentrations.156 
The mechanism by which butyrate reduces oxidative stress is unknown. Scavenger 
activity of butyrate is unlikely due to its chemical structure. However, butyrate may 
affect DNA repair systems and levels of enzymatic or non-enzymatic (anti-) oxidant 
systems. For example, fermentable fibre supplementation resulted in a decreased 
colonic myeloperoxidase activity and a restoration of the colonic concentration of 
the antioxidant glutathione in a rat model of TNBS-induced colitis.157 In addition, 
butyrate enhanced the activity of glutathione-S-tranferase in HT-29 cells88 and 
increased catalase activity in artery smooth muscle cells of rats.158  
Although human in vivo data are not yet available, butyrate may enhance the 
protection against mucosal oxidative stress by affecting the activity of intracellular 
antioxidants, DNA repair systems or (anti-) oxidant enzymes. 
 
C
ha
pt
er
 2
 
 
32 
Butyrate and the colonic defence barrier 
Besides the effects of butyrate on carcinogenesis, inflammation and oxidative 
stress, butyrate has been shown to affect several components of the colonic 
defence barrier leading to enhanced protection against luminal antigens. One 
important component of this barrier is the mucus layer covering the epithelial lining 
consisting of mainly mucin glycoproteins and trefoil factors. Mucin glycoproteins 
are classified into neutral and acidic subtypes and the latter category further 
includes sulfomucins and sialomucins. Sulphated mucins are generally considered 
to be more resistant to bacterial degradation.159 Several epithelial mucin (MUC)-
genes have been identified in humans, of which MUC2 is predominantly expressed 
in the human colon.160 Alterations in goblet cell function, composition and thickness 
of the intestinal mucus layer have been found in several intestinal disorders. For 
example, a reduced mucus thickness and a decreased MUC2 production has been 
reported in UC patients.161  
In in vitro studies, butyrate increased the MUC2 gene expression in specific cell 
lines.162-165 In addition, 0.1-1 mmol/L butyrate administered to human colonic 
biopsy specimens ex vivo stimulated mucin synthesis.166 Luminal butyrate 
administration of 5 mmol/L, but not 100 mmol/L, increased mucus secretion in an 
isolated perfused rat colon.167 In another rat study, caecal and faecal SCFA 
concentrations were found to correlate with mucus thickness. In humans effects of 
butyrate alone on mucus synthesis, thickness of the mucus layer and MUC 
expression in vivo have not been reported. 
The effects of a number of fermentable dietary fibres on the mucus layer have 
been studied with varying results. For example, resistant starch increased the 
number of acidic mucins, but did not affect the number of goblet-cells in rats.61 In 
contrast, fructo-oligosaccharides increased the number of goblet-cells in piglets.168 
In a human intervention study with patients with an ileo-anal pouch, inulin 
supplementation did not alter MUC2 expression nor the ratio between sulpho- and 
sialomucins.169  
Trefoil factors (TFF) are mucin-associated peptides that contribute to the 
viscoelastic properties of the mucus layer. TFF are thought to reduce the 
recruitment of inflammatory cells and to be involved in the maintenance and repair 
of the intestinal mucosa, although the exact mechanism for this effect is not yet 
known.170 Intestinal trefoil factor (ITF or TFF3) is almost exclusively secreted by the 
intestinal goblet cells.171 In a rat TNBS model of colitis, TFF3 expression was 
decreased during active disease, and intra-colonic administration of butyrate 
increased TFF3 expression112,172. However, butyrate inhibited the expression of 
TFF3 in colon cancer cell lines173,174 and in colonic tissue of newborn rats.173  
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Other components of the colonic defence barrier that are involved in the 
maintenance of the colonic barrier, which may be influenced by butyrate are 
transglutaminase, anti-microbial peptides and heat shock proteins (HSP).  
The enzyme transglutaminase is actively involved in intestinal mucosal healing and 
correlates with the severity of inflammation in UC.175 In a rat model of colitis, 
butyrate restored the colonic transglutaminase levels.62,176 Anti-microbial peptides 
such as cathelicidin (LL-37) and defensins, protect the gastrointestinal mucosa 
against the invasion and adherence of bacteria and thereby prevent infection.177-179 
Several in vitro studies have shown that butyrate upregulates the expression of LL-
37 in different colon epithelial cell lines as well as in freshly isolated colorectal 
epithelial cells.180 HSP confer protection against inflammation by suppressing the 
production of inflammatory modulators.181,182 Butyrate induced the expression of 
HSP70 and HSP25 in Caco-2 cells182 and in rats.61,181,183 However, in a study in 
rats with DSS induced colitis, butyrate inhibited HSP70 expression. This was 
related to protection against the decrease in cell viability, increase in mucosal 
permeability and neutrophil infiltration in DSS colitis. It was concluded that the 
induction of heat shock response has a protective effect before an injury, whereas 
activation of heat shock response leads to cytotoxic effects after a pro-
inflammatory stimulus.184  
In addition, there is evidence from in vitro studies with human colon cancer cell 
lines that butyrate is involved in repair after mucosal damage through an increase 
in the rate of cell migration. Efficient repair of superficial injuries and mucosal 
ulcers is important in maintaining and re-establishing the epithelial barrier.185  
In summary, there are several lines of evidence suggesting that butyrate reinforces 
the colonic defence barrier by affecting several components of this barrier, such as 
the promotion of epithelial migration and the induction of mucins, trefoil factor, 
transglutaminase activity, anti-microbial peptides and heat shock proteins. 
However, most of these effects still have to be confirmed in the human situation. 
Butyrate and intestinal epithelial permeability 
Intestinal epithelial permeability has been widely studied as an important parameter 
of the intestinal defence barrier. Under normal conditions, the epithelium provides a 
highly selective barrier that prevents the passage of toxic and pro-inflammatory 
molecules from the external milieu into the submucosa and systemic circulation. 
Macromolecules pass the epithelial barrier mainly via the paracellular route for 
which tight junctions are the rate limiting structures.186 Increased permeability, 
indicating impaired epithelial barrier function, is thought to be involved in the 
pathophysiology of several gastro-intestinal inflammatory diseases, but can either 
be a cause or a consequence of inflammation.187  
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Several studies have assessed the effects of butyrate on intestinal permeability in 
vitro as well as ex vivo. At low concentrations, butyrate (up to 2 mmol/L) induces a 
concentration-dependent reversible decrease in permeability in a Caco-2 and HT-
29 cell lines.188,189 This decrease in permeability may be related to the butyrate 
associated increased expression of tight junction proteins observed in different 
cultured cell lines, but this effect was shown to be cell type dependent190,191. At 
higher concentrations (8 mmol/L) however, butyrate increased the permeability in a 
Caco-2 cell line.189 An ex vivo study, using adult rat distal colon mucosa mounted 
in an Ussing chamber, demonstrated that acute exposure to butyrate at a 
concentration of 10 mmol/L, but not 1 or 5 mmol/L increased paracellular 
permeability in rat colon.192 This has also been demonstrated in rats fed a diet 
containing fermentable fructo-oligosaccharides (FOS). The rapid bacterial 
fermentation of FOS led to accumulation of high concentrations of SCFA that 
increased intestinal permeability and was associated with increased translocation 
of Salmonella.193 However, in humans, daily FOS supplementation of 20 g did not 
increase intestinal permeability.194  
It can be concluded that the effect of butyrate on intestinal permeability depends on 
its concentration and on the model system or species used. The effects of butyrate 
at different concentrations remain to be evaluated in the human in vivo situation.  
Butyrate and satiety 
It has been hypothesised that SCFA produced in the large intestine also can 
influence upper gut motility and satiety.195 Endocrine L-cells present in large 
numbers in the colonic mucosa secrete peptides such as glucagon-like-peptide 1 
(GLP-1), peptide YY (PYY) and oxyntomodulin, which are involved in appetite 
regulation.196 In several animal studies using fermentable carbohydrates such as 
inulin196, lactitol197 and fructo-oligosaccharides198,199, an increased satiety, 
decreased weight gain and increased endogenous production of GLP-1 and/or 
PYY was reported. In humans, fructooligosaccharides increased satiety200 and 
increased plasma GLP-1 concentrations.201 However, lactitol did not affect plasma 
concentrations of this gut peptide.197  
The increased satiety is possibly promoted through the production of SCFA. This is 
supported by a number of studies. Butyrate increased the expression of PYY and 
proglucagon in vitro in rat epithelial cells 202 and increased PYY release, but not 
that of GLP-1, in the isolated colon of rats203,204 and rabbits.205 In addition, colonic 
SCFA infusion in rats stimulated PYY release.206 However, colonic infusion with 
SCFA in humans did not increase plasma levels of either PYY or GLP-1.207 
Activation of the SCFA receptor GPR43 expressed in endocrine L-cells may play a 
role in this effect on satiety.148 
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There is increasing evidence that the effect of fermentable dietary fibre on satiety is 
mediated through the colonic production of SCFA. However most evidence 
originates from rat studies, while again human evidence remains limited.  
Adverse effects of butyrate 
In contrast to the wide range of positive effects of butyrate on the intestinal 
mucosa, a small number of studies have also shown some adverse effects. Two rat 
studies revealed that rectal administration of butyrate (8-1000 mmol/L), dose-
dependently increased colonic visceral sensitivity.208, 209 However, these effects 
have not yet been reported in humans.   
In faeces of weaning children low butyrate concentrations have been measured.210 
It has been hypothesised that overproduction or accumulation of SCFA may be 
toxic to the intestinal mucosa of premature infants and might play a role in the 
pathogenesis of neonatal necrotizing enterocolitis. It has been demonstrated that 
the severity of mucosal injury to butyrate, measured in newborn rats, was dose 
dependent and also depended on the maturation of the intestine.173,211,212 It 
remains to be established whether luminal butyrate in premature infants can 
increase towards levels that are toxic for the intestinal mucosa.212 In addition, as 
mentioned before, increased permeability and Salmonella translocation has been 
found after fructo-oligosaccharide supplementation in a study with rats, which may 
be the result of SCFA accumulation.193 However, this was not confirmed in the 
human situation.194  
Conclusions 
SCFA are important end-products of microbial fermentation. Among the SCFA 
produced in the human intestine, butyrate has been widely studied and has been 
shown to play an important role in the maintenance of colonic health. Increased 
butyrate production in the large intestine seems to be responsible for at least some 
of the protective effects of fermentable dietary fibre. However, it should be taken 
into account that the effects of increased butyrate production may be accompanied 
by other effects of dietary fibres and its fermentation, such as changes in the 
composition of the intestinal microbiota and increased faecal bulking.  
The effects of butyrate are diverse and complex and involve several distinct 
mechanisms that go beyond the classical impact as an energy source for the 
intestinal epithelial cells. Frequently described are the effect on gene expression 
due the inhibition of histone deacetylase and the suppression of NF-κB activation. 
Hence, butyrate exerts multiple effects such as the inhibition of colonic 
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carcinogenesis, inflammation and oxidative stress, the improvement of the colonic 
defence barrier function and the promotion of satiety.  
It should, however, be noted that also some equivocal results have been reported, 
which partly can be explained by the different butyrate concentrations and models 
used. In addition, a few animal and in vitro studies demonstrate negative effects at 
higher butyrate concentrations on permeability and visceral sensitivity of the large 
intestine. 
In conclusion, in the last decade several new insights into possible mechanisms 
and effects revealed that butyrate is a pivotal metabolite produced within the large 
intestine. However, these new insights are mainly based on in vitro data, animal 
models and some clinical intervention studies. More emphasis should be put on 
human in vivo studies to elucidate the role of butyrate in health and disease. 
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Abstract 
Background 
Short chain fatty acids (SCFA) are often hypothesised to play a role in the maintenance of colonic 
health. However, most studies focus on butyrate, while the effects of other SCFA with different chain 
lengths are studied less extensively. In addition, effects are hard to compare as they involve separate 
studies and/or different models. Therefore, the aim was to compare the effects of C2 to C6 SCFA on 
parameters of inflammation, antioxidant capacity and epithelial integrity in one study.  
 
Methods 
Using a co-culture system combining Caco-2 cells with human whole blood cultures the effects of 1, 5, 
and 20 mmol/L of the different SCFA on cytokine release were evaluated. In addition, the effects of the 
SCFA on glutathione (GSH) and glutathione disulfide (GSSG) levels and the transepithelial electrical 
resistance (TEER) were analysed using Caco-2 cells.  
 
Results 
Butyrate showed a dose-dependent inhibition of several pro-inflammatory cytokines, such as IL-6, IL-17, 
IL-1β and TNF-α. The anti-inflammatory cytokine IL-10 was increased by 1 mmol/L butyrate, while 5 and 
20 mmol/L decreased its concentration. Although less pronounced than butyrate, also various significant 
effects on cytokine release were observed for propionate, valerate and caproate, but not acetate. All 
SCFA dose-dependently increased GSH and decreased GSSG concentrations in differentiated Caco-2 
cells, while only the highest concentration of butyrate improved the TEER significantly.  
 
Conclusion 
From the different SCFA produced by colonic microbial fermentation in vivo, not only butyrate, but also 
other SCFA are able to decrease pro-inflammatory cytokine production and to improve the antioxidant 
status.  
Effects of SCFA in an in vitro co-culture model⏐51 
Introduction 
Short-chain fatty acids (SCFA) are important end products of luminal microbial 
fermentation of predominantly non-digestible dietary carbohydrates. SCFA with 
different carbon chain lengths (acetate (C2), propionate (C3), butyrate (C4), 
valerate (C5) and caproate (C6)) are produced in varying amounts depending on 
the diet and the composition of the intestinal microbiota.1 More than 95% of the 
SCFA produced is rapidly absorbed. Besides being an important energy source for 
the colonocytes, SCFA have been shown to play a positive role in the maintenance 
of colonic health and barrier function.2 From the different SCFA, butyrate has by far 
been the most extensively studied. Beneficial effects of butyrate have for example 
been reported in patients with inflammatory bowel disease.3-5 Previous studies 
have demonstrated that such anti-inflammatory effects of butyrate could be 
mediated by up regulation of PPAR-γ6 and inhibition of NF-κB activation7, which 
affect the level of inflammatory mediators such as interleukins (IL), tumour necrosis 
factor (TNF) and interferon-γ (IFN-γ). These cytokines are secreted by a variety of 
different cell types that mediate and regulate immunity, inflammation and 
haematopoiesis. The type of cytokines produced also partly determines whether 
naive T-helper cells develop into T-helper 1, T-helper 2 or T-helper 17 cells, each 
expressing different cytokine patterns8,9 On the other hand, regulatory T-cells are 
able to suppress immune activation. One proposed mechanism of this effect is via 
production of anti-inflammatory cytokines such as IL-10 and transforming growth 
factor beta (TGF-β).10  
Limited numbers of studies using different models have investigated the anti-
inflammatory effects of SCFA with different chain lengths. One in vitro study using 
isolated human neutrophils, colon cultures from mice and the Colo320DM cell line, 
has demonstrated anti-inflammatory effects of propionate and acetate, which were 
comparable, although slightly less potent, to those of butyrate.11 This is in line with 
another in vitro study using human umbilical vein endothelial cells that showed less 
potent effects of valerate and propionate on leukocyte infiltration compared to 
butyrate.12  
 
In addition to the anti-inflammatory properties of butyrate, a number of studies 
have reported that butyrate was able to modulate oxidative stress13,14 and epithelial 
permeability.15,16 Oxidative stress is involved in the inflammatory process by the 
generation of reactive oxygen and nitrogen species by inflammatory cells. 
Increased inflammation and oxidative stress have been shown to disrupt mucosal 
barrier function of the intestinal epithelium, resulting in increased permeability.17 A 
decrease of oxidative stress by butyrate has for example been demonstrated by a 
reduction of H2O2 induced DNA damage in isolated human colonocytes 
preincubated with butyrate14 and by a restoration of the levels of the antioxidant 
glutathione (GSH) in a rat colitis model after dietary fibre supplementation that 
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increased the production of butyrate.13 The transepithelial electrical resistance 
(TEER) in Caco-2 cells was found to be increased by butyrate at low 
concentrations (2 mmol/L).15,16 However, data on the effects of other SCFA 
regarding oxidative stress and permeability are hardly available.  
 
The present study aims to compare the effects of the different SCFA with chain 
lengths varying from two to six carbon atoms on parameters of inflammation, 
antioxidant capacity and permeability in one in vitro model. Using a co-culture 
system combining Caco-2 cells with human whole blood cultures, i.e. the EDI-Co 
gut model18, the influence of the different SCFA on cytokine release were 
evaluated. Since other parameters may also reflect the functionality of the Caco-2 
cells, we further evaluated the effects on the antioxidant capacity by determination 
of the GSH and glutathione disulfide (GSSG) levels, the transport and metabolic 
use of the various SCFA as well as the effects on transepithelial electrical 
resistance (TEER).  
Materials and Methods 
SCFA 
The sodium salts of acetate, butyrate and valerate were purchased from Merck 
(Amsterdam, the Netherlands). Sodium propionate and caproic acid were 
purchased from Sigma (Zwijndrecht, the Netherlands). The different SCFA were 
dissolved in cell culture medium, checked for the pH and neutralised with NaOH if 
necessary. SCFA were tested in 3 concentrations: 1, 5 and 20 mmol/L. In addition, 
medium without SCFA was included as control. 
Co-culture of Caco-2 cells with whole blood cells 
Caco-2 cells, a widely used human colonic epithelial cell line (German collection for 
microorganisms and cell cultures, Braunschweig, Germany), were grown in culture 
medium (MEM-E-with Earle's salt base (Biochrom, Berlin, Germany)) 
supplemented with 20% fetal calf serum (Biochrom), 1% non-essential amino acids 
(Biochrom), 1% glutamine (Sigma) and 1% penicillin/streptomycin (Sigma) and 
were maintained at 37oC in a humidified 5% CO2 atmosphere. The medium was 
changed every 2-3 days. 
For the co-culture experiments with whole blood to evaluate the release of different 
cytokines (Figure 3.1), cells (passages 3-6 of stock cells) were seeded into 
transwell inserts (pore size 0.4 μm, diameter 6.5 mm) (Corning, NY, USA)) at 2 x 
104 cells/well in 0.2 mL culture medium. Transwell inserts were then placed in 0.9 
mL medium (i.e. at the basolateral side) in a 24-well plate (Corning). Cells were 
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allowed to attach, reach confluency and differentiate for 8 days. Before the start of 
the co-culture experiment, the TEER was measured as an indicator of epithelial 
integrity using the Millicell-Electrical Resistance System (Millipore, Bedford, USA). 
In all instances, the TEER value exerted a level of more than 300 Ω/cm2, 
demonstrating an intact barrier function of the culture system. Thereafter, the 
medium of the transwell inserts was replaced with medium containing the SCFA 
with different chain lengths (C2-C6) in 3 concentrations (1, 5 or 20 mmol/L). Each 
concentration was tested in duplicate. Subsequently, the transwell inserts were 
transferred to 24 well plates containing a whole blood culture from a healthy donor. 
The co-culture experiment was performed with blood of 3 healthy donors (A, B and 
C). After 4.5 hours of co-incubation, the whole blood cultures in the lower 
compartment were stimulated with LPS (Calbiochem, Nottingham, UK) and 
Staphylococcus aureus enterotoxin B (SE-B; Bernhard-Nocht-Institute, Hamburg, 
Germany) both at 0.1 μg/mL. As compared to PBMC a higher concentration is 
necessary to stimulate cytokine release in the whole blood cell culture. After a total 
co-incubation period with SCFA of 24 hours, transwell inserts were re-transferred 
to the plate containing culture medium only in the lower compartment and the 
TEER was measured again. The whole blood cultures were further incubated for 
two hours until the supernatants from the lower compartment were carefully 
collected. Duplicates were pooled and stored at -20oC for analyses of cytokines.18 
 
 
 
 
 
Figure 3.1 Picture of the EDI-Co gut co-culture system. Caco-2 cells were grown on the apical side in 
the transwell insert (1). After differentiation they were incubated with SCFA. The 
basolateral side (lower compartment) is filled with the whole blood culture (2). Whole blood 
cells were stimulated and after 24 hours of co-incubation supernatant of the lower 
compartment was collected for cytokine determination (see Material and Methods).  
 
Determination of cytokines 
The following cytokines were determined using a standard multiplexed 
immunoassay according to manufacturers’ instructions (RBM, Austin, USA): 
granulocyte-macrophage colony stimulating factor (GM-CSF), IFN-γ, IL-10, 
IL-12p40, IL-12p70, IL-15, IL-17, IL-18, IL-1α, IL-1β, IL-1 receptor antagonist (IL-
1ra), IL-2, IL-23, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, monocyte chemotactic protein-1 
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(MCP-1), macrophage inflammatory protein-1α (MIP-1α), macrophage 
inflammatory protein-1β (MIP-1β), TNF-α and TNF-β. Concentrations of TGF-β 
were determined using a specific ELISA kit according to manufacturers’ 
instructions (R&D Systems, Abingdon, UK).  
Determination of transport and metabolic use of the SCFA 
For the determination of the epithelial transport and metabolic use of the SCFA by 
the Caco-2 cells the same procedure was followed as described for the co-culture 
experiment above, without the addition of the whole blood. After the 24 hours of 
incubation with SCFA, supernatants from the upper and lower compartment were 
collected for SCFA analyses. Samples were stored at -20oC until analysis by GC 
as described before.1 
Cell culture for the analysis of GSH and GSSG  
In order to study the effects of SCFA on GSH and GSSG, Caco-2 cells (passage 6-
7 of stock cells) were seeded in 6-well plates at 2x105 and 8x105 cells per well for 
experiments with proliferating cells and differentiated cells, respectively. A 24 hour 
incubation with SCFA in 2 mL of culture medium containing the different SCFA 
(C2-C6) in 3 concentrations (1, 5 or 20 mmol/L) or L-buthionine-sulfoximine (BSO, 
Sigma) in 3 concentrations (0.02, 0.2 or 2 mmol/L) was performed 2 days after 
seeding, when cells were in the proliferating state as well as 7 days after seeding 
when cells were in the differentiated state. At the end of the 24 hour incubation 
period, cells were washed with Hanks Buffered Salt Solution (Biochrom), 
trypsinised, washed with cold PBS and after centrifugation (5 min, 4oC, 470g), cells 
were lysed by addition of 1 mL cold 0.1% triton-X-100 (Sigma) and 0.6% 5-
Sulfosalicilic acid (Sigma). After 3 minutes in a sonication bath with ice water, 
samples were centrifuged (5 min, 4oC, 3000g). Supernatants were stored at -80oC 
until determination of GSH and GSSG using the recycling method described by 
Vandeputte et al.19 In brief, the increase in absorbance at 412 nm, caused by the 
GSH and GSSG driven reduction of 5’5’dithiobis 2-nitrobenzoic acid (Sigma) at 0.2 
mmol/L in the presence of nicotinamide adenine dinucleotide phosphate (Sigma) at 
0.15 mmol/L and GSSG-reductase (Sigma) at 1 U/mL, was measured for 3 
minutes. The slope of the increase in absorbance of the samples was compared to 
the slope of GSH and GSSG standards. To measure only the GSSG concentration 
with the same method, cell lysates were preincubated with 2-vinylpyridine (3% final 
concentration) for one hour, to remove GSH. The GSH concentration was 
calculated by subtracting two times the GSSG concentration from the total GSH 
concentration. The final concentrations were adjusted for the total protein content 
measured using the BCAtm protein assay kit (Pierce, Rockford IL, USA).  
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Statistical analysis 
All statistical analyses were performed with SPSS 15.0 software. All results were 
expressed as the stimulation index (SI) to indicate the effect of the specific SCFA 
compared to the effect of the medium control without SCFA, which was set equal 
to 1. The TEER value was expressed as the % of the TEER value at the start of 
the experiment. A linear mixed model with a random intercept was used to analyse 
the SI of the cytokine release as well as the TEER value. The Bonferroni correction 
was applied to correct for multiple testing, by setting the confidence interval at 
99.67%. When the confidence interval did not include “1”, the effect of the 
intervention was considered to be significantly different. Concerning the experiment 
for the evaluation of the effects of the different SCFA on GSH/GSSG, no 
significances were calculated as the experiment was performed once in duplicate. 
Results 
Influence of the SCFA on cytokine release 
Using a co-culture system with Caco-2 cells in combination with whole blood from 
healthy donors, the anti-inflammatory potential of different SCFA (C2-C6) was 
evaluated.  
Concentrations of IL-12p70, IL-15 and IL-23 were below the detection limit and 
were excluded from further analyses. All other cytokines showed increased 
concentrations after stimulation as compared to the unstimulated control. The 
mean SI of all these different cytokines after incubation with the various SCFA are 
presented in Table 3.1 and accompanied by representative graphic examples of 
cytokines in Figure 3.2.  
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Figure 3.2 Examples of dose-dependent effect of C2-C6 SCFA on cytokine release in an in vitro co-
culture system. The cytokine release from stimulated whole blood cells of 3 different 
healthy donors (3 lines; A ----, B --¼-- and C --U--) in the basolateral compartment is 
shown as stimulation index (SI). The release of the respective cytokine in the cultures 
without SCFA treatment was set at 1. 
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In the in vitro co-culture model, butyrate showed a dose-dependent inhibition of 
several of the cytokines determined, namely IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-
6, IL-12p40, IL-17, GM-CSF, TNF-α, TNF-β, MCP-1 and MIP-1β. Significances 
differed between these cytokines and are presented in Table 3.1. Several 
significant inhibitory effects on cytokine release were also observed for valerate, 
propionate, and caproate although these effects were less potent compared to 
those of butyrate. Acetate did not affect the release of any of the cytokines. A 
number of cytokines was significantly inhibited by butyrate only, such as GM-CSF, 
IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-17 and MCP-1. Summarizing, the findings did result 
in a rank order of inhibitory potency being butyrate >> valerate > propionate > 
caproate with regard to the inhibition of the above mentioned inflammatory cytokine 
release (Table 3.1 and Figure 3.2).  
In contrast to the inhibition of several pro-inflammatory cytokines, incubation with 
some of the SCFA led to an increase of IL-10, IL-7, IL-8 and MIP-1α: The release 
of IL-7 was stimulated by 1 and 5 mmol/L butyrate and by 5 and 20 mmol/L 
valerate. MIP-1α was increased by 20 mmol/L valerate only. With respect to IL-10 
and IL-8, diverse patterns occurred with significant dose-dependent dual effects: 
IL-10 was increased by 1 mmol/L, but decreased by 20 mmol/L butyrate. IL-8 was 
increased by high concentrations of propionate (20 mmol/L), valerate (5 and 20 
mmol/L) and caproate (20 mmol/L), but was not significantly affected by butyrate. 
Transport and metabolic use of the SCFA 
After 24 hours of incubation of the Caco-2 cells with the SCFA in the transwells, 
the concentrations of SCFA at the apical compartment decreased due to 
absorption and metabolism of the SCFA (Table 3.2). All SCFA were able to pass 
through the Caco-2 cell layer although the barrier function of the monolayer was 
intact at the beginning of the cell culture. Approximately 50% of the initial 20 
mmol/L of all SCFA was recovered from the basolateral side (C2: 43%; C3: 52.5%; 
C4: 47.5%; C5: 51.7%; C6: 49.5%). The sum of the apical and basolateral recovery 
of the 1 mmol/L was lowest for butyrate (29.9%) and valerate (31.2%). 
Influence of the SCFA on the TEER values 
Since we observed different effects of the C2-C6 SCFA on the inflammatory status, 
we further studied whether these SCFA influenced the TEER values and the anti-
oxidant capacity of the Caco-2 cells. The change in the TEER values in the 
transwell system due to the 24 hours incubation with the different SCFA was 
determined as a parameter of the integrity of the Caco-2 cell layer. The TEER 
value remained unchanged during the experiment when only medium without 
SCFA was present at the apical and basolateral side. In contrast, the mean TEER 
value decreased with 35.2 % (SD: 12.2) after 24 hours of incubation of the Caco-2 
cells without SCFA but with the stimulated whole blood culture on the basolateral 
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side. Figure 3.3 shows the mean change in TEER values due to incubation with the 
different SCFA (C2-C6) in 3 concentrations (1, 5 and 20 mmol/L) compared to the 
situation without incubation without SCFA indicated as SI (±SD). Although changes 
of the TEER were observed after incubation with the different SCFA, they did not 
reach significance except for the highest concentration of butyrate (20 mmol/L) that 
showed a significant increase in the TEER value compared to the TEER value of 
the control without butyrate (Figure 3.3). 
 
 
Table 3.2  Concentrations of SCFA and percentage of recovered SCFA after 24 hours (t=24h) of 
incubation with the Caco-2 cells at the apical and basolateral compartment of the 
transwells. 
 Acetate (C2) Propionate (C3) Butyrate (C4) Valerate (C5) Caproate (C6) 
Apical side t=0 
(mmol/L) 1 5 20 1 5 20 1 5 20 1 5 20 1 5 20 
Apical side t=24h 
(mmol/L) 0.06 1.07 7.43 0.23 1.02 5.73 0.09 0.89 6.18 <0.01 0.68 5.68 0.13 0.72 5.01 
Basolateral side  
t=24h  (mmol/L) 0.24 0.59 1.78 0.30 0.80 2.15 0.04 0.58 2.04 0.06 0.49 2.02 0.14 0.63 1.98 
Apical side t=24h 
(%) 6.0 22.9 39.8 16.3 19.4 31.0 9.1 17.0 32.0 0.0 14.4 32.2 13.4 18.1 27.8 
Basolateral side 
t=24h (%) 103.6 56.9 43.0 99.3 68.3 52.5 20.8 49.9 47.5 31.2 47.2 51.7 61.3 70.8 49.5 
Total (%)* 109.6 79.8 82.8 115.6 87.7 83.5 29.9 66.9 79.5 31.2 61.6 83.9 74.7 88.8 77.3 
* Total (%) reflects the % of the corresponding SCFA recovered as compared to the initial concentration 
(t=0). 
 
Influence of the SCFA on GSH/GSSG  
In order to study the influence of the C2-C6 SCFA on the GSH and GSSG level of 
the epithelial Caco-2 cells, we decided to use undifferentiated as well as 
differentiated cells, which are both generated in the gut and may be affected in a 
distinct way. In contrast to the proliferating cells that did not reach confluency when 
the incubation with SCFA started, the differentiated cells were confluent and dome-
like structures were observed that confirmed their differentiated state (data not 
shown).  
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Figure 3.3 Mean change in TEER values due to incubation with the different SCFA (C2-C6) in 3 
concentrations (1, 5 and 20 mmol/L) compared to the situation without incubation with 
SCFA indicated as SI (±SD). The TEER value of the experiment without SCFA treatment 
was set at 1. 
 *: Significant increase in the TEER value compared to the control with 0 mM of 
corresponding SCFA. 
 
 
After incubation with medium only (control values) proliferating cells contained 33.7 
μmol/g protein GSH (standard deviation (SD): 0.91) and 3.0 μmol/g protein GSSG 
(SD: 0.18), while the concentrations in differentiated cells were 6.5 μmol/g protein 
GSH (SD: 0.93) and 0.9 μmol/gram protein GSSG (SD: 0.08). In both the 
proliferating and the differentiated cells all concentrations of the GSH depleting L-
buthionine-sulfoximine (BSO)20, used as positive control, decreased concentrations 
of GSH and GSSG (Figure 3.4). The effects of the different SCFA are shown as 
stimulation index (SI) as compared to the control values described above, which 
were set at 1. In differentiated cells, all SCFA induced a dose-dependent increase 
of GSH with butyrate and valerate showing the highest increase. In contrast, the 
GSSG concentrations dramatically decreased after addition of all SCFA, leading to 
a 5-10 fold dose-dependent increase in the GSH/GSSG ratio (Figure 3.4). 
However, in proliferating cells all SCFA induced only slight increases of GSH and 
GSSG, resulting in no apparent effect on the GSH/GSSG ratio. 
 
 
*
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Differentiated cells Proliferating cells 
 
 
 
 
Figure 3.4 Effects of the various SCFA (C2-C6) on the level of GSH and GSSG and the GSH/GSSG 
ratio indicated as mean stimulation index SI (± standard deviation) compared to the control 
values adjusted for the protein content (based on duplicate experiments). The production of 
GSH and GSSG and their ratio in the cultures without SCFA treatment was set at 1. 
Concentrations of GSH and GSSG were measured in cell lysates from Caco-2 cells that 
were incubated for 24 hours with different concentrations of SCFA (1, 5 or 20 mmol/L). 
BSO, a GSH depleting agent, was used as a control. 
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Discussion 
The aim of the study was to compare the effects of SCFA with different chain 
lengths (C2-C6) on parameters of inflammation, cellular integrity and antioxidant 
capacity in vitro. This study showed that all SCFA, except acetate, were able to 
modulate the cytokine response in an in vitro co-culture system that combines 
Caco-2 cells with a whole blood culture. Butyrate (C4) showed the most potent 
effects, but also several clear inhibitory effects on cytokine responses were 
observed for caproate (C6) valerate (C5) and propionate (C3). Furthermore, all of 
the SCFA are able to induce a dose dependent increase of the concentrations of 
the antioxidant GSH in differentiated Caco-2 cells. The integrity of the Caco-2 cell 
layer as indicated by the TEER, significantly improved only after incubation with the 
highest concentration of butyrate.  
 
Anti-inflammatory properties of butyrate have previously been described in the 
literature7, while little is known about the effects of the other SCFA, although they 
are also abundantly produced within the colonic lumen, especially after 
consumption of a high fibre diet.21 In autopsy samples from sudden death victims, 
total SCFA concentrations varied from 137 to 197 mmol/kg chyme in the caecum to 
86 to 97 mmol/kg chyme in the descending colon.21,22 In these samples, 
C2:C3:C4:C5:C6 were found to be present in a molar ratio of approximately 
54:20:21:4:1.21 However, actual ratios may differ depending on the composition of 
the colonic microbiota and the substrates that are available for fermentation.1 In 
contrast to the in vivo situation, the applied in vitro model does not contain a mucus 
layer. Therefore, a lower concentration range of SCFA was used in our model (1,5, 
20 mmol/L), which is also in line with previous published in vitro data.23  
SCFA are reported to be rapidly absorbed24, which was also supported by the 
experiments in our in vitro study. In general, butyrate is considered to be the 
preferred energy source for colonocytes, while propionate is largely taken up by 
the liver and acetate enters the peripheral circulation to be metabolised by 
peripheral tissues.25 For valerate and caproate there are hardly any human data 
available. One study using rat colonocytes suggested that valerate and caproate 
are excellent substrates for colonic oxidation, similar to butyrate.26  
The data presented in our study may confirm these findings especially of valerate, 
since butyrate and valerate showed the lowest recovery rate probably suggesting a 
high degree of metabolism of these SCFA. 
 
To evaluate the effects of SCFA on the release of a  broad spectrum of mediators 
in the colon, a co-culture was used that combines differentiated human intestinal 
epithelial cells (Caco-2 cells) with human whole blood. Blood was derived from 
three different healthy donors to include inter-individual variation in the model. The 
major advantage of whole blood in contrast to the frequently used peripheral blood 
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mononuclear cell cultures is that whole blood cultures provide a more physiological 
environment and represent the entire spectrum of cellular as well as non-cellular 
components of the human immune system. In this co-culture model the gut 
epithelium not only serves as a natural barrier, separating non-absorbable 
substances from the immune cells, but also takes up and metabolises absorbable 
ingredients, as they would do in vivo. Equally important, it contributes significantly 
to a cytokine cross-talk comparable to what can be found in the human gut.18 
Therefore, this more complex in vitro model is expected to generate results that 
better reflect the physiologic situation, compared to mono-culture in vitro models, 
although the concentration of dendritic cells in the blood is rather low.. 
In the present study butyrate was found to decrease the release of a broad 
spectrum of cytokines including pro-inflammatory cytokines (e.g. TNF-α and IL-1β), 
IL-1ra, chemokines (e.g. MCP-1) and T-helper cell type 1 (e.g. IFN-γ) and type 2 
(e.g. IL-5) related cytokines in a dose-dependent manner. On the other hand, 
valerate, propionate and caproate were also able to affect the release of several 
cytokines, although to a lesser extent. Acetate did not affect cytokine production. 
Mostly, C3, C5 and C6 mimicked the effects of butyrate, but had different effects 
especially on the release of IL-8 and IL-10, which will be discussed later. Only 
butyrate, but no other SCFA tested, was able to inhibit the release of GM-CSF, IL-
1α, IL-1β, IL-4, IL-6 and IL-17.  
The effects of butyrate are in line with previous studies that showed that butyrate 
reduced concentrations of pro-inflammatory cytokines such as TNF-α, IL-1β and 
IL-6 in patients with Crohn’s disease5, in cultured isolated human lamina propria 
cells and in peripheral blood mononuclear cells.7 The most frequently reported 
mechanism by which butyrate exerts its anti-inflammatory effects is its ability to 
inhibit the activation of the transcription factor NF-κB that plays a central role in 
immune and inflammatory responses.4,7 It has been described that the inhibition of 
NF-κB activity can be the result of butyrate’s ability to inhibit histone deacetylase.27 
Hyperacetylation of histones disrupts their association with DNA, resulting in a 
more “open” chromatin structure that facilitates access to transcription factors of 
specific genes. The extent to which the other SCFA are able to inhibit NF-κB is 
unknown. Because propionate and valerate have also been demonstrated to 
possess the ability to induce histone hyperacetylation28-30, it could be hypothesised 
that the observed anti-inflammatory effects of valerate and propionate are also the 
result of an inhibition of NF-κB activity. Butyrate is a stronger inhibitor of histone 
deacetylase as compared to valerate and propionate28-30, which may explain the 
differences in magnitude of the effects. However, the fact that caproate does not 
demonstrate an effect on histone deacetylase while it is able to significantly 
decrease concentrations of TNF-α and TNF-β points towards the existence of an 
alternative mechanism, for example through alteration of the DNA methylation 
status.31 
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Previous in vitro studies have shown that butyrate is able to inhibit the pro-
inflammatory IFN-γ production and signalling.32,33 The present study does not 
report a significant effect of any of the SCFA on IFN-γ. However, a clear trend 
towards an inhibition of IFN-γ, was observed especially using butyrate (Figure 3.2). 
This inhibition was not considered significant due to the variation between the three 
blood donors and the very stringent statistical test with a confidence interval of 
99.67%. However, when a confidence interval of 99% is chosen, the decrease of 
IFN-γ is significant for 5 and 20 mmol/L of butyrate and 20 mmol/L of propionate 
and valerate.  
In contrast to the pronounced decrease of the secretion of a broad spectrum of 
pro-inflammatory and further cytokines, the secretion of the anti-inflammatory 
cytokine TGF-β was not significantly affected by all SCFA. Another anti-
inflammatory cytokine, IL-10, was differentially affected depending upon the 
concentrations and the SCFA used. While incubation with butyrate at a 
concentration of 1 mmol/L increased IL-10, higher concentrations decreased its 
secretion. These results are supported by a previous study with butyrate using 
human peripheral blood mononuclear cells34, which described that concentrations 
up to 1 mmol/L increased the concentrations of IL-10. Besides IL-10, also the 
secretion of IL-8 showed differences between the SCFA: IL-8 was not significantly 
affected by butyrate, while high concentrations of propionate, valerate and 
caproate increased its secretion. With regard to butyrate, inconsistent results have 
been reported using a variety of intestinal epithelial cell lines with an up-
regulation38 or a down-regulation35,37 of IL-8 production depending on the duration 
of the incubation36 and concentrationof butyrate.35  
Summarizing our data on the cytokine release, the abovementioned findings 
indicate that SCFA, especially C3-C5, may decrease inflammation by inhibiting the 
release of pro-inflammatory cytokines, rather than increasing the release of the 
anti-inflammatory cytokines. 
 
Besides inflammation also other processes determine the cell’s functionality, such 
as epithelial integrity and antioxidant capacity, which may be interrelated. 
Therefore, the effects of the various SCFA on the TEER and glutathione levels as 
parameters for epithelial integrity and antioxidant status, respectively, were further 
evaluated. 
In the literature there are several paradoxical reports concerning the effect of 
SCFA on epithelial barrier function.16,39 It has been reported that butyrate at low 
concentrations (up to 2 mmol/L) induced a concentration-dependent reversible 
decrease in permeability in Caco-2 and HT-29 cell lines16,39, while at higher 
concentrations (8 mmol/L), butyrate increased the permeability in Caco-2 cells, 
when it was exposed for more than 48 hours.16,39 In addition, propionate and 
acetate also decreased permeability, with a maximal responses for propionate at 
16 mmol/L, and 32 mmol/L for acetate.39 The data presented in our study 
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confirmed a significantly increased TEER value of the differentiated Caco-2 cell 
layer, only when butyrate was used at the highest concentration (20 mmol/L) 
suggesting an increased epithelial integrity and improved barrier function. Because 
the effects of the SCFA on barrier function was not the primary aim of the present 
study, we only determined the TEER as a marker for permeability, it would be 
interesting to further study other markers such as expression of different tight 
junction proteins, or mannitol or horseradish peroxidase fluxes over the epithelial 
layer.  
GSH is an important component of the antioxidant defence and a lack of GSH has 
been shown to result in severe degeneration of intestinal epithelial cells in mice.40 
A decrease of GSH accompanied by an increase of its oxidised form, GSSG is an 
indicator of oxidative stress as can also be observed in patients with inflammatory 
bowel disease.41 The 24 hour incubation with all SCFA resulted in a clear increase 
of GSH and decrease of GSSG in the differentiated colonic epithelial cells, with 
butyrate and valerate showing the most pronounced effects. The increase in GSH 
could possibly be related to the fact that SCFA are an energy source for the colonic 
epithelial cells, since glutamine, the preferred energy source in the small intestine, 
is also able to increase GSH.42 This may also explain why butyrate and valerate 
show the most pronounced effects, as these SCFA were preferentially 
metabolised. Due to the increase of GSH and the decrease of GSSG by the SCFA, 
the ratio of GSH and GSSG is increased 5-10 fold in a dose-dependent manner. 
These data are in line with a previous report showing an increase in GSH after 
incubation with butyrate using vascular smooth muscle cells.43 In contrast, in the 
human colon cancer cell line HT-29, butyrate was found to decrease GSH 
concentrations.20,44 These equivocal results could be explained by the different cell 
lines and concentrations used, but they may also be due to the state of the cells 
since we could demonstrate in the present study that proliferating cells contain 
more GSH and GSSG and do not respond as differentiated cells do to SCFA. Our 
observation that the effects of butyrate on GSH depend on the phenotypic state of 
the cell has also been reported with regard to its effect on proliferation.45  
As the human colon is continuously exposed to a variety of toxic stimuli that are 
able to induce inflammatory effects, improved epithelial barrier function and 
antioxidant status due to the presence of increased concentrations of the different 
SCFA could thereby contribute to protection against inflammation. 
 
In conclusion, this study performed with a co-culture model showed that among the 
various SCFA produced by luminal microbial fermentation, butyrate exerts the most 
potent effects on the inhibition of the release of several cytokines that have been 
shown to play an important role in inflammatory intestinal bowel diseases, 
improvement of the TEER and stimulation of the antioxidant glutathione. 
Remarkably, such effects were also observed for valerate, propionate and 
caproate with a rank order of potency being butyrate >> valerate > propionate > 
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caproate.  Future studies could further focus on the effects of combinations of 
these SCFA as produced in vivo during colonic homeostasis. 
Our study supports the proposed beneficial role of butyrate, but also of other C3-
C6 SCFA on the maintenance of colonic health. If interventional dietary strategies 
designed to maximise colonic levels of these SCFA exert clinical and public health 
benefits remains to be shown. 
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Abstract 
Background 
Butyrate, a short chain fatty acid produced by colonic microbial fermentation of undigested 
carbohydrates, has been implicated in the maintenance of colonic health. This study evaluates whether 
butyrate plays a role in oxidative stress in the healthy colonic mucosa. 
 
Methods 
A randomised, double blind, cross-over study with 16 healthy volunteers was performed. Treatments 
consisted of daily rectal administration of a 60 mL enema containing 100 mmol/L sodium-butyrate or 
saline for two weeks. After each treatment, a blood sample was taken and mucosal biopsies were 
obtained from the sigmoid colon. In biopsies, the trolox equivalent antioxidant capacity, activity of 
glutathione-S-transferase, concentration of uric acid, glutathione (GSH), glutathione disulphide and 
malondialdehyde and expression of genes involved in GSH and uric acid metabolism was determined. 
Secondary outcome parameters were CRP, calprotectin and intestinal fatty acid binding protein in 
plasma and histological inflammatory scores. 
 
Results 
Butyrate treatment resulted in significantly higher GSH  (p<0.05) and lower uric acid (p<0.01) 
concentrations compared to placebo. Changes in GSH and uric acid were accompanied by increased 
and decreased expression, respectively, of their rate limiting enzymes determined by RT-PCR. No 
significant differences were found in other parameters. 
 
Conclusion 
This study demonstrated that butyrate is able to beneficially affect oxidative stress in the healthy human 
colon. 
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Introduction 
Butyrate is a four-carbon short-chain fatty acid produced by bacterial fermentation 
of mainly undigested dietary carbohydrates within the colonic lumen. Increased 
butyrate production has often been hypothesised to be one of the beneficial effects 
of prebiotics. The effects of butyrate on colonic mucosal health have been widely 
studied. Apart from being the preferred energy source for colonic epithelial cells, 
butyrate can induce changes in gene expression influencing colonic function, 
mainly by inhibiting histone deacetylase.1 Several studies have shown that butyrate 
has anti-carcinogenic and anti-inflammatory effects.2 In vitro, butyrate has been 
shown to reduce inflammation by inhibition of NFκB activation3 and upregulation of 
PPARγ.4 In vivo, several studies have demonstrated a decrease in inflammation 
due to rectal administration of butyrate or mixtures of SCFA in patients with active 
ulcerative colitis5,6 and diversion colitis7,8, although not all studies were able to 
show significant effects.8 
Oxidative stress is involved in both inflammation9 and the process of initiation and 
progression of carcinogenesis.10 During oxidative stress there is an imbalance 
between the generation of reactive oxygen species (ROS) and the antioxidant 
defence mechanisms, leading to a cascade of reactions in which lipids, proteins 
and/or DNA may get damaged. Increased oxidative stress in the intestinal 
epithelium has for example been shown to disrupt mucosal barrier function of 
intestinal epithelial cells, resulting in increased permeability.11 In the inflamed 
colon, neutrophilic granulocytes are an important source of potent oxidizing 
metabolites such as superoxide radicals and hydroxyl radicals. To protect against 
ROS, multiple antioxidant defence mechanisms exist, including antioxidant 
enzymes, such as glutathione-S-transferase (GST) and glutathione peroxidase 
(GPX), and non-enzymatic antioxidant molecules, such as glutathione (GSH) and 
uric acid. 
Limited evidence shows that oxidative stress in the colonic mucosa can be 
modulated by butyrate. In two in vitro studies, pre-incubation of isolated rat12 or 
human13 colonocytes with butyrate resulted in a significant reduction of H2O2-
induced DNA damage. In rats, resistant starch intake decreased the levels of 
colonocyte DNA damage induced by a high protein diet. This DNA damage 
correlated negatively with caecal butyrate concentrations.14 The mechanism by 
which butyrate reduces oxidative stress is unknown. Primary antioxidant capacity 
of butyrate is unlikely as butyrate does not act as a free-radical scavenger due to 
its chemical structure. However, butyrate may act as a secondary antioxidant by 
affecting DNA repair systems and levels of enzymatic or non-enzymatic 
antioxidants. For example in a rat model of TNBS-induced colitis, fermentable fibre 
supplementation resulted in increased colonic concentrations of butyrate, a 
decreased colonic myeloperoxidase (MPO) activity and a restoration of the colonic 
GSH concentration.15 In addition, butyrate has been reported to enhance GST 
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expression in HT-29 cells.16-18 However, these effects have not yet been 
demonstrated in vivo in humans.  
In the present study the effects of butyrate on several parameters of oxidative 
damage and antioxidant defence are evaluated in human colonic biopsies of 
healthy volunteers. As secondary parameters, markers of inflammation are 
included. 
Materials and Methods 
Subjects 
Sixteen healthy non-smoking volunteers (4 males, 12 females, median age 23 (18-
62) years) participated in the study. The subjects were on a stable Western diet 
and had no history of gastrointestinal diseases. In addition, they did not use 
immunosuppressive drugs, antibiotics, anti-diarrhoeal drugs and laxatives during 
and in the last three months prior to the study. Subjects did not consume pre- or 
probiotics during and two weeks prior to the study. Subjects gave their written 
informed consent before participating. The study has been performed in accordance 
with the principles of the declaration of Helsinki and was approved by the Medical 
Ethics Committee of the University Hospital Maastricht, the Netherlands. 
Study design 
This study was performed according to a randomised double-blind placebo 
controlled cross-over design with two test periods of two weeks separated by a 
wash-out period of two weeks. Throughout the two test periods, subjects were 
instructed to maintain their habitual diet and their usual pattern of physical activity. 
Volunteers self-administered a 60 mL enema once daily for two weeks containing 
either a sodium butyrate solution (100 mmol/L) or a placebo solution (140 mmol/L 
NaCl) with a neutral pH in a random order. The butyrate enemas were made 
isotonic by the addition of NaCl (40 mmol/L). Volunteers were instructed to self-
administer the enema prior to sleeping, and to stay in a left-lateral supine position 
for at least 15 min. Compliance was evaluated on the basis of a questionnaire and 
the returned enema-bottles. 
In the morning after the administration of the last enema and after an overnight 
fast, a sigmoidoscopy was performed without prior bowel cleansing by a 
gastroenterologist who was blinded for the intervention, and mucosal biopsies were 
taken from a standardised location of the sigmoid (approximately 20 cm from the 
anal sphincter at the location of the arteria iliaca communis). Two biopsies were 
used for analyses of oxidative stress parameters and one biopsy was used for RNA 
isolation. These biopsies were immediately frozen in liquid nitrogen. Two other 
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biopsies were fixed in formalin and embedded in paraffin for histological 
determination of the overall inflammatory score. After the endoscopic procedure, a 
blood sample was obtained and centrifuged immediately (15 min, 1750g, 4°C). 
Plasma was stored at -80°C until analysis.  To standardise the diet prior to the 
sigmoidoscopy, the volunteers recorded their dietary intake three days before the 
first sigmoidoscopy and repeated this intake before the second sigmoidoscopy. 
Analyses of colonic biopsies 
Preparation of biopsy homogenates for oxidative stress analyses 
Two frozen biopsies were grinded with a mortar and pastel cooled in liquid 
nitrogen. The powder was resuspended in 240 μL ice-cold milliQ. From this 
suspension 90 μL was added to 9 μL of an acidic buffer (13% 5-Sulfosalicilic acid, 
100 mmol/L HCl in PBS) and was centrifuged (5 min, 14000g, 4°C). The 
supernatant was used for the determination of total GSH (tGSH) and glutathione 
disulfide (GSSG), the oxidised form of GSH. The remaining suspension was 
centrifuged (5 min, 14000g, 4°C) and the supernatant was stored at -80°C until the 
determination of GST activity, malondialdehyde (MDA), trolox equivalent 
antioxidant capacity (TEAC) and uric acid. Total protein content in the supernatants 
was quantified using a BCAtm protein assay kit (Pierce, Rockford IL, USA).  
GST 
GST activity was determined using the GST catalysed reaction of 
chlorodinitrobenzene (CDNB, Sigma, Zwijndrecht, the Netherlands) with GSH 
resulting in glutathione-dinitrobenzene, a yellow coloured product measured at 340 
nm.19 Fifteen μl of tissue supernatant was added to 1 mmol/L CDNB and 1 mmol/L 
GSH in 1 mL of 100 mmol/L potassium phosphate buffer (pH 6.5). The increase in 
absorbance at 25°C was measured during 2 min. After correction for the non-
enzymatic reaction, the activity of GST in the sample was calculated using the 
molar absorptivity coefficient of GSH-dinitrobenzene. One unit of GST activity is 
defined as the amount of enzyme catalyzing the conjugation of 1 μmol substrate 
per min. 
TEAC 
The total antioxidant capacity assay was performed in deproteinated samples as 
described by Fischer et al.20 In short, the ABTS•+ solution was prepared by 
incubating 0.15 mg/mL ABTS (Sigma) and 0.53 mg/mL ABAP (Polysciences, 
Eppelheim, Germany) in sodium phosphate buffer (145 mmol/L, pH 7.4) at 70°C 
until the absorbance of the solution at 734 nm was 0.70 ± 0.02. Samples were 
deproteinated by adding an equal volume of 10% trichloro acetic acid to the 
sample. Fifty μl deproteinated tissue supernatant was mixed with 950 μl of the 
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ABTS•+ solution. After 5 min of incubation at 37°C, the absorbance at 734 nm was 
measured. The decrease in absorbance was related to that of trolox standards. 
Uric acid 
Uric acid was determined in the deproteinated sample by HPLC as described 
previously21 with minor modifications. Ten μl of the deproteinated sample or 
standard was injected into a HPLC system (Agilent, Palo Alto, CA, USA) equipped 
with an Alltima HP C18 AQ column, 150 x 4.6mm, particle size 5µm (Grace, 
Deerfield, IL, USA). Samples were eluted with 0.1% trifluoric acid in milliQ. 
Detection was performed at 292 nm.  
TBARS 
The determination of TBARS is based on the formation of a coloured adduct of 
MDA-like breakdown products of lipids with 2-thiobarbituric acid (TBA).22 Forty µL 
tissue supernatant or standard was added to 225 µL of TBA reagent (0.012 M TBA, 
0.32 M H3PO4, 0.68 mmol/L butylated hydroxytoluene and 0.01% EDTA). The 
mixture was incubated in a water bath for 1 hour at 100°C. After cooling, the MDA-
products were extracted with 125 µL butanol. After centrifugation (5000g), 30 µL of 
the butanol layer was injected into the HPLC system equipped with a fluorescence 
detector (set on excitation wavelength of 532 nm and emission wavelength of 553 
nm) and an Alltima C18 column (150 x 3.0 mm particle size 5 µm (Grace, 
Deerfield, IL, USA)). Samples were eluted with 65% milliQ, 35% methanol, 
containing 0.05% trifluoric acid.  
tGSH and GSSG 
tGSH and GSSG concentrations were determined using the recycling method 
described by Vandeputte et al.23 In short, the increase in absorbance at 412 nm, 
caused by the GSH and GSSG driven reduction of 5’5’dithiobis 2-nitrobenzoic acid 
(Sigma) at 0.2 mmol/L in the presence of nicotinamide adenine dinucleotide 
phosphate (Sigma) at 0.15 mmol/L and GSSG-reductase (Sigma) at 1 U/mL, was 
measured for 3 minutes. The slope of the increase in absorbance of the samples 
was compared to the slope of GSH and GSSG standards. To measure only the 
GSSG concentration with the same method, tissue supernatants were 
preincubated with 2-vinylpyridine (3% final concentration) for one hour, to remove 
GSH. The GSH concentration was calculated by subtracting two times the GSSG 
concentration from the total GSH concentration. The GSH/GSSG ratio was 
calculated as a marker of oxidative stress. 
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Real-Time PCR (RT-PCR) 
The expression of all essential genes in the uric acid and GSH pathway, apart from 
GST that was measured at the level of activity, were determined using RT-PCR. 
RNA was isolated from one frozen biopsy using TRIzol reagent (Invitrogen, 
Carlsbad, USA). RNA was purified with an RNeasy mini kit (Qiagen, Venlo, The 
Netherlands) combined with a DNase treatment using the RNase-Free DNase Set 
(Qiagen). 500ng Total RNA was used as a template for the cDNA reaction, which 
was synthesised using the iScript cDNA Synthesis kit (Bio-Rad, Veenendaal, The 
Netherlands). The cDNA was diluted to a concentration of 0.32 ng/μL. Each 
reaction contained 12.5 μL iQ Sybr Green Supermix (Bio-Rad), 1 μL each of 10 
μmol/L gene-specific forward and reverse primers, 4 μL cDNA template solution 
and 6.5 μL sterile H2O. Primer sequences are listed in Table 4.1. Housekeeping 
genes included were 18SrRNA, GAPDH and CANX. Reactions were run on the My 
IQ Single Colour RT-PCR Detection System (Bio-Rad). PCR conditions used were 
3 min at 95°C, followed by 40 amplification cycles of 10 sec at 95°C and 45 sec at 
60°C. 
 
Table 4.1 Primer information of housekeeping genes and essential genes involved in GSH and uric 
acid metabolism. 
   Sequence ID Forward primer (5’ → 3’) 
 
Reverse primer (5’ → 3’) 
CANX NM_001024649 CCACTGCTCCTCCTTCATCTCC CGGTATCGTCTTTCTTGGCTTTGG 
GAPDH NM_002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
18SrRNA M10098 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
GPX1 NM_000581 CCGACCCCAAGCTCATCACC GATGTCAGGCTCGATGTCAATGG 
GPX2 NM_002083 ATCCTGAACAGTCTCAAGTATG TGGGTCATCATAAGGGTAGG 
GPX3 NM_002084 ACATGCCTACAGGTATGCGTGATTG TGGAGTGGAGAACTGGAGAGAAAGG 
GR NM_000637 CAGGGACTTGGGTGTGATGAAATGC GAGGTAGGGTGAATGGCGACTGTG 
GS NM_000178 AAGACACTCGTGATGAACAAGC GGAGAGGAATGACAAATACAGAGG 
GCLC  NM_001498 TGGAAGTGGATGTGGACACC GTCTTGCTTGTAGTCAGGATGG 
GCLM  NM_002061 GGCACAGGTAAAACCAAATAGTAAC CAAATTGTTTAGCAAATGCAGTCA 
XDH NM_000379 CCTCTTCCTGGCTGCTTCTATCTTC TGACACACAGGGTGGTGAACTTG 
CANX: calnexin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; 18SrRNA: 18S ribosomal RNA; GPX: 
glutathione peroxidase; GR: glutathione reductase; GS: glutathione synthetase; GCLC: glutamate-cysteine ligase, 
catalytic subunit; GCLM: glutamate-cysteine ligase, modifier subunit; XDH: xanthine dehydrogenase. 
Histology 
Two mucosal biopsies were fixed separately in formaldehyde, embedded in 
paraffin and cut in 2 μm sections for H&E staining. Subsequently, the degree of 
inflammation was scored by one blinded observer on a four-point scale 
corresponding to none, mild, moderate or severe inflammation as previously 
described.24 
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Plasma markers 
ELISA kits were used for calprotectin (HBT, Uden, the Netherlands) and CRP 
(HBT) according to manufacturer’s instructions. Intestinal fatty acid binding proteins 
(I-FABP) are small cytoplasmic proteins expressed in the intestine. Systemic 
concentrations can be used as a marker for intestinal injury.25 Concentrations of I-
FABP were determined using a specific ELISA kit (HBT) according to 
manufacturer’s instructions. 
Statistical analysis 
Results are expressed as median and range. The non-parametric Wilcoxon signed-
rank test was used to identify significant differences. Pearsons correlations were 
determined between different parameters of oxidative stress. Differences were 
considered statistically significant when p<0.05. Statistical analyses were 
performed using SPSS 11.0 software.  
RT-PCR data were analysed using a Gaussian linear regression including the 
repeats, house keeping genes, and the intervention period. The inference criterion 
used for comparing the models is their ability to predict the observed data, i.e. 
models are compared directly through their minimised minus log-likelihood. When 
the numbers of parameters in models differed, they were penalised by adding the 
number of estimated parameters, a form of the Akaike information criterion (AIC).26 
For each gene, the treatment group was then added to the model. The gene under 
consideration was found to be differentially expressed if the AIC decreased 
compared to the model not containing the intervention. 
Results 
All 16 participants completed the study and returned all enema bottles empty. 
No side effects were reported. 
Oxidative stress parameters in colonic biopsies 
The effects of daily administration of 60 mL butyrate enemas (100 mmol/L) for 14 
days on parameters of oxidative stress in colonic biopsies are shown in Table 4.2. 
Butyrate treatment resulted in significantly higher concentrations of tGSH (27.2 vs. 
24.5 nmol/mg protein), GSH (26.5 vs. 22.9 nmol/mg protein) (p<0.05), and in lower 
uric acid levels (2.4 vs. 3.1 nmol/mg protein) (p<0.01) compared to placebo. In 
addition, a trend towards an increase in the GSH/GSSG ratio (90.8 vs. 71.1) 
(p=0.07) was found after butyrate treatment. No statistical differences were found 
in TEAC, GST, GSSG and MDA.  
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Table 4.2 Effect of butyrate enemas (100 mmol/L) once daily for 14 days on parameters of oxidative 
damage and antioxidant defence in colonic mucosal biopsies from 16 healthy volunteers. 
 
Placebo 
n=16 
Butyrate 
n=16 p-value 
TEAC (nmol trolox Eq/mg protein) 137.2 (112.6-210.7) 136.2 (116.2-207.6) 0.72 
Uric acid (nmol/mg protein) 3.1     (1.9-3.3) 2.4     (1.6-3.7) 0.01 
GST (U/mg protein) 0.34   (0.23-0.51) 0.32   (0.24-0.41) 0.55 
tGSH (nmol/mg protein) 24.5   (13.4-32.4) 27.2   (21.9-35.5) 0.03 
GSH (nmol/mg protein) 22.9   (12.0-31.5) 26.5   (20.4-35.2) 0.03 
GSSG (nmol/mg protein) 0.4     (1.9-2.13) 0.31   (0.08-2.69) 0.18 
GSH/GSSG ratio 71.1   (8.1-127) 90.8   (7.6-333.9) 0.07 
MDA (nmol/mg protein) 1.09   (0.69-2.2) 0.78   (0.44-1.44) 0.13 
Values expressed as medians (range) 
TEAC: trolox equivalent antioxidant capacity; GST: glutathione-S-transferase; tGSH: total glutathione; 
GSH: reduced glutathione; GSSG: glutathione disulfide; MDA: malondialdehyde 
 
 
A significant positive correlation was found between MDA and GSSG (R2=0.35), 
and a significant negative correlation was found between MDA and the GSH/GSSG 
ratio (R2=0.24). No significant correlation was found between MDA and GSH 
(Table 4.3). 
 
Table 4.3 Correlations between parameters of oxidative stress measured in colonic mucosal 
biopsies. 
 MDA 
 r R2 p-value 
GSSG 0.594 0.35 0.000 
tGSH -0.146 0.02 0.425 
GSH -0.289 0.08 0.109 
GSH/GSSG ratio  -0.485 0.24 0.005 
GSSG: glutathione disulfide; tGSH: total glutathione; GSH: reduced glutathione; MDA: malondialdehyde 
 
RT-PCR 
Fold changes including the confidence interval of these genes are shown in Figure 
4.1. mRNA expression of GPX1, GPX3 and GCLC in the mucosal biopsies were 
found to be significantly upregulated (1.07, 1.16 and 1.07, respectively) and mRNA 
expression of GPX2, GR, GS and XHD were found to be significantly 
downregulated (0.9, 0.93, 0.92 and 0.90, respectively).  
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Figure 4.1:  Effect of butyrate enemas (100 mmol/L) once daily for 14 days on colonic expression of 
genes involved in the GSH and uric acid pathway indicated as fold change and confidence 
interval. *: Significantly upregulated compared to placebo; **: Significantly downregulated 
compared to placebo. 
 GPX: glutathione peroxidase; GR: glutathione reductase; GS: glutathione synthetase; 
GCLC: glutamate-cysteine ligase, catalytic subunit; GCLM: glutamate-cysteine ligase, 
modifier subunit; XDH: xanthine dehydrogenase. 
Histology and plasma markers 
All H&E stained biopsy specimens were scored with 0 by the pathologist, indicating 
no increased inflammatory activity. 
Plasma concentrations of calprotectin, CRP and iFABP did not differ between the 
two treatments. 
Discussion 
In this study rectal butyrate administration was shown to enhance the antioxidant 
capacity of the colonic mucosa in healthy volunteers by increasing the GSH 
concentration. Also a decrease in uric acid concentrations was found. On the level 
of gene expression, this increase in GSH was accompanied by an increase in 
GCLC, the rate-limiting enzyme in GSH production. The decrease in uric acid was 
accompanied by a decrease in XDH, the enzyme that converts purines into uric 
acid and ROS. No effect of butyrate on inflammation and intestinal injury was found 
in this study with healthy volunteers. 
 
This is the first time that butyrate has been shown to increase the colonic 
concentrations of GSH in vivo in healthy humans. This increase in GSH in healthy 
volunteers is in line with a rat study with TNBS-induced colitis, in which a higher 
production of butyrate after dietary fibre supplementation resulted in an increase of 
colonic GSH.15 GSH is synthesised from glutamate, cysteine and glycine by the 
sequential actions of glutamate cysteine ligase (GCL) and glutathione synthase 
(GS). The rate-limiting enzyme for GSH synthesis is GCL, which consists of a 
heavy catalytic subunit (GCLC) and a light regulatory subunit (GCLM), each 
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encoded by separate genes. GSH is used to reduce hydrogen peroxide and 
lipidhydroperoxides catalysed by glutathione peroxidase (GPX). The produced 
GSSG can be converted back to GSH through the action of glutathione reductase 
(GR). GSH can also be used to detoxify endogenous and exogenous electrophiles 
through conjugation via glutathione-S-transferases (GST). 
On the level of gene expression, butyrate significantly affected several genes 
coding for different antioxidant enzymes, although fold changes were rather subtle. 
The increase in GSH was accompanied by a decrease of GS, an increase of GCLC 
and had no effect on GCLM. This is in accordance with other studies that have 
shown that an increase in GSH concentration was related to an increase in 
GCLC.27,28 Furthermore, butyrate increased the expression of the so-called 
cytosolic GPX1 and the plasma GPX3. A decrease in the expression of GPX2 was 
found, which is defined as the gastrointestinal GPX. This is in line with findings 
after resistant starch supplementation in 1,2-dimethylhydrazine-treated rats.29 The 
diverse effects on the different GPXs seem contradictory but may be explained by 
their distinct roles in cellular defence mechanisms.30 The expression of GR was 
decreased after butyrate treatment for which an obvious explanation is lacking. 
However, one has to keep in mind that increased gene expression does not always 
result in increased enzymatic activity. 
GSH is an important component of the antioxidant defence and a lack of GSH has 
been shown to result in severe degeneration of intestinal epithelial cells in mice.31 
In a rat model of colitis GSH administration improved the colonic histological score 
and reduced mucosal MDA concentrations.32 Reduced concentrations of GSH and 
increased concentrations of GSSG have been reported in patients with 
inflammatory bowel disease.33,34 However, in several other stress situations, an 
increase in GSH has been reported.35 Damage to the intestinal epithelium results in 
ATP release that ultimately leads to an increase in uric acid.36 Because in the 
present study a decrease in uric acid was found after butyrate treatment, damage 
to the epithelium is unlikely. This is further supported by the fact that no effects 
were seen on the included parameters of inflammation and epithelial damage. In 
addition, the GSSG concentrations slightly decreased, which resulted in a trend 
towards an increase of the GSH/GSSG ratio. MDA, the parameter of lipid 
peroxidation, also slightly decreased after butyrate supplementation although this 
was not statistically significant.  
 
In the present study a decrease in the colonic uric acid concentration was found 
after the butyrate intervention. In plasma, uric acid accounts for about half of the 
antioxidant capacity, while in colonic biopsies, it was found to have only a small 
contribution (<5%) to the total antioxidant capacity, supporting that this is not the 
major antioxidant in the colonic mucosa as previously reported.37  
In humans, uric acid is the final oxidation product of purine catabolism with 
xanthine dehydrogenase (XDH) being the rate-limiting enzyme. XDH can be 
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converted into xanthine oxidase by proteolytic activity that can be decreased by 
GSH. While XDH requires NAD+ and produces uric acid and NADH, xanthine 
oxidase requires oxygen and produces uric acid and ROS (Figure 4.2). Therefore, 
a decrease in uric acid production may also contribute to a decrease in ROS 
production and subsequently less oxidative damage.38 This may be of clinical 
relevance as in a previous study using a rat model of colitis, the xanthine oxidase 
inhibitor oxypurinol resulted in reduced concentrations of MDA.39 
The decrease in uric acid concentrations in the present study was accompanied by 
a decrease in expression of XDH. A direct effect of butyrate on xanthine oxidase 
activity could not be demonstrated in vitro (data not shown). 
 
 
 
 
 
Figure 4.2 Production of uric acid catalised by xanthine oxidase (XO) and xanthine dehydogenase 
(XDH). 
 
Butyrate administration did not affect the activity of GST in the present study. GSTs 
are a family of over 21 structurally different phase II enzymes, which are crucial in 
the cellular protection against oxidative stress.40 Previously, some cell culture 
studies have shown that butyrate upregulates several GST subclasses, such as 
GST-A3, GST-P1, and GST-T1.16-18 However, this did not always result in an 
increase of the GST activity.41 Therefore, it is possible that subtypes of GSTs were 
affected by the butyrate intervention without influencing its overall activity.  
 
We have demonstrated significant positive correlations between MDA and GSSG 
and negative correlations between MDA and the GSH/GSSG ratio. Increased 
concentrations of GSSG are an indicator of oxidative stress and have shown to 
correlate significantly with the disease activity index in patients with ulcerative 
colitis.33 The observed correlations support the validity of our assessments in 
human colonic biopsy samples from healthy individuals. 
 
Enemas were chosen for colonic administration of butyrate in order to standardise 
local concentrations. Another way to increase colonic butyrate concentrations 
would be through consumption of a high fibre diet. However, thereby local colonic 
concentrations of butyrate remain unknown and may differ between subjects 
depending on the fermentation capacity of their microbiota. Furthermore, after 
consumption of dietary fibre, butyrate is mainly produced in the proximal colon. By 
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using rectal enemas, butyrate reaches the distal colon, which is relatively easy 
accessible, and biopsies could be taken at this location without prior bowel 
cleansing in order to maintain the physiological situation. In a prior pilot study (data 
not shown), the volume of the 60 mL enemas was found to reach the sigmoid 
colon. The concentration of 100 mmol/L of butyrate was used as this is the 
expected local concentration after consumption of a high fibre diet. Previously, 
similar concentrations were used in studies with UC patients.5 A single enema only 
once daily before going to sleep was chosen to maximise the time that content of 
the enema is retained, as well as the compliance. A wash out period of two weeks 
was assumed to be long enough as butyrate is quickly absorbed and the intestinal 
mucosa undergoes rapid cell turnover.  
 
In conclusion, in the present study in healthy humans it has been demonstrated 
that locally administered butyrate in physiological concentrations increased the 
antioxidant GSH and possibly decreased ROS production, as indicated by a 
decreased uric acid production. As the human colon is continuously exposed to a 
variety of toxic stimuli, enhanced butyrate production in the colon could hereby 
result in an enhanced resistance against toxic stimuli and as such improve the 
barrier function. This might be relevant for both the pathophysiology as well as the 
treatment of gastrointestinal disorders such as post infectious irritable bowel 
syndrome, microscopic colitis, inflammatory bowel disease and diversion colitis. 
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Abstract 
Background 
Butyrate, produced by colonic fermentation of dietary fibres is often hypothesised to beneficially affect 
colonic health. This study aimed to assess the effects of butyrate on inflammation and oxidative stress 
in subjects with chronically mildly elevated parameters of inflammation and oxidative stress in colonic 
mucosa. 
 
Methods 
Thirty-five patients with ulcerative colitis in clinical remission daily administered 60 mL rectal enemas 
containing 100 mmol/L sodium-butyrate (n=17) or saline (n=18) during 20 days. Before and after each 
treatment 24-hour faeces was collected, a blood sample and mucosal biopsies from the unprepared 
sigmoid were obtained. In colonic biopsies, parameters of antioxidant defence and oxidative damage 
were determined as well as concentrations of myeloperoxidase and several pro and anti-inflammatory 
cytokines. In addition, faecal calprotectin and plasma CRP were determined. 
 
Results 
Butyrate enemas induced minor effects on colonic inflammation and oxidative stress. Only a significant 
increase of the colonic IL-10/IL-12 ratio was found in butyrate treated patients (p=0.02), and colonic 
mucosal concentrations of CCL5 were increased after butyrate compared to placebo treatment 
(p=0.03). Although in general butyrate did not affect colonic glutathione levels, the effects of butyrate 
enemas on total colonic glutathione appeared to be inversely related to the level of inflammation at the 
start of the study. 
 
Conclusion 
Although UC patients in clinical remission were characterised by low-grade oxidative stress and 
inflammation in the colonic mucosa, rectal butyrate enemas showed only minor effects on inflammatory 
and oxidative stress parameters. Possibly, higher concentrations than can be obtained by dietary 
means may be needed to obtain beneficial effects. 
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Introduction 
As several epidemiological studies show protective effects of dietary fibre intake on 
intestinal inflammation, colorectal cancer and cardiovascular disease1-4, there is 
increasing interest in adding indigestible fibres to dietary products. Short-chain fatty 
acids (SCFA), mainly acetate, propionate and butyrate, are important end-products 
of luminal microbial fermentation of these fibres and have been shown to play a 
role in the maintenance of colonic health and barrier function.5 Moreover, butyrate 
is the major energy source for colonocytes6 and several in vitro and animal studies 
have shown that butyrate is able to reduce inflammation mainly by inhibition of 
NFκB activation.7 Previous in vitro studies have demonstrated that from the 
different SCFA, butyrate showed the most potent inhibitory effects on pro-
inflammatory cytokine production8(submitted for publication). In addition, an in vivo 
study in healthy human volunteers showed that butyrate supplementation 
increased the colonic levels of the antioxidant glutathione (GSH).9 Other studies 
have also shown positive effects of butyrate on oxidative stress. In isolated human 
colonocytes, preincubation with butyrate was associated with a reduction of H2O2-
induced DNA damage.10 In a rat colitis model, increased colonic butyrate 
production after dietary fibre supplementation resulted in a restoration of colonic 
GSH levels.11 This indicates that besides anti-inflammatory properties, butyrate 
may also play a role in the modulation of oxidative stress. 
Most of the human intervention studies with butyrate administration published so 
far focused on overall clinical outcome parameters in patients with diversion colitis 
and active ulcerative colitis (UC). UC is a chronic inflammatory disorder of the 
colon that is characterised by alternating periods of flare-ups and quiescent 
disease. It is generally hypothesised that UC is the result of an exaggerated 
intestinal host response against luminal bacteria or their components, particularly in 
genetically susceptible individuals. Another factor that has been proposed to play a 
role in the pathophysiology of UC is oxidative stress, which is the result of excess 
production of reactive oxygen species due to aberrant cellular metabolism and 
increased activation of phagocytic leucocytes in the inflamed colon.12,13 In active 
UC patients, the administration of rectal enemas containing butyrate or mixtures of 
SCFA have been proven effective in lowering clinical symptoms and overall 
inflammatory scores.14,15 
In addition to this clinical therapeutic setting, it is also of interest whether butyrate, 
being an important end-product of dietary fibre fermentation, could have beneficial 
effects in a mildly disturbed gut health situation, such as in patients with UC in 
remission. These patients have no or minimal clinical symptoms during quiescent 
disease, but are still reported to maintain a chronic low-grade inflammation and 
oxidative stress of the colonic mucosa.16-18 Possible beneficial effects of butyrate 
administration in this patient group can be expected as two studies reported that 
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fermentable dietary fibre supplementation, which resulted in increased faecal 
butyrate levels, was effective in maintaining remission in UC patients.19,20  
The present study aimed to determine whether increasing intraluminal colonic 
butyrate levels could improve a low-grade level of colonic inflammation and/or 
oxidative stress in humans. 
Methods 
Patients 
UC patients in remission were recruited from the South Limburg IBD registry.21 
Patients had a well-defined diagnosis of UC established by clinical, endoscopical, 
histological and/or radiological criteria. Patients were in clinical remission and were 
excluded from participation if the Endoscopic Grading System (EGS)22 score was 
higher than 5 at the first endoscopy. The patients were between 18-65 years of age 
and consumed a stable Western diet. Exclusion criteria comprised: proctitis only, 
pregnancy, lactation, changes in medication and/or pre- and probiotic intake 2 
weeks prior to and during the study, the use of corticosteroids, enemas or 
suppositories two weeks prior to or during the study, the use of antibiotics 3 months 
prior to or during the study, other clinically significant systemic diseases and 
previous radiotherapy or chemotherapy. All patients gave their written informed 
consent before participation. The study was performed in accordance with the 
principles of the declaration of Helsinki and was approved by the Medical Ethics 
Committee of the University Hospital Maastricht, the Netherlands.  
Study design 
This study was performed according to a randomised double-blind placebo-
controlled parallel design. During an intervention period of 20 days patients self-
administered a 60 mL rectal enema once daily containing either a sodium butyrate 
solution (100 mmol/L) or a placebo solution (140 mmol/L NaCl) with a neutral pH. 
The butyrate enemas were made isotonic by the addition of NaCl (40 mmol/L). 
Patients were instructed to self-administer the enemas prior to sleeping, and to 
remain in a left-lateral supine position for at least 15 minutes. Compliance was 
evaluated on the basis of a questionnaire and the returned enema-bottles. One 
week prior to the intervention period and during the study, patients completed a 
daily questionnaire regarding use of medication, bowel habits (defaecation 
frequency and faeces consistency score according to the Bristol scale23) and the 
following symptoms scored as mild (1) moderate (2) or severe (3): nausea, 
abdominal cramps, abdominal pain, bloating, flatulence, blood in the faeces, visible 
mucus in the faeces and other). The mean daily scores of defaecation frequency, 
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faecal consistency and symptoms were calculated from both the week before the 
intervention period as well as from the 20-day intervention period. 
Before the start and the day after the intervention period, a sigmoidoscopy was 
performed in the morning after an overnight fast and without prior bowel cleansing. 
At each time point the gastroenterologist filled in two scoring systems, the Colitis 
Activity Index (CAI)24 and the EGS.22 During the sigmoidoscopy, mucosal biopsies 
were taken from a standardised location in the sigmoid (approximately 20-25 cm 
from the anal verge at the crossing with the arteria iliaca communis). Two biopsies 
were used for analyses of oxidative stress parameters, one biopsy for inflammatory 
parameters and one for gene expression analysis by real time PCR (RT-PCR). 
These biopsies were snap-frozen in liquid nitrogen. Two other mucosal biopsies 
were fixed in formalin and embedded separately in paraffin for histological 
evaluation of the overall inflammatory score.25 After the endoscopic procedure, a 
fasting blood sample was obtained for determination of C-reactive protein (CRP) by 
the department of Clinical Chemistry of the Maastricht University Medical Centre. 
In addition, each patient collected 24-hour faeces before the start of the 
intervention period and during the day before the last sigmoidoscopy. The faeces 
was weighed, homogenised and aliquots were stored at -80°C for determination of 
faecal calprotectin. The patients recorded their dietary intake three days before the 
first sigmoidoscopy and consumed the same diet during the three days before the 
second sigmoidoscopy in order to standardise the diet prior to the sigmoidoscopy. 
Inflammatory and oxidative stress parameters in colonic mucosal 
biopsies 
One frozen biopsy intended for cytokine determinations was grinded with a mortar 
and pastel cooled in liquid nitrogen and resuspended in 100 μL ice-cold PBS 
containing 10 μL/mL of a cocktail of protease inhibitors (Sigma, Zwijndrecht, the 
Netherlands). The homogenate was centrifuged for 5 minutes (21000 g, 4°C) and 
the supernatant was stored at -80°C until analyses of myeloperoxidase (MPO) and 
cytokines. The following cytokines were determined using a multiplex 
immunoassay kit26 according to manufacturer’s instructions (Bio-Rad, Veenendaal, 
the Netherlands): interleukin (IL)-1β, IL-5, IL-6, IL-8, IL-10, IL-12(p70), interferon 
(IFN)-γ, monocyte chemotactic protein-1 (MCP-1), and chemokine CCL5 (C-C motif 
ligand 5, also known as RANTES). In short, 50 μL of the undiluted biopsy 
supernatant or standard was incubated with the antibody-coated beads in a 96 well 
1.2 μm filter plate. After 30 minutes of incubation, a cocktail of biotinylated 
secondary antibodies was added to each well and incubated for another 30 
minutes. After subsequent incubation for 10 minutes with streptavindin-PE, the 
fluorescence intensity of the beads was measured using the Bio-Plex system in 
combination with the Bio-Plex Manager software version 3.0 (Bio-Rad). In the 
remaining supernatant myeloperoxidase was determined using a specific ELISA kit 
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(HBT, Uden, the Netherlands) according to manufacturers’ instructions. Two other 
frozen biopsies intended for oxidative stress analyses were grinded and 
resuspended in 240 μL ice-cold milliQ water. From this suspension 90 μl was 
added to 9 μL of an acidic buffer (13% 5-Sulfosalicilic acid, 100 mmol/L HCl in 
PBS) and centrifuged for 5 minutes (21000 g, 4°C). The supernatant was used for 
the determination of total GSH (tGSH) and glutathione disulfide (GSSG), the 
oxidised form of GSH using the recycling assay described by Vandeputte et al.27 
with minor modifications as described previously.9 The remaining original 
suspension was centrifuged for 5 minutes (21000 g, 4°C) and the supernatant was 
stored at -80°C for the determination of glutathione-S-transferase (GST) activity, 
malondialdehyde (MDA) concentrations, trolox equivalent antioxidant capacity 
(TEAC) and uric acid concentrations as described previously.9 Total protein content 
in the supernatants was quantified using a BCAtm protein assay kit (Pierce, 
Rockford IL, USA).  
Real-Time PCR (RT-PCR)  
The expression of glutamate-cysteine ligase, catalytic subunit (GCLC) and 
xanthine dehydrogenase (XDH) were determined using RT-PCR, which are the 
rate limiting enzymes for GSH and uric acid synthesis, respectively. RNA was 
isolated from a frozen biopsy using TRIzol reagent (Invitrogen, Carlsbad, USA) and 
purified with the RNeasy mini kit (Qiagen, Venlo, The Netherlands) combined with 
a DNase treatment using the RNase-Free DNase Set (Qiagen). 500 ng total RNA 
was used as a template for the cDNA reaction, which was synthesised using the 
iScript cDNA Synthesis kit (Bio-Rad). The cDNA was diluted to a concentration of 
0.32 ng/μL. Each reaction contained 12.5 μL iQ Sybr Green Supermix (Bio-Rad), 1 
μL of 10 μmol/L gene-specific forward and reverse primers, 4 μL cDNA template 
solution and 6.5 μL sterile H2O. As housekeeping genes, 18SrRNA, GAPDH and 
CANX, were used. Primer sequences are given in Table 5.1. Reactions were run 
on the My IQ Single Colour RT-PCR Detection System (Bio-Rad). PCR conditions 
used were 3 minutes at 95°C, followed by 40 amplification cycles of 10 seconds at 
95°C and 45 seconds at 60°C.  
 
Table 5.1 Primer information of housekeeping genes and genes that are essential in GSH and uric 
acid metabolism.   
   Sequence ID Forward primer (5’ → 3’) 
 
Reverse primer (5’ → 3’) 
CANX NM_001024649 CCACTGCTCCTCCTTCATCTCC CGGTATCGTCTTTCTTGGCTTTGG 
GAPDH NM_002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
18SrRNA M10098 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
GCLC  NM_001498 TGGAAGTGGATGTGGACACC GTCTTGCTTGTAGTCAGGATGG 
XDH NM_000379 CCTCTTCCTGGCTGCTTCTATCTTC TGACACACAGGGTGGTGAACTTG 
CANX: calnexin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; 18SrRNA: 18S ribosomal RNA; 
GCLC: glutamate-cysteine ligase, catalytic subunit; XDH: xanthine dehydrogenase. 
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Faecal calprotectin  
Approximately 100 mg of wet faeces was diluted 50 times in extraction buffer (0.1 
mol/L Tris, 0.15 NaCl, 1 mol/L Urea, 10 mmol/L CaCl2, 0.1 mol/L Citric acid, 5 g/L 
BSA, pH; 8.0).28 Samples were shaken for 30 minutes and subsequently 
centrifuged for 20 minutes (10000 g, 4°C). The supernatant was used for analysis 
of calprotectin using a standard ELISA kit (HBT) according to the manufacturer’s 
instructions.  
Statistical analysis 
The non-parametric Wilcoxon signed-rank two-tailed test was used to identify 
significant differences over time within the butyrate or placebo treated group. 
Mann-Whitney U two-tailed test for non-parametric data was used to identify 
significant differences between the changes in the butyrate compared to the 
placebo group. Spearman's rank correlation coefficient was determined to identify 
significant correlations between parameters. Differences were considered 
statistically significant if p<0.05. Statistical analyses were performed using SPSS 
11.0 software.  
RT-PCR data were analysed using a Gaussian linear regression as described 
previously.9 Finally, data were presented as fold change and the confidence 
interval. The gene under consideration was denoted to be differentially expressed if 
the confidence interval did not include 1. 
Results 
Patient characteristics 
Forty UC patients agreed to participate in the study. After initial screening, four UC 
patients appeared to have a relapse before the start of the study and were 
therefore excluded. Due to antibiotic use one other patient in the butyrate group 
was excluded during the study period. Thirty-five UC patients completed the study: 
18 in the placebo group (50% male, median age: 59 (38-64) years) and 17 in the 
butyrate group (65% male, median age: 54 (31-65) years), respectively.  
In the placebo group, 7 patients (39%) were on maintenance therapy for UC using 
mesalazine (n=4), azathioprine (n=1), azathioprine in combination with mesalazine 
(n=1) or sulfalazine (n=1). In the butyrate group, 13 patients (76%) were on 
maintenance therapy for UC using mesalazine (n=12) or sulfalazine (n=1). In all 
subjects, the dose and type of medication did not change during the study period.  
The compliance based on returned empty enema bottles and questionnaires was 
99% in both the placebo and the butyrate group.  
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Faeces consistency and frequency and the mean daily symptom score did not 
differ as a result of the enemas during the intervention period within each group, 
nor between the butyrate and the placebo group (Table 5.2).  
 
Table 5.2 Daily symptom score, defaecation frequency and consistency scores according to the 
Bristol scale (from 1: hard lumps, to 7: watery diarrhoea) before and during the intervention 
period with a daily enema containing 100 mmol/L butyrate or placebo for 20 days (median 
(range))*. 
 Butyrate group Placebo group 
  Before 
 n=17 
 During  
 n=17 
 Before 
 n=18 
 During  
 n=18 
Daily symptom score  0.6 (0-7.4)  0.4 (0-5.6)  0.4 (0-13.2)  0.4 (0-5.4) 
Stool consistency score  4.7 (3.1-6.0)  4.5 (3.8-6.0)  4.1 (3.0-5.7)  4.2 (2.1-5.4) 
Stool frequency  1.6 (1.0-3.6)  1.6 (0.9-3.2)  1.4 (0.9-6.9)  1.6 (0.7-3.9) 
* None of the differences between and within the two groups is statistically significant. 
 
Inflammatory parameters 
Table 5.3 shows the effects of the butyrate and placebo intervention on the 
different parameters of inflammation determined in colonic mucosal biopsies (i.e. 
IL-1β, IL-5, IL-6, IL-10, IL-12, IL-10/IL-12 ratio, IFN-γ, IL-8, CCL5, MCP-1, MPO), in 
faeces (i.e. calprotectin), in plasma (i.e. CRP) as well as by using general scoring 
systems (i.e. CAI, EGS and histology score). A significant increase in the mucosal 
IL-10/ IL-12 ratio was found within the butyrate group (p=0.022), but not if 
comparing the changes between the butyrate and placebo group. Within the 
placebo group only a significant decrease in the concentrations of CCL5 was 
observed (p=0.012) and this was also significant if the changes between the 
butyrate and placebo group were compared (p=0.029). All other parameters of 
inflammation did not differ significantly within or between placebo and butyrate 
treatment (Table 5.3).  
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Table 5.3  Parameters of inflammation and clinical symptoms before and after the intervention period 
with a daily enema containing 100 mmol/L butyrate or placebo for 20 days (median 
(range)). 
 
 Butyrate group Placebo group 
  Before 
 n=17 
 After 
 n=17 
 Before 
 n=18 
 After 
 n=18 
IL-1β  
(ng/g protein) 
 1.96    
 (0.42-242.33) 
 1.48  
 (0.59-39.37) 
 1.14 
 (0.45-79.43) 
 1.64   
 (0.42-18.42) 
IL-5  
(ng/g protein) 
 0.005  
 (0.002-0.054) 
 0.005   
 (0.002-1.118) 
 0.004   
 (0.002-0.059) 
 0.009   
 (0.002-0.060) 
IL-6  
(ng/g protein) 
 0.19     
 (0.09-0.93) 
 0.16   
 (0.08-4.89) 
 0.21     
 (0.07-7.20) 
 0.17   
 (0.01-3.43) 
IL-10  
(ng/g protein) 
 0.076   
 (0.004-0.437) 
 0.107 
 (0.020-0.993) 
 0.084   
 (0.011-4.913) 
 0.095  
 (0.011-0.863) 
IL-12  
(ng/g protein) 
 0.073   
 (0.002-0.293) 
 0.033  
 (0.002-0.261) 
 0.061   
 (0.002-0.383) 
 0.032   
 (0.003-0.379) 
IL-10/IL-12 ratio  1.40     
 (0.03-18.00) 
 5.10 * 
 (0.33-86.00)  
 3.46     
 (0.16-28.00) 
 5.04  
 (0.23-74.00) 
IFN-γ  
(ng/g protein) 
 5.81     
 (0.55-48.01) 
 4.77   
 (0.72-16.72) 
 6.57     
 (3.82-22.42) 
 6.23 
 (3.59-16.36) 
IL-8  
(ng/g protein) 
 2.89     
 (0.66-40.65) 
 4.62  
 (1.33-138.79) 
 5.65     
 (0.63-119.72) 
 3.79     
 (1.46-32.27) 
CCL5  
(ng/g protein) 
 485.4   
 (247.2-1413.6) 
 550.7 ** 
 (269.7-1455.6) 
 621.4 
 (392.1-8784.4) 
 579.1 *  
 (322.9-1512.9) 
MCP-1  
(ng/g protein) 
 21.64  
 (8.79-51.02) 
 28.19  
 (10.68-95.61) 
 22.40   
 (13.39-262.87) 
 26.21   
 (16.26-56.70) 
MPO  
(μg/g protein) 
 82.7  
 (24.3-1931.3) 
 90.3   
 (23.9-1792.1) 
 64.8    
 (20.1-2395.9) 
 55.0    
 (23.7-717.9) 
Calprotectin 
(μg/g faeces) 
 54.1  
 (3.2-496.6) 
 88.8   
 (6.7-486.5) 
 62.0    
 (6.7-359.7) 
 39.5     
 (3.9-403.4) 
CRP  
(mg/l) 
 2.8  
 (1.0-14.9) 
 3.4 
 (1.0-14.0) 
 1.7 
 (1.0-12.4) 
 1.0  
 (1.0-35.0) 
Histology  
score 
 0  
 (0-1) 
 0  
 (0-1) 
 0 
 (0-1) 
 0 
 (0-1) 
CAI   2 
 (0-10) 
 2 
 (0-9) 
 2  
 (1-7) 
 2.5 
 (1-5) 
EGS  0 
 (0-5) 
 1    
 (0-8) 
 0.5    
 (0-3) 
 0 
 (0-3) 
* P<0.05 compared to pre-treatment values of the same group (Wilcoxon signed-rank test); ** P<0.05 
for comparison of the change between the placebo and the butyrate group (Mann-Whitney U test); IL: 
interleukin; IFN-γ: interferon-γ; CCL5: chemokine (C-C motif) ligand 5; MCP-1: monocyte chemotactic 
protein-1; MPO: myeloperoxidase; CRP: C-ractive protein; CAI: colitis activity index; EGS: endoscopic 
grading system. Cytokines and MPO were determined in colonic mucosal biopsies and CRP was 
determined in plasma. 
 
Oxidative stress parameters 
Table 5.4 shows the effects of the butyrate and placebo intervention on the 
different parameters of oxidative stress measured in colonic mucosal biopsies (i.e. 
total GSH, GSH, GSSG, GSH/GSSG ratio, UA, TEAC, GST, MDA). These 
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parameters did not differ significantly within or between placebo and butyrate 
treatment.  
 
Table 5.4 Parameters of oxidative stress determined in colonic mucosal biopsies before and after the 
intervention period with a daily enema containing 100 mmol/L butyrate or placebo for 20 
days (median (range))*. 
 Butyrate group Placebo group 
  Before 
 n=17 
 After 
 n=17 
 Before 
 n=18 
 After 
 n=18 
tGSH  
(nmol/mg protein) 
 20.8  
 (16.1-25.1) 
 20.7 
 (17.1-27.0) 
 22.6    
 (17.9-27.6) 
 21.8  
 (15.2-27.8) 
GSH  
(nmol/mg protein) 
 16.0   
 (11.9-24.7) 
 17.7 
 (14.5-23.6) 
 16.9  
 (10.8-24.7) 
 18.0 
 (10.1-25.3) 
GSSG  
(nmol/mg protein) 
 1.0  
 (0.1-4.5) 
 1.6 
 (0.1-4.3) 
 2.2      
 (0.2-4.6) 
 2.0  
 (0.1-5.3) 
GSH/GSSG  
ratio 
 17.9   
 (2.7-247.5) 
 13.3 
 (3.5-213.7) 
 7.5 
 (2.5-102.7) 
 9.0  
 (2.7-153.5) 
UA  
(nmol/mg protein) 
 2.9 
 (1.8-4.1) 
 2.6 
 (1.5-3.7) 
 2.5  
 (1.7-4.1) 
 2.8 
 (1.7-3.6) 
GST  
(U/mg protein) 
 0.12  
 (0.08-0.17) 
 0.14 
 (0.09-0.16) 
 0.13     
 (0.08-0.19) 
 0.14 
 (0.09-0.18) 
TEAC  
nmol trolox eq/mg protein 
 118.2  
 (82.1-171.6) 
 111.1 
 (82.8-191.5) 
 121.9   
 (94.6-163.6) 
 110.6 
 (87.2-163.7) 
MDA  
(nmol/mg protein) 
 0.62 
 (0.26-2.16) 
 0.92  
 (0.08-2.7) 
 0.91     
 (0.34-1.75) 
 0.93 
 (0.18-2.43) 
* None of the differences between and within the two groups is statistically significant. tGSH: total 
glutathione; GSH: glutathione; GSSG: glutathione disulfide; UA: uric acid; GST: glutathione-S-
transferase; TEAC: trolox equivalent antioxidant capacity; MDA: malondialdehyde. 
 
However, a significant negative correlation (p = 0.018) was found between the level 
of inflammation measured by calprotectin at the start of the study and the change 
in tGSH due to the butyrate intervention (Figure 5.1).  
Expression of GCLC and XDH 
mRNA expression of the genes coding for the rate limiting enzymes for GSH 
(GCLC) and uric acid (XDH) synthesis in the mucosal biopsies were determined as 
a previous study in healthy volunteers showed that these expression levels were 
regulated by butyrate.9 Compared to placebo, the butyrate intervention did not 
significantly affect the expression of GCLC (fold change (confidence interval): 0.94 
(0.89-1.01)), while the expression of XDH was significantly downregulated after the 
butyrate intervention compared to placebo (fold change: 0.89 (0.81-0.97)).  
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Figure 5.1 Correlation between the change in the concentrations of total GSH (tGSH) in the colonic 
biopsies (concentration tGSH in the biopsy taken after the treatment with butyrate or 
placebo minus the concentration in the biopsy taken at the start of the study) and the 
concentrations of calprotectin determined in faeces obtained at the start of the study. 
 
Discussion 
In the present study UC patients in remission were included to evaluate the effects 
of butyrate supplementation in a situation of chronically mildly elevated levels of 
inflammation and oxidative stress.16-18 The results of the present study showed 
minor effects of butyrate on colonic inflammation. Only a significant increase of the 
colonic IL-10/IL-12 ratio was found within butyrate treated patients, and colonic 
concentrations of CCL5 were increased after butyrate compared to placebo 
treatment. In addition, in contrast to previous results in healthy volunteers no 
significant effects of butyrate administration on parameters of oxidative stress were 
found. Although in general butyrate did not affect colonic GSH levels, the effects of 
butyrate enemas on total colonic GSH correlated negatively with the level of 
inflammation at the start of the study.  
 
R2 = 0.36 
p = 0.018 
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A comparison of pre-treatment values of the included UC patients with values from 
healthy volunteers9, confirmed the presence of a low-grade inflammation and 
oxidative stress in these patients as indicated by significantly increased levels of IL-
1β, IL-12, IFN-γ, calprotectin and GSSG, and significantly decreased levels of 
GSH, the GSH/GSSG ratio, GST activity and TEAC.9 Rectal enemas were chosen 
as route of butyrate administration in order to standardise the location and 
concentration of butyrate in the distal colon. An additional advantage of this 
specific region is that mucosal biopsies could be obtained from this distal part of 
colon without the need for prior bowel cleansing, as this could affect the 
physiological situation. The actual concentrations of butyrate would be unknown 
when using a dietary fibre intervention to increase local concentrations of butyrate 
and this would also have led to other changes that could have affected colonic 
health, such as the composition of the colonic microbiota. The concentration of 
butyrate given was based on expected local concentrations after consumption of a 
high fibre diet.9 To minimise confounding effects of diet and medication, patients 
were asked to adhere to their habitual diet including the use of pro- and prebiotics 
and all patients were on stable medication throughout the entire study period. 
However, the use of medication was not equally distributed between the butyrate 
and the placebo group: 76% of the butyrate-treated and 39% of the placebo-
treated patients used maintenance therapy for UC. The most frequently used drug 
was 5-aminosalicylate, which uses the same transporter for absorption from the 
intestinal lumen as butyrate. Although we acknowledge that this might have 
affected the bioactivity of butyrate, it was ethically not acceptable to stop or 
interfere with this maintenance therapy. However, a previous study has shown that 
butyrate enemas in combination with 5-aminosalicylate was significantly more 
effective than 5-aminosalicylate alone in the management of refractory distal 
colitis.29  
 
The results of this double blind, placebo controlled trial demonstrated minor effects 
on inflammation: only a significant increase of the colonic IL-10/IL-12 ratio was 
found within butyrate treated patients, and colonic concentrations of the chemokine 
CCL5 were increased after butyrate compared to placebo intervention. Previously, 
using human monocytes, Seaman et al.30 have also demonstrated that butyrate 
inhibits the pro-inflammatory cytokine IL-12, while it increased the production of the 
anti-inflammatory cytokine IL-10. With regard to chemokine production, 
controversial effects of butyrate have been reported using different conditions and 
intestinal epithelial cell lines.31-34 It has been reported that butyrate was able to 
either increase or decrease IL-8 production depending on the duration of the 
incubation32 and the concentration of butyrate applied.31 In the present study, 
enemas containing 100 mmol/L butyrate once daily for three weeks resulted in 
increased concentrations of CCL5, while other chemokines (MCT-1 and IL-8) were 
unaffected. In vitro, CCL5 is a potent chemotactic agent for eosinophils, basophils, 
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monocytes, NK cells, and CD4 memory T lymphocytes.35 By affecting chemokine 
concentrations different immune cell types are activated for host defence against 
luminal antigens36, although the relevance of this increase in only CCL5 remains to 
be determined. Other determined cytokines were not significantly affected by the 
butyrate intervention, while previous in vitro studies have reported reduced 
concentrations of pro-inflammatory cytokines after incubation with 
butyrate7(submitted for publication). However, most effects were observed after the 
addition of a pro-inflammatory stimulus and can therefore not be compared to the 
present study.  
To our knowledge this is the first study reporting the effect of butyrate in a situation 
with low-grade inflammation and oxidative stress. Apart from the findings 
mentioned above, no changes in other cytokines and overall inflammatory 
parameters were observed. This is in contrast to what was expected as various 
studies in UC patients with active disease revealed a significant improvement of 
clinical and inflammatory parameters due to butyrate administration.14,15,29,37,38 
Some other clinical trials, however, did not find beneficial effects39 or observed only 
trends towards clinical improvement.40,42 The studies that reported beneficial 
effects on clinical scores used enemas containing SCFA mixtures15,38 or similar 
concentrations of butyrate14,29,37 as used in the present study, but those enemas 
were administered twice daily compared to the once daily administration in the 
present study. A single rectal nightly enema was given, as this is less cumbersome 
to the patient and thereby is expected to increase their compliance. However, more 
prolonged exposure and/or higher dosages might be required for stronger anti-
inflammatory effects.  
 
To protect against oxidative stress, the intestinal epithelium contains multiple 
enzymatic and non-enzymatic antioxidants including GSH, which is considered an 
essential antioxidant in the colon.43 When GSH is used to reduce hydrogen 
peroxide and lipidhydroperoxides, GSSG is formed that can be reconverted to 
GSH44. GSH deficiency has been proposed to be a therapeutic target in UC.45,46 As 
expected GSH was found to be decreased and GSSG was found to be increased 
compared to previously reported data in healthy volunteers.9 However, the butyrate 
intervention did not change these concentrations nor the expression of GCLC, one 
of the rate-limiting enzymes for GSH synthesis, in UC patients in remission. It was 
expected that butyrate would increase the concentrations of GSH since a previous 
study by our group demonstrated that an identical once daily rectal administration 
of 100 mmol/L butyrate for 14 days significantly increased colonic GSH 
concentrations and GCLC expression in healthy subjects.9 In addition, a fibre-
supplemented diet two weeks prior to and during the induction of colitis in rats led 
to an increased production of butyrate and a restoration of the colonic GSH 
levels.11 In agreement with the previous study in healthy volunteers, the butyrate 
intervention resulted in a significant decrease in XDH, the enzyme responsible for 
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the formation of uric acid. During uric acid production reactive oxygen species are 
produced, and therefore a decrease in its activity could decrease oxidative stress.9  
In the present study, significant negative correlations were found between the level 
of inflammation at the start of the study and the change in tGSH, indicating that the 
effects of butyrate on GSH may depend on the level of inflammation. Therefore, we 
hypothesise that butyrate at the concentration used in the present study may only 
be able to increase GSH if inflammation is minimal or absent. In active UC patients 
butyrate oxidation is decreased47,48 and furthermore, butyrate oxidation could be 
inhibited by hydrogen sulphide, which is increased in UC patients compared to 
healthy controls.49 In addition, in UC patients, colonic inflammation has also been 
shown to cause downregulation of the H+-coupled butyrate transporter.50 
Therefore, as the uptake and/or oxidation of butyrate may differ in UC patients with 
varying degrees of inflammation, the dose of butyrate needed to achieve a 
beneficial effect could be different depending on the level of inflammation. It seems 
that in UC patients either the butyrate concentrations should be increased or the 
exposure time extended.  
The exposure time to butyrate can be increased if colonic levels of butyrate are 
increased by dietary means, for example through the addition of fermentable 
dietary fibres to the diet. It remains to be determined whether the concentration 
needed for beneficial effects of butyrate during low-grade inflammation and 
oxidative stress can be achieved, especially in the distal colon, via these dietary 
interventions. However, beneficial effects on inflammation and oxidative stress may 
not be entirely due to the increased butyrate production, but may rather by the 
result of a broad range of effects of fermentable fibre supplementation, such as the 
production of other SCFA, a decreased intraluminal pH and changes in microbial 
composition. 
 
In conclusion, this intervention study with nightly butyrate enemas for three weeks 
in patients with UC, characterised by low-grade inflammation and oxidative stress, 
showed minor effects on inflammation and no significant effect on oxidative stress 
parameters. On the other hand, the effect of butyrate on tGSH appeared to be 
inversely related to the level of inflammation. Future studies should focus on the 
level of butyrate needed to result in beneficial effects during low-grade as well as 
active inflammation and whether these could be achieved via fermentable fibres as 
a dietary component.  
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Abstract 
Background 
The mucus layer is an important dynamic component of the epithelial barrier. It contains mucin 
glycoproteins and other compounds secreted by the intestinal epithelium, such as secretory IgA. 
However, a standardised in vivo sampling technique of mucus in humans is not yet available. Therefore, 
the aim was to assess the validity and feasibility of mucin and protein determinations in human colonic 
mucus collected under physiological conditions. 
 
Methods 
Triplicate colonic mucus samples were collected in 11 healthy volunteers using cytology brushes during 
sigmoidoscopy. As an indication of the quantity of collected mucus, total protein and mucin 
concentrations were determined by measuring oligosaccharide equivalents and monosaccharides. Also 
secretory IgA and sialic acid concentrations were determined and proteomic analysis was performed 
using SELDI-TOF-MS. 
 
Results 
Mean values of secretory IgA and sialic acid corrected for the amount of mucus ranged from 0.16 to 
1.81 gram secretory IgA /mmol oligosaccharide equivalents and from 12.6 to 48.6 gram sialic acid 
/mmol oligosaccharide equivalents. Proteomic analysis of mucus is feasible and cluster analysis 
showed subject specific profiles. 
 
Conclusion 
Using cytology brushes, human colonic mucus can be sampled and under physiological conditions. 
These samples could give information on the composition and quality of the mucus layer. 
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Introduction 
The intestinal mucus layer is the first line of defence to the external environment 
and protects the mucosa against mechanical, chemical or microbiological 
aggressions.1 It is composed of a loosely adherent layer and a layer firmly attached 
to the mucosa. The mucus layer mainly contains mucus glycoproteins (mucins), 
which are secreted by goblet cells and consist of a central protein backbone with 
high numbers of oligosaccharides attached through O-linkage with N-acetyl-
galactosamine to serine or threonine in the protein core. The oligosaccharide side 
chains of colonic mucins mainly comprise galactosamine, glucosamine, fucose, 
galactose and can be either acidic containing sialic acid or sulphate groups, or 
neutral.2 
In addition to mucins, a large number of other secreted proteins can be found in 
the mucus layer, such as trefoil factor family proteins and secretory IgA (sIgA), 
which are able to interact with mucins or benefit from the viscoelastic, aqueous 
environment provided by the mucus gel.1 The main functions of sIgA are to 
neutralise toxins and prevent epithelial adherence and penetration of invasive 
pathogenic micro-organisms by direct non-specific binding.3 Trefoil factors are 
mucin-associated proteins that are involved in the protection of gastrointestinal 
epithelium and mucosal healing, and contribute to the viscoelastic properties of the 
mucus layer.4,5  
Alterations in the intestinal mucus layer, which may lead to diminished protection of 
the colonic mucosa, have been reported in various intestinal disorders.2,6,7 For 
example in ulcerative colitis, a reduced mucus thickness, depleted goblet cells, 
altered glycosylation, reduced sulphation and a reduced presence of sIgA have 
been reported.7,8 Other factors such as diet9, stress10,11 and age12,13 can also affect 
the colonic mucus layer. Studies with rats have shown that dietary fibre deficiency 
leads to a decreased mucus thickness9, while acute exposure to stress decreased 
colonic IgA levels.10 Although studies on the effect of age on the colonic mucus 
layer are hardly available, changes have been demonstrated to occur in the gastric 
mucus layer with advancing age12,13. Farinati et al.12 showed that the number of 
human gastric mucus-secreting cells decreases with increasing age and Corfield et 
al.13 showed a decrease with advancing age in total sialic acid concentration in 
human gastric juice, suggesting that there is also a qualitative change in gastric 
mucus with increasing age. 
Because of its importance, techniques to sample intestinal mucus are of interest. 
Sampling under physiological conditions is important when subtle changes are 
expected, for example in case of dietary interventions. Currently, the human mucus 
layer can be studied using mucosal biopsy specimens or resection material. 
However, analyses in the latter can be affected by preoperative antibiotic treatment 
and operation associated stress.6 In addition, standard histological techniques 
dehydrate the mucus layer, hampering its visualisation.14 Analyses of components 
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of the mucus layer can also be performed in faeces, but this does not provide site-
specific information.15 Previously, rectal colonic mucus has been studied by using 
the mucosal patch technique16 or a filter paper inserted through a rigid 
sigmoidoscope.17,18 Although gastric mucus has been sampled in vivo before19, 
there are no reports on the collection of mucus samples from the large intestine in 
vivo.  
In this study, we used a cytology brush to collect mucus under physiological 
conditions in order to evaluate the composition of the mucus layer. In the collected 
colonic mucus samples both mucin components and proteins were determined 
using biochemical assays as well as surface enhanced laser desorption/ionization-
time of flight-mass spectrometry (SELDI-TOF-MS). 
Methods 
Subjects 
Twelve healthy non-smoking volunteers participated in the study (33% male, 
median age 23 (18-62) years). Subjects were on a stable Western diet, had no 
history of gastrointestinal diseases and did not use immunosuppressive drugs, 
antibiotics, anti-diarrhoeal drugs or laxatives in the three months prior to the study. 
All subjects gave written informed consent. The medical ethics committee of the 
University Hospital Maastricht approved the study. 
Collection of colonic mucus 
Triplicate colonic mucus samples were obtained during sigmoidoscopy over the 
last 30 cm of the colon without prior bowel cleansing using cytology brushes 
(Boston Scientific, Natick, USA; Figure 6.1).  
Sterile cytology brushes (protected by a sleeve and a cap) were inserted through 
the working channel of the flexible endoscope to collect mucus from a standardised 
location of the sigmoid (approximately 20 cm from the anal verge at the location of 
the arteria iliaca communis). On the site of sampling, the protecting cap was 
removed and the brush was placed on the colonic wall for 30 seconds while gently 
moving over the epithelium. Subsequently, it was retracted in its sleeve and 
removed from the endoscope. The brush was cut off, placed immediately in cold 
600 μL buffer (0.1 M TrisHCl, in 154 mM NaCl, 0.01% azide, 0.02% Tween-20, pH 
7.4) and rocked (5 min, 150 rpm, 4°C). From each sample, 50 μL was immediately 
frozen at -80°C for SELDI-TOF-MS. The remaining part was sonicated for 45 min 
on ice to retrieve all the mucus from the brushes. Mucus samples were then 
centrifuged (5 min, 350 g, 4°C) to remove bacteria, cells and large faecal particles. 
The supernatant was frozen at -80°C until further analyses. 
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Figure 6.1 Cytology brush for the collection of intestinal mucus during a sigmoidoscopy. The grey 
protection cap, preventing contamination during insertion of the brush, is pushed off and is 
indicated by an arrow in the right picture. 
 
Analyses of colonic mucus samples 
Oligosaccaride equivalents 
Mucins were extracted and determined as described previously.20,21 First, 
glycosidases were denatured and mucins were solubilised20. Samples were filtered 
(ultrafree MC 30000 NMWL, Millipore, Bedford, USA) during centrifugation (3000 g, 
until the complete sample passed the membrane). Subsequently, 200 μL methanol 
was added and centrifuged (3000 g) to wash the membrane. After drying by air, the 
mucin retentate was dissolved in PBS to the original volume and the amount of 
oligosaccharide side chains liberated from mucins were quantified using a 
fluorimetric assay.22 The total amount of mucins was expressed as μmol 
oligosaccharide equivalents.21  
Monosaccharide analysis 
High-performance anion-exchange chromatography with pulsed amperometric 
detection (HPAE-PAD) was performed using a Dionex ICS 3000 HPLC system 
equipped with a Dionex CarboPac PA-1 (4 mm ID x 250 mm) column and an amino 
trap column (4 mm ID x 50 mm) (Dionex, Amsterdam, the Netherlands). 
Monosaccharides were separated using an isocratic elution with 20 mM NaOH for 
25 min at 30°C at a flow-rate of 0.5 mL/min and detected with a pulsed 
amperometric detector.23 Filtered mucus samples were hydrolysed in 2 M 
trifluoroacetic acid for 1 hour at 121°C.24 Glucose, fucose, galactose, 
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galactosamine and glucosamine were used as a monosaccharide standard and 
fetuin as a glycoprotein standard.24 
Total protein concentration, sialic acids and sIgA  
Total protein concentrations in the unfiltered mucus samples were quantified using 
the BCAtm protein assay kit (Pierce, Rockford IL, USA). 
Bound sialic acids in sialoglycoproteins were determined by the acidic ninhydrin 
reaction.25 N-acetylneuraminic acid (Sigma, Zwijndrecht, the Netherlands) was 
used for a standard curve. Briefly, 50μL glacial acetic acid and 50 μl acidic 
ninhydrin reagens (0.5 g ninhydrin (VWR, Amsterdam, The Netherlands) in 12 mL 
glacial acetic acid and 8 mL 37% HCL) was added to 50 μL of the standards and 
unfiltered mucus samples, heated for 10 min at 100°C and after cooling, the 
absorbance of the samples was measured at 470 nm.  
SIgA concentrations in the unfiltered mucus samples were determined using an 
enzyme-linked immunosorbent assay (ELISA) as described previously.15 Briefly, 
plates were coated with monoclonal mouse α human anti-secretory component 
(IgA) antibody (1:10000; Sigma). Purified human IgA isolated from colostrum 
(Sigma), was used for the standard curve. SIgA was detected using a monoclonal 
biotinylated mouse anti-human IgA1/2 monoclonal antibody (1:500; BD 
Pharmingen, Breda, the Netherlands), followed by the addition of streptavidin-
conjugated horseradish peroxidase (1:10000; Sanquin CLB, Amsterdam, the 
Netherlands) and enzymatic colour development with tetramethylbenzidine 
(Sigma).  
Proteomics 
To study a wide range of (unknown) proteins present in the mucus layer, SELDI-
TOF-MS was applied. The SELDI-TOF-MS technology (Ciphergen Biosystems, 
Fremont, USA) consists of the protein chip array, mass spectrometer and data 
analysis software. Optimal conditions for mucus profiling were determined by 
testing three protein chip array surfaces (Q10, CM10 and IMAC-Cu) with different 
binding/washing conditions and dilutions of mucus. The binding/washing buffer for 
the anionic exchange arrays (Q10) contained 0.1% Triton X-100 with 0.1M Tris–
HCl (pH 8) or 0.1M sodium acetate (pH 6) and that for the cationic exchange arrays 
(CM10) contained 0.1% Triton-X100 with 0.1 mM ammonium acetate (pH 4.5 or pH 
6). Both Q10 and CM10 chips were pre-incubated with binding buffer. The metal 
affinity-binding IMAC-Cu chips were loaded with 50 μL 0.1 M copper sulphate by 
vigorous shaking for 10 min. After washing with water, the chip surface was 
neutralised using 150μL sodium acetate buffer pH 4 followed by a short wash with 
water and pre-incubation with binding buffer (0.1 M Tris-HCl, pH 7.4) containing 
0.1% Triton X-100 and 100 mM or 500 mM NaCl. Mucus samples were diluted 1:10 
or 1:100 in binding buffer (total volume of 100 μL) and applied at random and in 
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duplicate to the chip and incubated for 1 h shaking on a mixer. Afterwards, spots 
were washed six times with 150 μL binding buffer for 10 min (three times with and 
three times without 0.1% Triton X-100). Before application of the matrix (Sinapinic 
acid (SPA; Ciphergen Biosystems) in 50% acetonitrile/0.1% trifluoroacetic acid), 
another short wash with HPLC-gradewater was performed and the chips were 
airdried for 10 min. The matrix was applied twice (0.8 μL each time, 1 min apart) 
and the chips were airdried prior to reading by a ProteinChip Reader IIC instrument 
(Ciphergen Biosystems), using the following settings: detector sensitivity 9; 
detector voltage 2900; positions 20-80 were read with an increment of 10; 50 laser 
shots were collected on each position; two warming shots were fired at each 
position; lag time focus of 241 ns; laser intensity 180. Calibration was done with a 
7–30 kDa proteins mixture. After baseline subtraction, peak labelling was 
performed with CiphergenExpress Software (version 3.0) for peaks with a signal-to-
noise (S/N) ratio of ≥3 in the m/z range from 1.5–30 kDa, and then normalised by 
total ion current. 
Statistics 
Results are expressed as median and range. A two-sided p-value ≤0.05 was 
considered to be statistically significant. Pearson correlations coefficients were 
calculated between mucin and protein determinations. The mean variation 
coefficient and the interclass correlation coefficient (ICC) including the 95% 
confidence interval were calculated to evaluate the reliability of triplicate samples. 
The ICC was interpreted as follows: ICC ≤0.4 = poor reproducibility; 0.4-0.75 = fair 
to good reproducibility; ≥0.75 excellent reproducibility of the variance within 
persons (i.e. triplicate samples) compared to the variance between persons.26 
Statistical analyses were performed using SPSS 11.0 software. For analyses of 
proteomic profiles including all peaks, hierarchical clustering was used based on 
similarity as described by Eisen et al.27 
Results 
Eleven healthy volunteers completed the study. One subject was excluded 
because no brushes could be taken due to severe faecal contamination in the 
colonic lumen. 
Mucins and total protein 
To evaluate the quantity of mucus in the collected samples, the concentrations of 
mucins and total protein were determined in the samples. As indicators for mucin 
concentrations, the amounts of oligosaccharide equivalents and the individual and 
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sum of the monosaccharides (fucose, galactosamine, glucosamine and galactose) 
were determined. In Table 6.1, the Pearson correlation coefficients between total 
protein and indicators of mucin concentrations are shown. The amount of 
oligosaccharide equivalents correlated significantly with the sum of 
monosaccharides and with all individual monosaccharides. Total protein 
concentrations did not correlate with the sum of monosaccharides, but correlated 
significantly with the amount of oligosaccharide equivalents as well as with the 
concentrations of galactose. 
 
Table 6.1 Pearson correlation coefficients between individual and total monosacchacharides, total 
oligosaccharide equivalents and total protein concentrations measured in mucus samples 
from all subjects. 
      Sum of   
Monosaccharides  
 Oligosaccharide  
     equivalents 
  Total protein 
Fucose       0.987**          0.959**         0.299 
Galactosamine       0.976**          0.951**         0.326 
Glucosamine       0.995**          0.981**         0.291 
Galactose       0.996**          0.978**         0.359* 
Sum of monosaccharides       1          0.983**         0.326 
Oligosaccharide equivalents       0.983**          1         0.348* 
*  p<0.05; ** p<0.01 
 
Sialic acid and sIgA 
To correct for the amount of mucus collected, concentrations of sialic acid and sIgA 
were expressed per mmol oligosaccharide equivalents. Mean triplicate values of 
sialic acids ranged from 12.6 to 48.6 g/mmol oligosaccharide equivalents (Figure 
6.2A). The median variation coefficient of triplicate samples per subject was 33.3% 
(6.5-75.1) and the ICC was 0.19 (-0.14-0.61). Mean triplicate values of sIgA 
concentrations ranged from 0.16 to 1.81 g/mmol oligosaccharide equivalents 
(Figure 6.2B). The median variation coefficient of triplicate samples per subject was 
37.6% (14.0-80.6) and the ICC was 0.59 (0.24-0.85). 
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Figure 6.2 Concentrations of sialic acid (A) and sIgA (B) expressed as g/mmol oligosaccharide 
equivalents (OE) in triplicate colonic mucus samples collected from 11 healthy volunteers 
using cytology brushes.  
 
SELDI-TOF-MS analysis 
Using all three protein chip array surfaces (Q10, IMAC-Cu, CM10) only small 
differences were found comparing 1:10 with 1:100 dilutions of mucus samples. The 
1:100 dilution was chosen to reduce the risk of ion suppression due to the 
presence of abundant proteins in the mucus samples. On CM10 chips, best results 
were achieved with binding buffer of pH 4.5 showing 61 different peaks (30 in the 
range 1–10 kDa and 31 from 10-100 kDa). Q10 chips displayed a total of 28 peaks 
with binding buffer pH 8, of which most peaks were observed in the range from 10–
100 kDa. Lowering the pH from 8 to 6 decreased the intensity of peaks in the whole 
spectrum. Using IMAC-Cu chips, an almost equal number of peaks was detected 
as with the CM10 chips. An increase in salt concentration to 500 mM had very little 
effect on the spectra. The CM10 chip was chosen for further analysis of all 
samples, because of the high number of peaks with a good intensity. Duplicate 
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proteomic analyses of one mucus sample resulted in highly reproducible profiles 
(data not shown). 
Representative protein profiles in the range of 1–25 kDa from triplicates of two 
donors on a CM10 chip are shown in Figure 6.3. 
 
 
 
 
 
 
 
 
Figure 6.3 Representative triplicate proteomic profiles from colonic mucus samples collected from two 
volunteers (A and B), measured using SELDI-TOF-MS. Arrows indicate α- and β-
haemoglobin. 
 
 
Using a hierarchical cluster analysis, it was shown that all three replicate mucus 
samples clustered in 5 out of 11 subjects. Two out of 3 replicate samples clustered 
in another 5 subjects (Figure 6.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Cluster analysis of the proteomic analysis by SELDI-TOF MS. Numbers refer to the 11 
volunteers. Mucus samples that cluster together are underlined with grey and black lines, 
indicating clustering of 2 out of 3 or clustering of all 3 samples, respectively. 
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Discussion 
In this study, we showed that colonic mucus could be sampled in vivo in humans 
using a cytology brush during an endoscopic procedure and mucins, sIgA and 
sialic acids could be determined. In addition, proteomic analysis of colonic mucus 
samples is feasible and subject specific profiles can be obtained. 
To our knowledge this was the first time that cytology brushes were used 
successfully to collect colonic mucus samples under physiologic conditions in vivo. 
However, although handling of the brushes was standardised, the amount of 
mucus collected cannot be adequately controlled. Therefore, this technique is not 
suitable for quantification of the mucus layer. For quantification of the intestinal 
MUC2 synthesis, infusion of 13C labelled threonine can be considered.28 The 
reported technique is, however, suitable for the evaluation of the composition of the 
mucus layer, including mucins and other proteins secreted by the epithelium. To 
compare differences in components between distinct mucus samples, correction 
for the amount of mucus sampled is warranted. As specific markers for the mucus 
layer are lacking, total protein, oligosaccharide equivalents and monosaccharides 
were determined as indicators for the quantity of mucus in the collected sample. As 
to be expected, concentrations of oligosaccharide equivalents showed a good 
correlation with the sum of monosaccharides, but the correlation between total 
protein concentrations and both indicators of mucin concentrations was rather 
poor. The total protein concentration was determined in the unfiltered sample using 
the BCA assay. This gives a global indication of the total amount of the collected 
sample. However, heavily glycosylated mucins that form the dominant 
macromolecular component of mucus are known to have poor reactivity with the 
BCA assay, which could explain the poor correlation. Therefore, in the present 
study the indicators of mucin concentrations were used for the standardization of 
the quantity of the samples. An alternative way to standardise the mucus samples 
could be by analyzing the amount of MUC2 using Western blotting, which is the 
predominant mucin in the human colon. 
We demonstrated that sIgA and sialic acids could be measured in the collected 
mucus samples. Although their concentrations were corrected for the total mucin 
concentrations, there still appeared to be a large variation between triplicate 
samples. Similar variations were observed when correction for total protein 
concentration or the sum of monosaccharides was applied (data not shown). The 
ICC gave a fair to good reproducibility for sIgA. This indicates that the variability 
between triplicates was relatively small compared to the variation between 
subjects. The ICC was low for sialic acid, indicating a poor reproducibility of the 
triplicates compared to the intersubject variance. This could probably be explained 
by the lack of difference in concentrations of sialic acid between subjects. Larger 
differences in sialic acid concentrations are expected when samples are taken from 
different locations of the large intestine or from different patient groups.  
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To minimise the variation between triplicates, the location and procedure of 
sampling were standardised. Because we aimed to sample mucus under 
physiological conditions, mucus was collected without bowel cleansing, which 
could provoke stress to the colonic mucosa and may alter the composition of the 
mucus layer. However, as a consequence, faecal contamination cannot be 
excluded. Possibly better results regarding the reproducibility could be obtained by 
using prior bowel cleansing or mildly rinsing the sampling location during the 
sigmoidoscopy. On the other hand, due to the viscous properties of the mucus 
layer it remains possible that proteins secreted in the mucus layer are not evenly 
distributed. 
Besides measuring sIgA and sialic acid concentrations, other proteins present in 
the mucus layer can be determined, such as cytokines, defensins or trefoil factors. 
This can be analysed by biochemical techniques that focus on individual molecules 
or by global protein analysis using SELDI-TOF-MS. This provides a complementary 
visualization technique to 1D and 2D gel electrophoresis that is more sensitive for 
the characterization of low molecular weight proteins and requires smaller amounts 
of sample. The value of the SELDI-TOF-MS lies in the ability to obtain and 
compare sprectra from a significant number of samples in a relatively short time 
with very little sample preparation. By comparing protein profiles from a larger set 
of samples from different patient groups during different physiological and 
pathological conditions, (unknown) proteins can be identified that characterise 
these groups.29,30 Good protein profiles were obtained from mucus samples 
collected in the present study. However, these profiles only provide information on 
the low molecular weight proteins up to 25 kDa using the cationic CM10 chip and is 
not suitable for the determination of larger proteins such as sIgA (385 kDa)31 and 
mucins (550 kDa (MUC2)).32 Although cluster analysis clearly pointed towards 
subject specific profiles, not all triplicates clustered together. Deviating samples 
might be caused by contamination with faecal matter or blood, the latter was 
visualised with clear peaks of α- and β-haemoglobin (Figure 6.3). 
 
In this methodological study we focussed on the feasibility of sampling and analysis 
of the colonic mucus obtained under physiological conditions. In this first study only 
triplicate samples of one anatomic location in healthy subjects were analysed. 
Future research could focus on changes in composition of the mucus layer in 
subjects with advancing age, between different patient groups, between different 
stages of the disease or after dietary interventions with for example dietary fibres. 
In addition, attention should be paid to the reproducibility of the colonic mucus 
sampling of one person over time and the variation over different locations in the 
intestine under pathological and non-pathological conditions. 
In conclusion, mucus samples collected with cytology brushes during endoscopy 
can provide useful information on the composition of this layer in vivo. However 
and importantly, some deviant triplicates indicate that analyzing only one mucus 
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sample may result in an observation bias and, therefore, at least three triplicate 
samples should be analysed independently. 
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Abstract 
Introduction 
The colonic mucus layer plays an important role in the protection of the intestinal epithelium and mainly 
consists of mucin glycoproteins (primarily MUC2 in the colon) but also contains trefoil factor 3 (TFF3) 
and secretory IgA. Butyrate is a major end-product of fermentation of dietary fibres and is associated 
with beneficial effects on colonic health. Previous in vitro and animal studies showed that butyrate 
modulates MUC2 and TFF3 expression and mucin secretion, although data from human studies are not 
yet available.  
 
Methods 
16 healthy volunteers and 35 UC patients in clinical remission administered daily a 60 mL rectal enema 
containing 100 mmol/L butyrate or placebo for two and three weeks, respectively. After each treatment, 
biopsies were taken from the distal sigmoid for quantitative RT-PCR and immunohistochemical analysis 
of MUC2 and TFF3. In addition, mucosal sections were stained with high iron diamine-alcian blue to 
distinguish between sialomucins and sulphomucins. To analyse total mucin secretion and secretory IgA 
concentrations, faeces was collected over a period of 24h during the day before endoscopic 
examination,  
 
Results 
The butyrate intervention did not significantly modulate the expression of MUC2 (fold change: 1.04 and 
1.05 in healthy volunteers and UC patients, respectively) or TFF3 (fold change: 0.91 and 0.94 in healthy 
volunteers and UC patients, respectively). Furthermore, the percentage of sialomucins, mucus secretion 
and secretory IgA concentrations were not affected by the butyrate intervention in both groups.  
 
Conclusion 
Butyrate exposure in healthy volunteers and UC patients in clinical remission did not affect quality 
parameters of the colonic mucus layer. 
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Introduction 
The intestinal mucus layer forms a dynamic defensive barrier between the luminal 
contents and the epithelial lining, which prevents invasion of intestinal bacteria, 
protects the epithelial lining against toxic substances and is a medium for 
lubrication and transport. Therefore, the mucus layer forms an important part of the 
colonic barrier1, which can be affected by environmental factors such as diet2 and 
has been shown to be impaired in various intestinal disorders, either as a cause or 
a consequence of the disease.3 The mucus layer mainly contains mucus 
glycoproteins (mucins), which are secreted by goblet cells and consist of a central 
protein backbone with large numbers of attached oligosaccharides containing sialic 
acid or sulphate residues. The mucins are classified into neutral and acidic 
subtypes and the latter category includes sialomucins and sulphomucins. Mucin 
subtypes vary spatially throughout the gastrointestinal tract and the acidic subtypes 
are found to dominate in the large intestine.4 Until now seventeen mucin-genes 
(MUC) genes have been identified in humans, of which MUC2 is predominantly 
expressed in the human colon.3  
In addition to mucins, a large number of other secreted proteins can be found in 
the mucus layer, such as trefoil factor family proteins (TFF) and secretory IgA 
(sIgA).1 The main function of sIgA is to neutralise toxins and to prevent epithelial 
adherence and penetration of pathogens.5 TFFs are mucin-associated proteins 
involved in protection of the gastrointestinal epithelium and mucosal healing, and 
contribute to the viscoelastic properties of the mucus layer.6,7 TFF1, TFF2 and 
TFF3 have been identified and are expressed in a site-specific pattern along the 
gastrointestinal tract. Trefoil factor 3 (TFF3) is predominantly produced by the 
intestinal goblet cells along the small and large intestine and has shown to be 
important for maintenance and repair of the intestinal mucosa.8  
An impaired mucus layer has been reported in active ulcerative colitis (UC), as 
shown by a reduced mucus thickness, sulphation, MUC2 synthesis and MUC2 
secretion. During clinical remission these parameters of the quality of the mucus 
layer did not significantly differ from the normal situation.3,9 It has been proposed 
that dietary factors are able to affect the mucus layer.10 For example, studies with 
rats have shown that dietary fibre deficiency leads to a decreased mucus 
thickness.2 Butyrate, a short chain fatty acid, is one of the main end-products of 
intestinal microbial fermentation of mainly dietary fibre. Its production has shown to 
be related with several beneficial effects on colonic health such as a reduction of 
inflammation, carcinogenesis and oxidative stress.11 A number of studies also 
indicate that butyrate affects the composition and the thickness of the colonic 
mucus layer.12-22 Several in vitro studies demonstrated that butyrate increased the 
MUC2 gene expression in different cell lines15,17,22, but a decreased MUC2 gene 
expression has been reported by others.12 In addition, butyrate stimulated mucin 
synthesis in human colonic biopsies ex vivo14 and increased mucus secretion in 
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isolated perfused rat colon.13 Other in vitro and animal studies demonstrate that 
butyrate affects TFF3 expression18,19,21, although not all study results point into the 
same direction. 
Although several in vitro, ex vivo and animal studies show that butyrate affects the 
mucus layer, to our knowledge these effects have not yet been evaluated in the 
healthy and/or mildly inflamed human situation. Therefore, the present study aims 
to determine the effects of butyrate administration on MUC2 and TFF3 expression, 
the proportion of sialomucins and sulphomucins, total mucin secretion, and sIgA 
concentrations in both healthy volunteers as well as in UC patients in clinical 
remission. 
Methods 
Patients 
Sixteen healthy subjects and thirty-five UC patients in clinical remission 
participated in this study. Patients had a well-defined diagnosis of UC established 
by clinical, endoscopical, histological and/or radiological criteria. Patients were in 
clinical remission and were excluded from participation if the Endoscopic Grading 
System (EGS)22 score was higher than 5 at the first endoscopy. The healthy 
subjects and patients were between 18-65 years of age and consumed a stable 
Western diet. Exclusion criteria comprised: proctitis only, pregnancy, lactation, 
changes in medication and/or pre- and probiotic intake 2 weeks prior to and during 
the study, the use of corticosteroids, enemas or suppositories two weeks prior to or 
during the study, the use of antibiotics 3 months prior to or during the study, other 
clinically significant systemic diseases and previous radiotherapy or chemotherapy. 
All healthy subjects and patients gave their written informed consent before 
participation. The study was performed in accordance with the principles of the 
declaration of Helsinki and was approved by the Medical Ethics Committee of the 
University Hospital Maastricht, the Netherlands.  
Study design 
The design of study with healthy volunteers was according to a randomised, double 
blind, placebo controlled, crossover design with a wash-out period of two weeks23, 
whereas, the study with UC patients was according to a randomised, double blind, 
placebo controlled parallel design. In short, during each intervention period, 
patients self-administered a 60 mL enema containing either a sodium butyrate 
solution (100 mmol/L) or a placebo solution (140 mmol/L NaCl) with a neutral pH. 
The butyrate enemas were made isotonic by the addition of NaCl (40 mmol/L). 
Patients were instructed to self-administer the enema once daily prior to sleeping, 
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and to remain in a left-lateral supine position for at least 15 min. The administration 
of the enemas continued for 14 and 20 days in healthy subjects and UC patients, 
respectively. Compliance was evaluated on the basis of a questionnaire and the 
returned enema-bottles.  
In the study with the healthy subjects a sigmoidoscopy was performed after each 
intervention period and in the study with UC patients a sigmoidoscopy was 
performed before and after the intervention period. Each sigmoidoscopy was 
performed in the morning after an overnight fast and without prior bowel cleansing. 
During all sigmoidoscopies, mucosal biopsies were obtained from a standardised 
location of the sigmoid (approximately 20-25 cm from the anal verge at the location 
of the arteria iliaca communis). Two mucosal biopsies for RT-PCR analysis were 
immediately frozen in liquid nitrogen and two other mucosal biopsies were fixed in 
formalin and embedded separately in paraffin for (immuno)histochemistry.  
The day before each sigmoidoscopy, participants collected 24-hour faeces. Part of 
the collected faeces was freeze-dried for the determination of mucin secretion and 
another aliquot was stored at -80°C for determination of faecal sIgA and 
calprotectin. 
RT-PCR for MUC2 and TFF3 
The expression of MUC2 and TFF3 was determined using RT-PCR. RNA was 
isolated from a frozen biopsy using TRIzol reagent (Invitrogen, Carlsbad, USA). 
RNA was purified with an RNeasy mini kit (Qiagen, Venlo, The Netherlands) 
combined with a DNase treatment using the RNase-Free DNase Set (Qiagen). 500 
ng total RNA was used as a template for the cDNA reaction, which was 
synthesised using the iScript cDNA Synthese kit (Bio-Rad, Veenendaal, The 
Netherlands). The cDNA was diluted to a concentration of 0.32 ng/μL. Each 
reaction contained 12.5 μL iQ Sybr Green Supermix (Bio-Rad), 1 μL each of 10 
μmol/L gene-specific forward and reverse primers, 4 μL cDNA template solution 
and 6.5 μL sterile H2O. Primer sequences are listed in Table 7.1. Housekeeping 
genes included were 18SrRNA, GAPDH and CANX. Reactions were run on the My 
IQ Single Colour RT-PCR Detection System (Bio-Rad). PCR conditions used were 
3 min at 95°C, followed by 40 amplification cycles of 10 sec at 95°C and 45 sec at 
60°C.  
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Table 7.1 Primer information of MUC2, TFF 3 and housekeeping genes. 
 Sequence ID Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
MUC2 NM_002457 GTCAACCCTGCCGACACCTG ACTCACACCAGTAGAAAGGACAGC 
TFF3 NM_003226 CTTGCTGTCCTCCAGCTCT CCGGTTGTTGCACTCCTT 
18SrRNA M10098 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
CANX NM_001024649 CCACTGCTCCTCCTTCATCTCC CGGTATCGTCTTTCTTGGCTTTGG 
GAPDH NM_002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
MUC2: mucin2; TFF3: trefoil factor 3; 18SrRNA: 18S ribosomal RNA; CANX: calnexin; GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase; 
 
(Immuno)histochemistry 
Serial tissue sections (2 μm) were stained with high iron diamine-alcian blue (HID-
AB) at pH 2.5 to distinguish non-sulphated (sialomucins) from sulphated 
(sulphomucins) acidic mucins24 and with immunohistochemical stainings for 
MUC225 and TFF3.26 Paraffin sections for immunohistochemistry were deparaffised 
and endogenous peroxidase was blocked with 3% (vol/vol) hydrogen peroxide in 
PBS for 30 minutes. Antigen retrieval was performed by boiling the sections in 10 
mmol/L citrate buffer (pH 6.0), After cooling down to room temperature, sections 
were incubated with 1% (wt/vol) blocking agent (Boehringer, Mannheim, Germany) 
in PBS for 30 minutes. Primary antibodies, monoclonal anti-MUC2 raised in 
mouse25 (We9, 1:200) and polyclonal anti-TFF3 raised in rabbit26 (1:2000) diluted 
in PBS were incubated overnight. Subsequently, slides were incubated with 
biotinylated secondary antibody and avidin-biotin peroxidase complex (Vectastain 
ABCkit, Vector laboratories, Burlingamer, UK) and binding was visualised in 0.5 
mg/mL 3,3’-diaminobenzidine, 0.02% (vol/vol) hydrogen peroxide in 30 mmol/L 
imidazole and 1 mmol/L EDTA (pH 7.0). 
Two blinded observers analysed the slides semi-quantitatively by scoring the 
percentage of non-sulphated sialomucins, MUC2 and TFF3 of at least three entire 
crypts from each biopsy specimen. 
Total mucin determination in faeces 
Mucins were extracted from freeze-dried faeces and quantified fluorimetrically as 
described previously.27 First, freeze-dried faeces was reconstituted in PBS and 
glycosidases were denatured and mucins were solubilised.28 Samples were 
filtrated (ultrafree MC 30000 NMWL, Millipore, Bedford, USA) during centrifugation 
(3000 g, until the complete sample passed the membrane). Subsequently, 200 μL 
methanol was added and centrifuged (3000 g) to wash the membrane. After drying 
by air, the mucin retentate was dissolved in PBS to the original volume and the 
amount of oligosaccharide side chains liberated from mucins were quantified using 
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a fluorimetric assay.29 The total amount of mucins was expressed as μmol 
oligosaccharide equivalents.27  
sIgA in faeces 
Secretory IgA concentrations in supernatants of 10% (w/v) faecal homogenates in 
PBS were determined using an enzyme-linked immunosorbent assay (ELISA) as 
described previously.30 Briefly, plates were coated with monoclonal mouse α 
human anti-secretory component (IgA) antibody (1:10000; Sigma). Purified human 
IgA isolated from colostrum (Sigma), was used for the standard curve. sIgA was 
detected using a monoclonal biotinylated mouse anti-human IgA1/2 monoclonal 
antibody (1:500; BD Pharmingen, Breda, the Netherlands), followed by the addition 
of streptavidin-conjugated horseradish peroxidase (1:10000; Sanquin CLB, 
Amsterdam, the Netherlands) and enzymatic colour development with 
tetramethylbenzidine (Sigma).  
Statistical analysis 
The non-parametric Wilcoxon signed-rank test was used to identify significant 
differences between dependent samples. Mann-Whitney U test for non-parametric 
data were used to identify significant differences between independent samples. 
Spearman's rank correlation coefficient was determined to identify significant 
correlations between parameters. Differences were considered statistically 
significant if p<0.05. Statistical analyses were performed using SPSS 11.0 
software.  
RT-PCR data were analysed using a Gaussian linear regression as described 
previously.23 Finally, data were presented as fold change with the confidence 
interval. The gene under consideration was denoted to be differentially expressed if 
the confidence interval (CI) did not include 1. 
Results  
Patient characteristics 
All 16 healthy volunteers (25% male, median age: 23 (18-62) years) completed 
both study periods with butyrate and placebo enemas. Thirty-five UC patients 
completed the study: 18 placebo-treated patients (50% male, median age: 59 (38-
64) years) and 17 butyrate-treated patients (65% male, median age: 54 (31-65) 
years). The compliance based on returned empty enema bottles and 
questionnaires was 99% both in the placebo and the butyrate group of the UC 
patients and was 100% for the healthy volunteers. 
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MUC2 and TFF3 mRNA expression levels  
Using RT-PCR the mRNA levels of both MUC2 and TFF3 were analysed in the 
mucosal biopsies. Both MUC2 and TFF3 mRNA was not significantly affected by 
the butyrate intervention in healthy volunteers nor in UC patients (Table 7.2). There 
was a trend, although not significant, towards a decrease in the expression of TFF3 
due to the butyrate intervention in both groups as indicated by the confidence 
interval that just included “1”. 
 
 
Table 7.2 Fold changes and confidence interval of the MUC2 and TFF3 as a result of the butyrate 
intervention in healthy subjects and UC patients in remission.  
Gene  Fold change  
Healthy subjects 1.04 (0.90-1.19) MUC-2 
UC patients 1.04 (0.94-1.14) 
Healthy subjects 0.91 (0.82-1.01) TFF3 
UC patients 0.92 (0.83-1.03) 
 
MUC2 and TFF3 protein expression 
The protein expression of MUC2 and TFF3 was analysed by 
immunohistochemistry. In both healthy volunteers and UC patients in remission, 
MUC2 and TFF3 was expressed throughout the entire crypt. No differences in 
MUC2 and TFF3 protein expression were seen after the butyrate intervention nor 
between both intervention groups. 
HID-AB 
To distinguish between sulphomucins and sialomucins, the HID-AB staining was 
applied on sections from the colonic mucosal biopsies obtained before and after 
the intervention with butyrate. The percentage of non-sulphated sialomucins did 
not differ significantly between both groups. Nor was there change in the 
percentage of sialomucins after the intervention with butyrate treatment compared 
to placebo in the healthy volunteers and UC patients in remission (Table 7.3). 
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Table 7.3 The percentage of sialomucins in colonic mucosal biopsy specimens of healthy volunteers 
(cross-over design) and UC patients in remission (parallel design) after placebo or butyrate 
treatment.  
Treatment    % sialomucins 
Healthy subjects Placebo  (n=16)    31 (20-65) 
 Butyrate (n=16)    39 (10-63) 
UC patients  Before    23 (5-60) 
 
Placebo (n=18) 
 After    18 (8-43) 
  Before    28 (8-48) 
 
Butyrate (n=17) 
 After     26 (5-55) 
No significant differences between groups and treatment. 
The HID-AB staining was used to distinguish between sialomucins and sulphomucins. 
Mucin determination in faeces 
As an indicator of the mucin secretion, the amount of mucins in 24 hour faecal 
collections were determined and expressed as μmol oligosaccharide equivalents 
per gram dry faeces. Mucin secretion was not different after butyrate treatment 
compared to placebo treatment in the healthy subjects and in UC patients in 
remission, nor were there any changes between both intervention groups (Table 
7.4). 
sIgA in faeces 
Faecal sIgA concentrations are shown in Table 7.4. A significant decrease in sIgA 
was observed (p = 0.028) in the UC patients after the placebo intervention, which 
was not seen after the butyrate intervention. In healthy volunteers and UC patients 
in remission there was no significant effect of the butyrate intervention on the sIgA 
concentrations. In addition, there were no differences in faecal sIgA concentrations 
between healthy subjects and UC patients in remission.  
 
Table 7.4 Mucin secretion expressed as μmol oligosaccharide equivalents (OE) /g dry weight, 
measured in faecal samples of healthy volunteers (cross-over design) and UC patients in 
remission (parallel design) after placebo or butyrate treatment.  
 Treatment  Mucins 
(μmol OE/g dry weight) 
sIgA  
(μg/mg protein) 
Healthy subjects Placebo (n=16) 2.2 (1.2-4.1) 5.8 (0.1-63.4) 
 Butyrate (n=16) 2.2 (1.3-8.7) 5.0 (0.1-48.5) 
UC patients Before 2.9 (0.7-6.7) 8.6 (<0.1-51.2) 
 
Placebo (n=18) 
After 2.6 (0.6-6.2) 2.8 (<0.1-21.2)* 
 Before 3.3 (0.2-5.6) 3.6 (<0.1-78.5) 
 
Butyrate (n=17) 
After  3.4 (0.1-7.8) 7.3 (0.2-67.4) 
* Significant decrease compared to the value before the placebo treatment (p<0.05). 
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Discussion 
The aim of the present study was to evaluate the in vivo effect of butyrate on the 
human colonic mucus layer in two groups, healthy volunteers and subjects with a 
minor degree of mucosal inflammation, i.e. UC patients in clinical remission. Our 
results show that butyrate does not affect the expression of MUC2 and TFF3 in 
colonic mucosal biopsies of both groups. Furthermore, the butyrate intervention did 
not change the percentage of sialomucins, nor the total mucin secretion and sIgA 
concentrations determined in faeces.  
 
The lack of an effect of butyrate on MUC2 and TFF3 in the present study 
contradicts to the findings of most of the in vitro and animal studies. The production 
and secretion of MUC2 are known to be important factors in the protection against 
colorectal diseases, since Muc2 gene targeted mice have been shown to develop 
colitis spontaneously.31 A recent study in mice by Gaudier et al. demonstrated that 
daily rectal enemas containing 1 mL 100 mmol/L butyrate for 7 days induced a 6-
fold increase in Muc2 gene expression in both the proximal and the distal colon.16 
Furthermore, the ex vivo addition of 0.1-1 mmol/L butyrate to human colonic 
biopsies stimulated mucin synthesis14 and an increase of MUC2 after butyrate 
supplementation up to 2 mmol/L has been reported in several colonic epithelial cell 
lines15,17,22, especially if a glucose-deprived medium was used.15 However, one 
other study reported that 5 mmol/L butyrate repressed MUC2 expression in HT-29 
cells.12 In the light of these previous findings it is rather surprising that no effect of 
butyrate on MUC2 was found in the present study. The discrepancy between the 
present study and former mice and in vitro studies could be due to the 
concentration of the butyrate supplementation. A previous in vitro study by Burger-
van Paasen et al. showed dose dependent effects of butyrate on MUC2 
expression40. Low concentrations (up to 5 mmol/L) increased MUC2 expression in 
LS174T cells, while higher concentrations of butyrate decreased its expression to 
control values40. In the present study, the nightly rectal enemas containing 100 
mmol/L butyrate were self-administered for 14 and 20 days in healthy volunteers 
and UC patients, respectively. This dose was chosen since such a local 
concentration could be reached when given a high fibre diet23 and furthermore this 
concentration showed to be beneficial in the treatment of active UC.32 However, it 
is possible that the dose, frequency and/or length of the intervention period was 
either not sufficient or even too high to achieve the same effect on MUC2 as 
previously has been reported in cell cultures and animal studies.  
 
Besides MUC2, TFF3 is another essential protein present in the colonic mucus 
layer. TFF3 knock-out mice are proven to be very sensitive to developing colitis33, 
while mice overexpressing TFF3 displayed increased resistance to intestinal 
damage and ulceration.34 In the present study no effect of butyrate on TFF3 could 
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be demonstrated, while previous in vitro and rat studies have shown equivocal 
effects of butyrate on TFF3. In a rat TNBS model of colitis, TFF3 expression was 
decreased during active disease, and intra-colonic daily administration of 80 
mmol/L butyrate for 7 days increased TFF3 expression.19 However, butyrate in 
concentrations of 1-5 mmol/L inhibited the expression of TFF3 in various cell 
lines.18,21 Although in the present study the effect of butyrate on TFF3 was not 
significant in the present study, both intervention groups showed a decrease of 
TFF3 expression. Further studies are needed to determine whether the effect of 
butyrate on TFF3 is also related to the administered dose and whether the effect 
depends on the presence and degree of inflammation.  
The most frequently reported mechanism by which butyrate could induce the 
changes of MUC2 and TFF3 is by inhibition of histone deacetylase.35,36 This results 
in hyperacetylation of histones and enhancement of the accessibility of 
transcription factors to nucleosomal DNA. However, it has also been reported that 
butyrate is able to induce changes in DNA methylation and acetylation of 
transcription factors.35 Therefore, it is possible that butyrate is able to increase the 
expression of one gene, while it decreases the expression of another gene. 
 
Other parameters of the mucus layer that were evaluated in the present study were 
distribution of sialomucins and sulphomucins, mucin secretion, and faecal sIgA 
concentrations. We evaluated these parameters because several animal studies 
have previously demonstrated that dietary fibre interventions, associated with a 
fermentation-mediated increase of butyrate, resulted in increased numbers of 
sulphomucin positive goblet cells37, increased sIgA production30,38, increased 
mucus secretion13 and increased thickness of the mucus layer.14-16,20,39 In the 
present study no significant increase in these parameters was observed due to the 
butyrate intervention. However, the significant decrease of sIgA in the placebo 
group was not found in the butyrate treated UC patients. Possibly, this difference 
between the butyrate and placebo group could be significant when larger numbers 
of patients would have been included. As determinations in faeces reflect changes 
in the entire gastrointestinal tract, it is possible that small changes restricted to the 
distal colon remained to be undetected. On the other hand, changes might also 
depend on the dose of the administrated butyrate, and therefore it cannot be 
excluded that other concentrations do show an effect.  
 
In contrast to the cross-over design that was applied to the study with healthy 
volunteers, a parallel design was chosen for the study with UC patients in order to 
limit the study duration because medical interventions apart from maintenance 
therapy are not allowed and the course of the disease may fluctuate over time. As 
a consequence, more UC patients than healthy subjects were included and pre-
treatment as well as post-treatment values were determined in the group of UC 
patients.  
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Although the primary aim of the present study was not to evaluate changes 
between healthy volunteers and UC patients in clinical remission, no significant 
differences between these groups were observed, despite the clear presence of 
low-grade inflammation and oxidative stress in these patients (data not shown).  
 
In contrast to results from previous in vitro and animal studies, butyrate 
administered in healthy volunteers and UC patients in clinical remission using 
nightly rectal enemas containing 100 mmol/L butyrate for 14 and 20 days, 
respectively, did not show a beneficial effect on various protein constituents of the 
colonic mucus layer. Most likely the concentration and duration of exposure are 
pivotal factors in achieving a beneficial effect of butyrate supplementation on the 
colonic mucus layer. It has to be determined whether this concentration can also 
be achieved by addition of fermentable dietary fibres to the diet.  
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General discussion 
Protective effects of dietary fibre intake on colorectal cancer1, cardiovascular 
disease2,3 and intestinal inflammation4 have been shown in several epidemiological 
studies. Nevertheless, not all studies were able to find such effects.5 One of the 
proposed mechanisms for these health-promoting effects of high dietary fibre 
intake is the increased fermentation-mediated production of short chain fatty acids 
(SCFA) in the colonic lumen. The most frequently studied SCFA is butyrate, which, 
besides being an energy source for the epithelial cells, influences a wide array of 
cellular functions affecting colonic health mainly by acting as an inhibitor of histone 
deacetylase (chapter 2). Generally, intestinal bacteria favour fermentation of 
carbohydrates (fibres) over proteins. Therefore, saccharolytic fermentation, which 
leads to the production of SCFA, is characteristic for the proximal colon that 
contains non-absorbed and non-fermented carbohydrates available as substrates. 
Proteolytic fermentation, yielding potentially harmful metabolites, mainly occurs in 
the distal colon where these substrates are depleted. In contrast to our remote 
ancestors who consumed a high fibre plant-based diet, today’s Western diet is low 
in fibre and it could be speculated that this plays a role in the increasing incidence 
of colonic pathology such as colorectal cancer6 and inflammatory bowel disease.7 
Therefore nowadays, functional food manufacturers are interested in adding 
fermentable fibres to dietary products. Their main challenge is to design and select 
the fibres that increase microbial SCFA production along the entire length of the 
colon.  
Evidence for the health promoting characteristics of SCFA originates from 
epidemiological studies. Beneficial effects of SCFA have, however, mainly been 
described in animal and in vitro studies and relatively little studies have evaluated 
the direct health promoting effects of these SCFA in humans. Human studies with 
SCFA have all been carried out in patients with active intestinal inflammation and 
mainly deal with clinical parameters (chapter 2). So far no studies have 
investigated the local effects of SCFA in the healthy or mildly disturbed colon, while 
healthy subjects or individuals with chronic mild intestinal complaints comprise an 
important target group for functional foods. Examples of patient groups 
characterised by such a chronically mildly disturbed colonic health are patients with 
irritable bowel syndrome, microscopic colitis, Crohn’s disease in remission or 
ulcerative colitis (UC) in remission. In the present thesis the latter patient group 
was used as a model and indeed, when comparing the parameters of inflammation 
and oxidative stress between healthy volunteers (chapter 4) and these UC patients 
in clinical remission (chapter 5), our data confirmed that these patients had an 
increased level of inflammation and oxidative stress. 
 
In the performed human intervention studies we were mainly interested in the local 
colonic effects of topical butyrate administration. When studying systemic effects, 
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blood can easily be sampled. In contrast, the colon is physically quite inaccessible 
for the sampling of tissue and luminal contents, in particular the proximal part of the 
colon. A full colonoscopy is cumbersome for the patient and there is a risk -
although small- for colonic perforation.8 Furthermore, to be able to reach the 
proximal colon, prior bowel cleansing is needed, which disturbs the normal 
physiologic environment and results in an unknown bias in the determined 
parameters. Restricting the endoscopic examination to the distal colon makes it 
possible to avoid prior bowel cleansing and the endoscopic procedure is shorter 
and thereby less cumbersome for the participants. Another reason why the human 
intervention studies described in the present thesis focus on the distal colon is that 
this part of the colon naturally contains the lowest concentration of SCFA and is 
often involved in various gastrointestinal disorders. 
 
In the present thesis results of three separate studies have been presented. In the 
first study an in vitro model was applied, which compared the effects of 5 different 
SCFA with carbon chain lengths varying from 2 to 6 atoms in three different 
concentrations. Secondly, in healthy volunteers the effects of butyrate, being the 
most potent SCFA, were investigated using a randomised placebo controlled 
cross-over design. Finally, the effects of butyrate on colonic health in UC patients 
in clinical remission were evaluated using a randomised placebo controlled parallel 
design. To evaluate the effects of the SCFA on colonic health, different parameters 
of colonic inflammation, oxidative stress and mucus composition were assessed. 
The results on these three topics will be discussed and integrated in the following 
sections. 
SCFA and colonic inflammation 
Different SCFA with varying carbon chain lengths (acetate (C2), propionate (C3), 
butyrate (C4), valerate (C5) and caproate (C6)) are being produced in the human 
colon by microbial fermentation. The amount and type of these SCFA depends 
largely on the structure of substrates available for fermentation and the 
composition of the gut microbiota. Using an in vitro model that combined colonic 
epithelial (Caco-2) cells with stimulated human whole blood cultures, it was shown 
that especially butyrate, but also valerate, propionate and caproate, possessed 
potent anti-inflammatory properties. No such effects on inflammation were 
observed for acetate (chapter 3). Anti-inflammatory effects of C3-C6 SCFA were 
demonstrated by a decrease in the release of different pro-inflammatory cytokines, 
such as TNF-α, IL-6 and IL-1β, due to incubation with these SCFA. Besides being 
the most potent anti-inflammatory compound, butyrate was the only SCFA that was 
able to significantly improve the TEER, which is an indicator of epithelial integrity.  
The human intervention studies in the present thesis focused on the local colonic 
effects of topically administrated butyrate on inflammatory activity, expressed as 
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MPO activity and several pro-inflammatory and anti-inflammatory cytokines in 
colonic mucosal biopsies as well as faecal calprotectin. Despite the clear anti-
inflammatory effect observed in vitro, no apparent decrease of inflammation was 
observed in the in vivo study with healthy human subjects (chapter 4). Even though 
the healthy colon does not present active inflammation, immune cells are still 
present and, although small, effects on inflammation could have been expected. To 
further evaluate the effects of butyrate on inflammation, patients with UC in 
remission were included in the subsequent study, as they are characterized by low-
grade colonic inflammation. In these patients, the butyrate intervention only 
resulted in a slight increase of the IL-10/IL-12 ratio and the chemokine CCL5, but 
overall no evident anti-inflammatory effect of butyrate was observed (chapter 5).  
The fact that the results from the in vitro study could not be reproduced in the 
human intervention studies may have several explanations. First of all, although a 
complex co-culture model was used, it remains a simplification of the in vivo 
situation that has multiple feedback systems to control inflammation. In addition, 
even though the Caco-2 cell line is a widely used model for the normal intestinal 
epithelium, it originates from tumour tissue, which may have an altered cellular 
metabolism. Furthermore, Caco-2 cells do not produce mucus. In contrast, in vivo, 
intestinal cells are covered by a thick mucus layer, which lowers the concentration 
of luminal components that are in contact with the colonocytes. This may affect the 
effective concentration in vivo. The dose of butyrate given by the rectal enemas 
was 100 mmol/L in 60 mL. This dose was chosen as this concentration could be 
reached locally when giving a high fibre diet and furthermore this concentration 
showed to be beneficial in the treatment of active UC.10,11 For practical reasons, 
once daily rectal enemas were chosen for the administration of butyrate. Although 
administration just before going to bed maximised the exposure, there was no 
continuous exposure to butyrate throughout the intervention period. Possibly, in 
humans, more prolonged exposure and/or higher dosages are required for stronger 
anti-inflammatory effects as were demonstrated in vitro. 
An alternative explanation for the fact that the anti-inflammatory effect could not be 
reproduced in the human intervention studies is the difference in the inflammatory 
state of the cells. The whole blood cultures in the in vitro study were stimulated with 
a pro-inflammatory stimulus after a short period of co-incubation of the co-culture 
system with the different SCFA. Such a pro-inflammatory stimulus is often applied 
to augment the effect of the SCFA.12 Whereas the human intervention studies were 
performed in the normal physiologic situation. A low level of inflammation is always 
present, which is essential for the resistance against infections.13 On the other 
hand, exaggerated immune responses are unwanted as they may contribute to a 
further deterioration of the intestinal barrier function. It could be concluded that 
butyrate, and to a lesser extent also propionate, valerate and caproate, are able to 
attenuate exaggerated immune responses as was demonstrated in vitro, but 
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butyrate maintains a low level of controlled inflammation as observed in the 
described human intervention studies. 
SCFA and oxidative stress 
Not only inflammatory parameters, but also parameters of oxidative stress were 
determined in our studies. Levels of GSH were significantly increased in colonic 
biopsies from healthy volunteers after the intervention with butyrate (chapter 4). 
GSH is an important component of the antioxidant defence network, as also 
demonstrated by severe degeneration of intestinal epithelial cells in GSH deficient 
mice.14 Butyrate increased the concentration of GSH in the in vitro study using 
unstimulated differentiated Caco-2 cells (chapter 3). In healthy volunteers, this 
increase in concentrations of GSH was accompanied by an increase in the 
expression of GCLC, the rate-limiting enzyme in GSH production. Surprisingly, this 
increase in GSH levels and GCLC expression was not observed in the study with 
UC patients in clinical remission (chapter 5). However, a significant negative 
correlation was found between the level of inflammation at the start of the study 
and the change in total GSH, indicating that the effects of butyrate on GSH may 
depend on the level of inflammation. Therefore, we hypothesise that butyrate at the 
concentration used in the present study may only be able to increase GSH when 
inflammation is minimal or absent. This implies that butyrate used in this 
concentration does not function as a therapeutic agent, but may be able to improve 
the protection against toxic stimuli in healthy individuals (i.e. preventive effect). 
Possibly, higher concentrations are needed for a therapeutic effect of butyrate in 
UC patients. This may be due to the fact that uptake and/or oxidation of butyrate 
differs in UC patients with varying degrees of inflammation.15-17 
The levels of uric acid were significantly affected by the butyrate intervention in 
healthy volunteers (chapter 4). The observed decrease in uric acid was 
accompanied by a decrease in XDH, the enzyme that converts purines into uric 
acid and superoxide. Although uric acid is an antioxidant, superoxide is a reactive 
oxygen species and we suggest that a decrease in its production protects against 
oxidative stress. In the study with UC patients the same significant decrease in 
expression of XDH was found, but the decrease in uric acid did not reach 
significance (chapter 5). Further studies are needed to determine whether an 
increased GSH and a decreased uric acid production leads to an improved barrier 
function and protection against inflammation in humans.  
 
Several studies have shown that increased inflammation is related to increased 
levels of oxidative stress. During inflammation, large quantities of reactive oxygen 
and nitrogen species are released that contribute to oxidative stress, antioxidant 
depletion and subsequent destruction of cells and disruption of the mucosal barrier 
function.18 In the clinical study with UC patients in remission, no significant 
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correlation was found between oxidative stress parameters (GSH/GSSG ratio and 
MDA) and inflammation. However, although these patients showed increased 
inflammatory activity compared to the healthy subjects, this activity was still low 
compared to patients with active inflammation. It can be expected that excessive 
inflammation, observed in patients with active UC, does correlate with the oxidative 
stress parameters. 
SCFA and the colonic mucus layer 
The colonic mucus layer is an important dynamic component of the epithelial 
barrier, which can be affected by diet and is impaired in several intestinal 
disorders.19 It contains mucin glycoproteins and many other compounds secreted 
by the intestinal epithelium, such as sIgA. Several studies have proposed a 
beneficial role for butyrate in the maintenance of the colonic mucus layer. However, 
the colonic mucus layer is difficult to study. Therefore we developed a standardised 
in vivo sampling technique to obtain human colonic mucus under physiological 
conditions during an endoscopic procedure using protected cytology brushes 
(chapter 6). The obtained colonic mucus samples were analysed for concentrations 
of mucins, sialic acid residues and sIgA. Furthermore, using SELDI-TOF-MS, low 
molecular weight proteins in the mucus samples were profiled to identify (unknown) 
proteins present in these samples. Sampling and analysis of colonic mucus was 
feasible using these brushes. However, this sampling technique was not sensitive 
enough to evaluate the rather subtle changes that occurred after the butyrate 
intervention, due to a relatively large variance between triplicate samples. Most 
likely, contamination with traces of faeces or blood was responsible for this 
variance. Although prior bowel cleansing could reduce this contamination, it was 
not applied since it could affect protein profiles in a yet unknown way. 
Other mucus related parameters were also studied in the mucosal and faecal 
samples obtained during both butyrate intervention studies, including RT-PCR and 
immunohistochemical analysis of MUC2 and TFF3, distribution of sialomucins and 
sulphomucins, total mucin excretion and sIgA concentrations in faeces (chapter 7). 
These analyses revealed no significant effects of butyrate on the determined 
mucus-related parameters. The lack of an effect of butyrate on colonic mucus 
contradicts the findings of most of the previous in vitro and animal studies, 
demonstrating that butyrate indeed affected MUC220 and TFF321 expression levels 
and increased mucus synthesis22 and secretion.23 Possibly the lack of effect in the 
present study could again be due to the ‘physiological’ dose applied as well as the 
once daily administration of butyrate. In addition, the limited number and size of the 
biopsies that could be obtained during a sigmoidoscopy influenced the choices of 
the parameters to be analysed. Future studies could also evaluate the thickness of 
the mucus layer as it has been shown that fibre deficiency leads to a decreased 
thickness and a decreased protective potential of the mucus layer using a model.19 
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Future perspectives and general conclusions  
Several in vitro studies, including the in vitro study described in the present thesis 
suggest a beneficial role of SCFA, especially butyrate, on colonic health. However, 
in the performed human intervention studies the effects on colonic health, 
measured by assessing parameters of inflammation, oxidative stress and the 
mucus layer, were not as prominent as expected based on the in vitro data that 
showed a reduction of inflammation, an increase in the antioxidant capacity and an 
improvement of the barrier function. Nevertheless, increased concentrations of 
colonic glutathione were conformed in healthy volunteers indicating that butyrate is 
able to beneficially modulate oxidative stress.  
In the intervention studies described in the present thesis a standardised topical 
administration of butyrate by enemas was applied to assess the contribution of 
butyrate to the proposed beneficial effects of dietary fibre on colonic health. This 
enabled us to study the effects of butyrate without changing the microbial 
composition, intraluminal pH and production of other metabolites. Another 
possibility to increase the colonic SCFA concentrations is the administration of 
dietary fermentable fibres or acetylated starches that are not digested and 
absorbed in the small intestine and rely on the colonic microbiota for the production 
of SCFA.24,25 This way there is a more continuous exposure of the colonocytes to 
SCFA, however the exact local concentrations of SCFA would remain unknown. 
Furthermore, an intervention with dietary fermentable fibres would also influence 
other factors that can affect colonic health besides the SCFA production.26 For 
example, fermentation of dietary fibres may lead to modification of the intestinal 
microbial composition, reduction of potentially harmful by-products of protein 
fermentation, reduction of colonic pH, inhibition of growth of pathogens, increase of 
intestinal bulk and acceleration of intestinal transit.  
Due to the invasiveness of the clinical studies it was chosen to evaluate the effects 
of only one concentration of butyrate on colonic health. The concentration of 100 
mmol/L of butyrate was applied, as this is the expected local concentration after 
consumption of a high fibre diet. However, although in vitro fermentation models 
can be used to predict the SCFA production, in vivo data are hardly available due 
to the inaccessibility of the human colon.9 Therefore, future research should also 
focus on the quantification of the production of SCFA in health and disease and to 
which extent these concentrations can be increased by fermentation of indigestible 
carbohydrates. It may be possible that other concentrations or more prolonged 
exposure to SCFA results in more similar effects as observed in vitro.  
 
In general, the results described in this thesis support the rationale for the addition 
of fermentable dietary fibres that increase colonic concentrations of SCFA to 
dietary products in order to improve host health. Nevertheless, large prospective 
human intervention trials with long-term fermentable dietary fibre supplementation 
are needed to evaluate whether increased colonic SCFA levels are causatively 
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related to improvements of functional parameters, such as colonic permeability and 
symptom scores. Because our studies demonstrated that the effects of SCFA on 
the colonic mucosa could depend on the state of the mucosal cells, future studies 
should also focus on the effects of SCFA in the healthy versus the (mildly) inflamed 
colon. 
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Summary 
Short chain fatty acids (SCFA) are end-products of luminal microbial fermentation 
of predominantly non-digestible dietary carbohydrates. SCFA with different carbon 
chain lengths (acetate (C2), propionate (C3), butyrate (C4), valerate (C5) and 
caproate (C6)) are produced in varying amounts depending on the diet and the 
composition of the intestinal microbiota. In contrast to potentially toxic metabolites 
that are formed through fermentation of proteins, SCFA are proposed to 
beneficially affect colonic health. Therefore, food manufacturers are interested in 
the development of non-digestible carbohydrates as ingredients for novel functional 
foods. Especially butyrate has become of major interest as it is the main energy 
source for colonocytes. In chapter 2 the current knowledge on the effects of 
butyrate on colonic health has been reviewed. From this review it can be concluded 
that butyrate can affect colonic health by reducing inflammation and 
carcinogenesis, decreasing oxidative stress, and improving the colonic defence 
barrier. However, these previous studies have mainly investigated the effects of 
butyrate in animal and in vitro models. Only limited numbers of human studies have 
been performed, which have all been carried out in patients with active intestinal 
inflammation and mainly focus on clinical parameters. Overall, these studies 
suggest that luminal administration of butyrate results in an amelioration of the 
symptoms and inflammation in active UC patients. 
So far no studies have investigated the local effects of SCFA in the healthy or 
mildly disturbed colon, while healthy subjects or individuals with chronic mild 
intestinal complaints comprise an important target group for functional foods.  
Although several in vitro studies have investigated the effects of butyrate on colonic 
homeostasis, the effects of other SCFA with different chain lengths have been 
studied less extensively. In addition, effects are hard to compare as they involve 
separate studies and/or different models. Therefore, the aim of the study described 
in chapter 3 was to compare the effects of C2 to C6 SCFA on parameters of 
inflammation, antioxidant capacity and epithelial integrity in one study using a co-
culture model of human epithelial cells (Caco-2) and human whole blood cultures. 
The results of this in vitro study showed that butyrate inhibits the release of several 
pro-inflammatory cytokines, improves of the trans-epithelial resistance and 
increases the concentration of the antioxidant glutathione. Remarkably, such 
effects were also observed for valerate, propionate and caproate with a rank order 
of potency being butyrate >> valerate > propionate > caproate. 
In chapter 4 the effect of butyrate, being the most potent SCFA, was investigated in 
16 healthy volunteers in a randomised placebo controlled cross-over study. The 
intervention with daily butyrate enemas (60 mL, 100 mM) for 14 days resulted in 
significantly increased colonic concentrations of the antioxidant glutathione as was 
also observed in the in vitro study. Furthermore, the colonic concentration of uric 
acid decreased, indicating that the intervention with butyrate decreased oxidative 
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stress in healthy volunteers. In the following study, the effects of butyrate enemas 
(60 mL, 100 mM) for 20 days on inflammation and oxidative stress were evaluated 
in patients with low-grade colonic inflammation using a randomised placebo 
controlled parallel design. For this study 36 patients with ulcerative colitis (UC) in 
clinical remission were included. The results, described in chapter 5, confirmed the 
presence of a low-grade inflammation and oxidative stress in these UC patients in 
clinical remission as indicated by significantly increased levels of pro-inflammatory 
cytokines (IL-1β, IL-12, IFN-γ), faecal calprotectin and oxidised glutathione, and 
significantly decreased levels of reduced glutathione, antioxidant enzyme activity 
and total antioxidant capacity in colonic biopsies compared to healthy controls. 
However, the butyrate intervention only resulted in a slight increase of the IL-10/IL-
12 ratio and the chemokine CCL5. Overall, no evident anti-inflammatory effect of 
this butyrate treatment was observed in these patients. Also no effects on colonic 
glutathione levels were found, but the effects of butyrate enemas on total colonic 
glutathione appeared to be inversely related to the level of inflammation at the start 
of the study. This may indicate that the effective dose of butyrate to decrease 
inflammation and oxidative stress depends on the level of colonic inflammation.  
Besides inflammation and oxidative stress, several studies have proposed a 
beneficial role for butyrate in the maintenance of the colonic mucus layer. The 
colonic mucus layer is the first line of defence to the external environment and 
protects the mucosa against mechanical stress and chemical or microbiological 
aggressors. Since the mucus layer is impaired during intestinal disease and it can 
be affected by the diet, it is interesting to evaluate the composition of the colonic 
mucus layer in relation to colonic health. However, as mucus samples are difficult 
to collect, it is complex to study the human colonic mucus layer in vivo. In chapter 6 
a standardised in vivo sampling technique to obtain human colonic mucus under 
physiological conditions during an endoscopic procedure using protected cytology 
brushes is described. The obtained colonic mucus samples were used for analysis 
of the concentrations of mucins, sialic acid residues and secretory IgA. 
Furthermore, using SELDI-TOF-MS, low molecular weight proteins in the mucus 
samples were profiled to identify (unknown) proteins present in these samples. 
Sampling and analysis of colonic mucus was feasible using these brushes and 
revealed subject specific protein profiles. However, this sampling technique was 
not sensitive enough to evaluate the rather subtle changes that can be induced by 
the butyrate intervention, due to a relatively large variance between triplicate 
samples of one subject. To evaluate the effects of the butyrate intervention in 
healthy volunteers and UC patients in clinical remission other mucus related 
parameters were studied in colonic mucosal biopsies and faecal samples obtained 
during both intervention studies. These parameters include RT-PCR and 
immunohistochemical analysis of MUC2 and TFF3, the distribution of sialomucins 
and sulphomucins, total mucin excretion and secretory IgA concentrations in 
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faeces. The results that are described in chapter 7 revealed no significant effects of 
butyrate on the determined mucus-related parameters analysed.  
In conclusion, the studies described in this thesis support the rationale for the 
addition of non-digestible fermentable dietary fibres to dietary products in order to 
increase colonic SCFA concentrations and thereby improve host health. Especially 
butyrate has shown to be an important metabolite that can decrease colonic 
inflammation, improve intestinal barrier function and reduce oxidative stress as 
observed in an in vitro model. Although not as prominent results were found in vivo, 
butyrate can improve the antioxidant defence capacity in healthy humans. 
However, the optimal SCFA concentration in health and disease remains to be 
determined. In addition, large prospective human intervention trials with long-term 
fermentable dietary fibre supplementation are needed to evaluate whether 
increased colonic SCFA levels are causatively related to improvements of 
functional parameters, such as colonic permeability and symptom scores. 
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Samenvatting 
Korte keten vetzuren (KKVZ) zijn eindproducten van bacteriële fermentatie van met 
name onverteerbare koolhydraten in de dikke darm. Afhankelijk van de 
samenstelling van het dieet en micro-organismen in de dikke darm worden KKVZ 
met koolstof (C) ketens van verschillende lengtes geproduceerd (acetaat (C2), 
propionaat (C3), butyraat (C4), valeraat (C5) en caproaat (C6). In tegenstelling tot 
de potentieel toxische metabolieten afkomstig van eiwit fermentatie, wordt 
verondersteld dat KKVZ gunstige effecten hebben op de gezondheid van de dikke 
darm. Daarom zijn levensmiddelen fabrikanten geïnteresseerd in het ontwikkelen 
van koolhydraten die niet verteerd worden in de dunne darm, maar wel 
gefermenteerd worden in het colon als ingrediënten voor nieuwe functionele 
voeding. Er is met name veel interesse in het verhogen van de concentratie van 
butyraat in het colon omdat het de belangrijkste energiebron is voor de 
epitheelcellen. Hoofdstuk 2 geeft een overzicht van de huidige kennis over de 
effecten van butyraat op de gezondheid van het colon. Uit dit overzicht kan 
geconcludeerd worden dat butyraat de gezondheid van het colon bevordert door 
de ontsteking en oxidatieve stress te verlagen, carcinogenese te remmen en de 
barrière functie van het colon te versterken. Deze effecten zijn echter met name 
aangetoond met behulp van diermodellen en in vitro onderzoeken. Slechts weinig 
studies hebben de gezondheidsbevorderende effecten van butyraat en andere 
KKVZ onderzocht in mensen. De humane studies naar de effecten van KKVZ die 
uitgevoerd zijn betreffen alleen studies met patiënten met actieve ontsteking van 
de dikke darm en bekijken met name het effect op klinische parameters. Over het 
algemeen tonen deze studies aan dat rectale toediening van KKVZ en/of butyraat 
symptoom scores en ontstekingswaarden kan verlagen in patiënten met actieve 
colitis ulcerosa. Tot op heden zijn er geen studies waarin de directe effecten van 
KKVZ zijn onderzocht in gezonde vrijwilligers en patiënten met slechts een milde 
ontsteking van het colon, terwijl deze mensen een belangrijke doelgroep vormen 
voor het nuttigen van de nieuwe functionele voedingsproducten. 
Diverse in vitro onderzoeken hebben de effecten van butyraat op de gezondheid 
van het colon onderzocht, maar de mogelijke effecten van de andere KKVZ zijn 
nauwelijks bestudeerd. Daarnaast zijn de effecten moeilijk te vergelijken omdat ze 
in verschillende studies en met behulp van verschillende modellen zijn onderzocht. 
Daarom had het onderzoek beschreven in hoofdstuk 3, de doelstelling om de 
effecten van de KKVZ met verschillende lengtes, variërend tussen 2 en 6 koolstof 
atomen, in één studie te vergelijken met betrekking tot parameters voor ontsteking, 
de antioxidant capaciteit en epitheliale integriteit. Hierbij werd gebruik gemaakt van 
een ‘co-culture’ model van een humane epitheliale cel lijn (Caco-2) en humaan 
volbloed. De resultaten van dit in vitro onderzoek laten zien dat butyraat de meest 
potente effecten heeft op de remming van pro-inflammatoire cytokines, verbetering 
van de transepitheliale resistentie en de toename van het antioxidant glutation. 
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Deze effecten werden ook waargenomen voor valeraat, propionaat en caproaat, 
maar niet voor acetaat. De grootte van de effecten was als volgt: butyraat >> 
valeraat > propionaat > caproaat.  
Omdat butyraat de sterkste effecten had, zijn in hoofdstuk 4 de effecten van 
butyraat op de gezondheid van het colon onderzocht in 16 gezonde vrijwilligers in 
een gerandomiseerde placebo gecontroleerde cross-over studie. De interventie, 
die bestond uit dagelijks een butyraat klysma (60 mL, 100 mM) gedurende 14 
dagen, toonde een significante stijging van de concentratie van het antioxidant 
glutation in het weefsel van de dikke darm. Deze resultaten zijn in 
overeenstemming met de resultaten van de in vitro studie beschreven in hoofdstuk 
3. Daarnaast werd ook een daling in de concentratie urinezuur gemeten. Deze 
resultaten lijken te wijzen op een vermindering van de oxidatieve stress als gevolg 
van de toediening van butyraat. In een volgende studie werden de effecten van 
een dagelijks butyraat klysma (60 mL, 100 mM) gedurende 20 dagen op ontsteking 
en oxidatieve stress geëvalueerd in patiënten met een laaggradige ontsteking van 
de dikke darm. Voor deze studie met een gerandomiseerd placebo gecontroleerd 
parallel design, werden 36 patiënten met colitis ulcerosa in klinische remissie 
geïncludeerd. De resultaten van deze studie die zijn beschreven in hoofdstuk 5, 
bevestigen de aanwezigheid van een laaggradige ontsteking en een lichte 
verhoging van oxidatieve stress in deze patiënten. Ten opzichte van waardes 
gemeten in gezonde vrijwilligers werden in biopten van het colon van deze 
patiënten significant hogere concentraties pro-inflammatoire cytokines (IL-1β, IL-
12, IFN-γ), geoxideerd glutation en calprotectine gemeten. Tevens waren de 
hoeveelheden van het gereduceerd glutation, antioxidant enzymen en de totale 
antioxidant capaciteit in biopten van het colon juist verlaagd in de patiënten ten 
opzichte van gezonde controles. De interventie met butyraat resulteerde slechts in 
een lichte verhoging van de IL-10/IL-12 ratio en het chemokine CCL5. Over het 
algemeen werden er geen grote effecten van de interventie met butyraat op 
ontsteking of oxidatieve stress geobserveerd in de patiënten met colitis ulcerosa in 
remissie. Echter, uit de resultaten kon wel opgemaakt worden dat het effect van 
butyraat op totaal glutation omgekeerd correleerde met de mate van ontsteking. 
Hieruit kan geconcludeerd worden dat de effectieve dosis van butyraat mogelijk 
afhangt van de mate van ontsteking van de darm.  
Verschillende studies met cellijnen en diermodellen hebben aangetoond dat 
butyraat ook een effect kan hebben op de mucuslaag, die op de epitheelcellen van 
de darmwand ligt. Deze mucuslaag vormt een belangrijke beschermlaag tegen 
mechanische stress en chemische of microbiologische stressoren die aanwezig 
zijn in het darmlumen. Het bestuderen van de mucuslaag is zeer interessant, maar 
het wordt bemoeilijkt door het verkrijgen van monsters van deze humane 
mucuslaag in vivo. In hoofdstuk 6 wordt een gestandaardiseerde techniek 
beschreven om met een cytologie borsteltje, gedurende een endoscopie, monsters 
te nemen van de mucuslaag onder fysiologische omstandigheden. In deze 
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monsters konden verschillende analyses worden gedaan, zoals het bepalen van 
de hoeveelheid mucines, siaalzuur residuen en secretoir IgA. Daarnaast konden 
met  behulp van SELDI-TOF-MS, persoon specifieke eiwit profielen van de mucus 
monsters worden verkregen. Deze techniek om monsters te verkrijgen was echter 
niet sensitief genoeg om de subtiele effecten van de interventie met butyraat aan 
te tonen. Om de effecten van butyraat op de mucuslaag in gezonde vrijwilligers en 
patiënten met colitis ulcerosa in remissie te onderzoeken werden vervolgens 
andere parameters geanalyseerd: expressie van MUC2 en TFF3 en verdeling van 
sialo- en sulfomucines in colonbiopten, en totale mucine secretie en secretoir IgA 
concentraties in faeces. De resultaten die beschreven staan in hoofdstuk 7, 
toonden echter geen significante effecten van butyraat op de gemeten mucus 
gerelateerde parameters. 
Concluderend kan worden vastgesteld dat de verschillende studies beschreven in 
dit proefschrift de hypothese ondersteunen die stelt dat toevoeging van 
onverteerbare, fermenteerbare koolhydraten die leiden tot een verhoging van de 
KKVZ concentratie in de dikke darm aan de voeding kan bijdragen aan een 
verbetering van de darmgezondheid. Met name butyraat blijkt een belangrijke 
metaboliet te zijn dat ontsteking en oxidatieve stress in de dikke darm kan verlagen 
en de barrière functie van de darm kan versterken, zoals geobserveerd werd in een 
in vitro model. Ondanks dat de resultaten van de in vivo studies niet even 
prominent waren,  werd een toename van de antioxidant capaciteit geobserveerd 
na toediening van butyraat in gezonde vrijwilligers. Echter meer onderzoek is nodig 
om de optimale KKVZ concentratie gedurende gezondheid en ziekte te bepalen. 
Daarnaast zijn er grotere prospectieve lange termijn humane interventie studies 
met fermenteerbare koolhydraten nodig om te evalueren of een verhoging van 
KKVZ causaal gerelateerd is met een verbetering van functionele parameters als 
permeabiliteit van de darm en symptoom scores.  
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onderzoek heeft mij zeer gemotiveerd. Ik heb het zeer gewaardeerd dat je ondanks 
je drukke agenda de tijd nam om te discussiëren over nieuwe onderzoeksideeën 
en interessante resultaten. Daisy, met jou als dagelijkse begeleider heb ik 
ongelofelijk veel geluk gehad. Jouw deur stond echt altijd open. Dankzij jouw snel, 
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ik zeer veel van je mogen leren. Freddy, jouw inzet en kritische blik bij het opzetten 
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daadkracht en enthousiasme zijn ook belangrijke ingrediënten geweest van dit 
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wetenschap, maar vergen ook grote inzet van vele personen. Ik wil dan ook graag 
mijn waardering uitspreken naar de patiënten en gezonde vrijwilligers die hebben 
meegewerkt aan de studies beschreven in dit proefschrift.  
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Het hoofd van de afdeling maag-darm en leverziekten van het MUMC, Prof. 
Reinhold Stockbrügger en zijn opvolger Prof. Ad Masclee wil ik ook graag 
bedanken voor de mogelijkheid die ze hebben geboden om deze onderzoeken in 
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mensen erg dankbaar. Ten eerste wil ik graag Andrea bedanken, die mij met raad 
en daad bij verschillende analyses heeft bijgestaan. Als ervaren analist heb ik veel 
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bedankt voor de fijne samenwerking met betrekking tot de analyses op het gebied 
van oxidatieve stress. De gemeten effecten van butyraat op de antioxidant 
capaciteit hebben geleid tot vele interessante discussies en nieuwe hypothesen. 
Ook wil ik Marc, Marie-Jose en Roger bedanken voor hun ondersteuning en 
aanwijzingen bij het uitvoeren van de verschillende analyses met betrekking tot 
oxidatieve stress. Prof. Wim Buurman en Prof. Cees Dejong wil ik graag bedanken 
voor de fijne samenwerking met de afdeling Heelkunde. Bij de afdeling Pathologie 
zijn verschillende kleuringen uitgevoerd. Prof. Adriaan de Bruïne, bedankt voor 
deze samenwerking en de uren die u heeft vrijgemaakt voor het beoordelen van de 
coupes.  
 
Ook is er samengewerkt met andere afdelingen buiten het MUMC en hiervoor wil ik 
ook graag een aantal personen bedanken. Raymond Schipper, Jolan de Groot en 
Jeroen van de Bovenkamp van de Universiteit Wageningen, bedankt voor de 
samenwerking en discussies over de analyses van de mucus samples. Arnoud 
Loof, bedankt voor het uitvoeren van de SELDI-TOF-MS analyses van de vele 
mucus samples aan de Radboud Universiteit in Nijmegen. Aan de Erasmus 
Universiteit in Rotterdam zijn in samenwerking met Ingrid Renes de MUC2 en 
TFF3 kleuringen uitgevoerd. Jullie expertise op dit gebied was onmisbaar. Een 
grote blijk van dank gaat ook naar Ger Rijkers en Ben de Jong, die geholpen 
hebben bij het uitvoeren van de luminex assays in het St. Anthonius Ziekenhuis in 
Nieuwegein. Annet, bedankt voor het bepalen van de korte keten vetzuur 
concentraties bij TNO in Zeist. 
 
Mein Dank gilt auch Manfred Schmolz und Gerburg Stein, die mich am EDI in 
Reutlingen, in Deutschland, in Empfang genommen und mich bei der Durchführung 
der Co-Kultur-Experimente mit die kurzkettigen Fettsäuren betreut und unterstützt 
haben. Während dieser Wochen am EDI konnte ich sehr viel lernen, wofür ich euch 
sehr dankbar bin! 
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Naast het harde werken was er ook tijd voor de koffie/thee pauzes die zorgden 
voor de nodige ontspanning. Daarvoor wil ik ook mijn andere collega AIO’s en 
onderzoekers hartelijk bedanken!  
 
En dan natuurlijk mijn paranimfen: Steven en Geerte. Ik vind het fijn dat jullie bij de 
verdediging van mijn proefschrift achter mij willen staan. Steven, samen zijn wij als 
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collega met wie ik kon discussiëren over artikelen en nieuwe resultaten, maar ook 
te rade kon gaan over technische zaken als het repareren van mijn auto of 
vastlopende computers. Ik vind het jammer dat ik niet meer tegenover je zit. 
Succes met het afronden van jouw proefschrift. Geerte, wij zijn al vriendinnen 
vanaf de elementary school in Managua en sinds het begin van onze promoties in 
Maastricht was het duidelijk dat wij elkaars paranimf zouden worden. Bedankt voor 
alle gezellige uurtjes sporten, eten en kletsen. 
 
Dan rest mij nog mijn vrienden en (schoon)familie te bedanken. Ook al was het 
soms lastig uit te leggen wat ik nu precies aan het doen was, jullie waren altijd 
oprecht geïnteresseerd. Jullie steun, vriendschap en gezelligheid zou ik niet willen 
missen.  
 
Lieve papa en mama jullie hebben mij altijd gesteund in alles was ik wilde doen en 
gaven me het vertrouwen dat ik het ook kon. Ook al is Maastricht niet echt dichtbij, 
ik heb het nooit als ver ervaren. Lieve zussen, Judith en José, ondanks dat wij alle 
drie onze eigen weg bewandelen, blijft onze band sterk en daar ben ik erg 
dankbaar voor. 
 
Lieve Max, jij bent misschien nog wel de grootste motor achter dit proefschrift. Jij 
kunt mij als geen ander inspireren, gelukkig maken en begrijpen. Nu onze boekjes 
dan echt allebei af zijn, kunnen we samen aan een nieuw hoofdstuk beginnen. Ik 
kan niet wachten op onze toekomst samen! Jij bent mijn grootste geluk. 
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Henrike Maria Hamer was born on May 13th 1981 in Delft, the Netherlands. After 
completing secondary school in 1999 at the ‘Zandevelt College’ in ‘s Gravenzande, 
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the department of Clinical Nutrition where she took part in a twin study to evaluate 
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Institute of Nutrition and Food Technology in Santiago, Chile in 2003. After her 
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2004 she started working as a PhD fellow at the department of Internal Medicine 
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this period is described in the present thesis. She presented parts of the research 
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